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DNA	 is	 the	 macromolecule	 that	 encodes	 the	 genetic	 information	 of	 life.	 It	 defines	 the	
structure,	organization	and	function	of	each	cell	and	therefore	it	is	crucial	to	preserve	the	
integrity	of	 the	DNA	during	 lifespan.	However,	 the	DNA	 is	 constantly	exposed	 to	various	
genotoxic	threats	that	lead	to	around	1.000	to	1.000.000	lesions	per	cell	each	day	(Lindahl,	




In	 eukaryotes	 chromosomal	 DNA	 is	 organized	 into	 a	 highly	 condensed	 structure	 called	









































Rad50-Nbs1	 (MRN)	complex	 (Petrini	and	Stracker,	2003),	which	directly	attracts	 the	PIKK	
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subsequently,	 p-ATM	phosphorylates	 all	 three	members	 of	 the	MRN	 complex	 to	 initiate	







Double-strand break repair - Homologous recombination 
Two	major	pathways	facilitate	the	repair	of	DSBsnamely	homologous	recombination	(HR)	
and	non-homologous	end-joining	(NHEJ).	HR	mediates	the	error-free	repair	of	DNA	breaks	












and	 loading	 of	 the	 RAD51	 recombinase,	 forming	 an	 ssDNA-containing	 nucleoprotein	
filament.	Once	bound	 to	ssDNA,	RAD51	can	search	 for	and	 invade	a	homologous	duplex	
DNA	template.	Subsequently,	restoration	of	the	original	DNA	sequence	is	achieved	by	DNA	
synthesis	and	ligation	(Fig.	2)	(Liu	et	al.,	2014).






Ku80,	which	attracts	 the	DNA-dependent	kinase	DNA-PKcs	 to	 form	the	DNA-PK	complex.	
DNA-PKcs	mainly	undergoes	autophosphorylation,	but	also	displays	activity	towards	other	











Figure 2. Overview of DSB repair by the homologous recombination (HR) pathway.	5’–3’	DNA	end	resection	is	
initiated	by	the	MRN	complex	together	with	CtIP	and	the	3’	ssDNA	is	coated	by	RPA.	BRCA1	and	CtIP	physically	



































S-phase	and	only	 if	classical	NHEJ	 is	not	functional	 i.e.	when	proteins	 like	Ku70/80,	DNA-
PKcs	or	XRCC4/LigaseIV	are	unavailable	or	 inactive	(Lieber,	2010).	This	alternate	pathway	





















 NHEJ	also	has	an	essential	 role	during	 the	somatic	gene	 rearrangement	process	
V(D)J	recombination	and	throughout	the	process	of	immunoglobulin	(Ig)	gene-diversification	
called	class-switch	recombination	(CSR).	These	processes	take	place	at	the	immunoglobulin	
heavy	chain	 (IgH)	 locus	 that	comprises	 the	variable	 (V),	diversity	 (D)	and	 joining	 (J)	gene	
segment	 and	 the	 constant	 region	 (C)	 (Fig.	 5).	 During	 V(D)J	 recombination	 the	 RAG1/2	
complex	deliberately	generates	 sequence-specific	DSBs.	One	segment	of	each	V,	D	and	 J	
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	 53BP1	 is	an	 important	 regulator	of	DSB	 repair	pathway	choice,	which	promotes	
NHEJ.	Upon	DSB	 induction,	 53BP1	binds	 to	 nucleosomes	 that	 are	both	di-methylated	 at	
H4K20	and	mono-ubiquitylated	at	H2AK15	(Fradet-Turcotte	et	al.,	2013)	 (the	subsequent	
modifications	 will	 be	 discussed	 in	 more	 detail	 below).	 Its	 binding	 affinity	 proximal	 to	
DSBs	 is	mediated	 through	 histone	 acetyltransferase	 TIP60/TRRAP-induced	 acetylation	 of	
histone	H4	on	lysine	(K)	16	(H4K16ac)	upon	damage	induction	that	blocks	53BP1	binding	










































Chromatin structure changes through histone posttranslational 
modifications and chromatin remodeling
Various	 regulatory	 mechanisms	 control	 the	 folding-state	 of	 DNA	 to	 provide	 access	 to	
proteins	involved	in	DNA-based	metabolic	processes	including	transcription,	DNA	replication	
and	DNA	repair.	 First,	histones	can	be	posttranslationally	modified	 through	 the	action	of	
enzymes	that	covalently	modify	residues	at	their	 inner	core	or	at	their	N-	and	C-terminal	
tails.	 In	 that	way	not	only	 the	physical	properties	of	 the	chromatin,	but	also	 the	binding	
of	 non-histone	 proteins	 to	 chromatin	 can	 be	 altered.	 Besides	 phosphorylation,	 histones	
can	also	be	ubiquitylated,	SUMOylated,	methylated,	acetylated	and	poly(ADP-ribosyl)ated;	
the	 combinatorial	 nature	 of	 these	modifications	 forms	what	 is	 called	 the	 ‘histone	 code’	
(Jenuwein	and	Allis,	2001).	















of	 proteins	 have	been	 found	 to	 contain	 SQ/TQ	motifs,	which	 can	undergo	DNA	damage	
dependent	phosphorylation	by	kinases	from	the	phosphatidylinositol-3	kinase	(PIKK)-family	
including	ATM,	ATR	and	DNA-PKcs	 (Matsuoka	et	 al.,	 2007).	 Phosphorylation	 can	 thereby	














phosphorylate	 histone	 H2AX	 on	 tyrosine	 T142	 independently	 from	 DNA	 damage.	While	






chromatin	 assembly	 of	MDC1	 and	 counteracting	 an	 apoptotic	 response	 driven	 by	 T142	
phosphorylation	(Cook	et	al.,	2009;	Krishnan	et	al.,	2009).	MDC1	then	provides	a	binding	
platform	 for	 several	 downstream	 DDR	 factors	 at	 DSBs	 (Stucki	 and	 Jackson,	 2006).	 The	

















in	 the	 accessibility	 of	 the	heterochromatin	and	enables	 the	 repair	 of	 the	damaged	DNA	
(Klement	et	al.,	2014).	















facilitates	 the	 binding	 of	 the	 ubiquitin	 carboxyl-terminus	 to	 a	 ε-amino	 group	 of	 a	 lysine	






















specificity	 is	determined	by	the	E3	 ligase,	 its	 interacting	partners	and	the	substrate	 itself	
(Mattiroli	and	Sixma,	2014).	Ubiquitin	can	be	conjugated	as	single	molecule	on	one	or	more	
lysine	residues	of	a	substrate	but	also	 in	chains	due	to	 the	presence	of	7	 lysine	residues	
(K6,	K11,	K27,	K29,	K33,	K48	and	K63)	within	the	ubiquitin	amino	acid	sequence	that	can	
undergo	 autoubiquitylation.	 Ubiquitin	 chains	 are	 named	 after	 the	 ubiquitylated	 lysine	
linking	 the	ubiquitin	molecules.	The	 regulatory	 role	of	ubiquitylation	differs	according	 to	
its	type	of	linkage:	monoubiquitylation	can	for	instance	affect	transcription	and	chromatin	
remodeling,	 while	 polyubiquitylation	 by	 means	 of	 K48-linked	 ubiquitin	 chain	 formation	
can	 target	 proteins	 for	 proteasomal	 degradation.	Moreover,	 K63-linked	 ubiquitin	 chains	
are	required	for	a	proper	response	to	DSBs	and	provide	a	binding	platform	for	several	DSB	
signaling	 proteins	when	 generated	 in	 the	 vicinity	 of	 these	 lesions	 (Panier	 and	Durocher,	
2009).	
	 At	 the	vicinity	of	DSBs	RNF8	binds	 to	phosphorylated	MDC1	via	 its	FHA	domain	
and	initiates	the	ubiquitin	signaling	cascade	(Huen	et	al.,	2007;	Kolas	et	al.,	2007;	Mailand	
et	 al.,	 2007)	 providing	 an	 important	 link	 between	 the	 two	 PTMs.	 Together	 with	 the	 E2	
enzyme	UBC13,	RNF8	creates	K63-linked	ubiquitin	chains	on	histone	H1	within	DSB-flanking	
chromatin	(Fig.	1)	(Doil	et	al.,	2009;	Pinato	et	al.,	2011;	Stewart	et	al.,	2009;	Thorslund	et	
al.,	 2015).	 Furthermore,	RNF8	also	 attracts	 the	polycomb	protein	BMI1,	which	has	been	
shown	 to	monoubiquitylate	H2A	and	H2AX	at	K119	and	K120	 in	 cooperation	with	other	
components	of	 the	polycomb	 repressive	 complex	1	 (PRC1)	 like	E3	 ligase	RNF2	 (Facchino	
et	 al.,	 2010;	 Ginjala	 et	 al.,	 2011;	 Ismail	 et	 al.,	 2010;	 Pan	 et	 al.,	 2011;	Wu	 et	 al.,	 2011).	




















the	 amount	 of	 BRCA1-CtIP	 and	BRCA1-PALB2	 complex	 formation	 and	 consequently	DNA	
end-resection	and	BRCA2-RAD51	 loading	at	DSBs,	 respectively	 (Coleman	and	Greenberg,	
2011;	Hu	et	al.,	2011;	Typas	et	al.,	2015).	
	 Besides	RAP80,	also	53BP1,	RNF168	and	RNF169	 interact	directly	with	K27-	and	
K63-linked	 ubiquitin	 (Gatti	 et	 al.,	 2015).	 RNF169	 thereby	 is	 an	 RNF168-related	 ubiquitin	
1
21
ligase	 that	provides	an	 interesting	example	 for	negative	 regulation	of	 the	DDR	by	simply	





HERC2	 interacts	with	 RNF8	 in	 a	manner	 dependent	 on	 its	 phosphorylation	 at	 threonine	
Thr4827	 (Bekker-Jensen	 et	 al.,	 2010).	 Moreover,	 the	 RNF8-dependent	 SUMOylation	






	 Besides	H2A,	also	H2B	has	been	reported	to	be	a	 target	 for	monoubiquitylation	
when	DNA	damage	 is	 induced.	H2B	ubiquitylation	 is	 facilitated	by	the	E3	ubiquitin	 ligase	
RNF20-RNF40,	which	 form	a	heterodimer.	 This	 E3	 ligase	 is	 recruited	 to	DSBs	upon	ATM-
dependent	phosphorylation	and	 is	 important	for	the	timely	repair	of	DSBs.	Furthermore,	
RNF20	has	been	shown	to	promote	the	accumulation	of	NHEJ	as	well	as	HR	repair	factors	
and,	 interestingly,	 also	 the	 accrual	 of	 chromatin	 remodeler	 SMARCA5/SNF2h	 which	
facilitates	repair	(discussed	below)	(Moyal	et	al.,	2011;	Nakamura	et	al.,	2011).
	 The	tight	control	of	the	ubiquitylation	cascade	by	ubiquitin	ligases	and	the	indirect	
contribution	 of	 chromatin	 remodeling	 enzymes	 entails	 yet	 another	 important	 level	 of	
regulation	that	is	mediated	by	the	group	of	deubiquitylating	enzymes,	shortly	termed	DUBs.	
Five	distinct	 families	 subdivide	 approximately	90	potential	DUBs	encoded	by	 the	human	
genome:	 ovarian	 tumor	 proteases	 (OTUs),	 ubiquitin-specific	 proteases	 (USPs),	 ubiquitin	
carboxy-terminal	hydrolases	(UCHs),	Machado-Joseph	disease	enzymes	(MJDs)	and	JAB1/
MPN/MOV34	metalloenzymes	(JAMMs).	OTUB1	binds	directly	to	and	inhibits	the	E2	enzyme	







Both	DUBs	 actively	 degrade	 RNF168-induced	 ubiquitin	 conjugates	 at	 DSBs,	which	 averts	






chromatin	 remodeling	 and	 DNA	 repair	 (Flotho	 and	Melchior,	 2013;	 Hickey	 et	 al.,	 2012;	



























	 Three	 different	 SUMO	modifiers	 can	 be	 distinguished	 in	 human	 cells:	 SUMO-1,	









	 SUMO	 can	 be	 bound	 by	 SUMO-interacting	motifs	 (SIMs),	 which	 are	 formed	 by	
a	stretch	of	hydrophobic	amino	acids,	or	a	specific	ZZ	zinc	finger	 (Danielsen	et	al.,	2012;	
Song	 et	 al.,	 2004;	 Vertegaal,	 2010).	 Like	 all	 PTMs,	 SUMOylation	 is	 reversible	 and	 SUMO	
conjugates	 can	 be	 removed	 form	 target	 proteins	 by	 SUMO-specific	 proteases	 (Li	 et	 al.,	
2010b;	Mukhopadhyay	and	Dasso,	2007)	thus	providing	a	dynamic	response	mechanism	for	
cells	to	react	on	external	and	internal	conditions	and	stimuli.	
	 SUMOylation	 has	 been	 implicated	 in	 the	 response	 to	 different	 types	 of	 DNA	
damage	 (Bergink	 and	 Jentsch,	 2009).	 All	 components	 of	 the	 3-step	 SUMO	 conjugation	




of	DSB	 induced	by	 laser	 radiation(Galanty	 et	 al.,	 2009).	Moreover,	 the	 PIAS4-dependent	
recruitment	 of	 RNF168	 and	 the	 abrogated	 ubiquitin	 conjugate	 formation	 in	 PIAS1-	 and	
PIAS4-depleted	cells	indicate	substantial	cross-talk	between	the	ubiquitin	cascade	and	the	
SUMOylation-mediated	 response	 to	DSBs	 (Galanty	et	 al.,	 2009;	Morris	 et	 al.,	 2009).	 The	
underlying	mechanism	 is	 thought	 to	 involve	the	PIAS4-mediated	SUMOylation	of	HERC2,	
which	promotes	RNF8-UBC13	binding	and	K63-linked	ubiquitin	chain	formation,	of	which	
the	 latter	 is	 required	 for	RNF168	accrual.	However,	RNF168	 itself	 is	 also	SUMOylated	by	

























	 SUMO	has	 also	 been	 implicated	 in	DSB	 repair	 by	 regulating	 the	 disassembly	 of	
repair	complexes	at	sites	of	DNA	damage.	The	recruitment	of	the	SUMO-targeted	ubiquitin	
E3	 ligase	 (StUbL)	 RNF4	 relies	 on	 its	 SIM	domains,	 PIAS1	 and	PIAS4	 as	well	 as	 a	 number	





































































of	 a	 target	 lysine	 of	 a	 protein.	 This	 modification	 is	 catalysed	 onto	 histones	 by	 histone	
acetyltransferases	 (HATs)	 and	 removed	 by	 histone	 deacetylases	 (HDACs).	 Through	 the	
neutralization	 of	 the	 positive	 charge	 of	 lysine	 residues,	 acetylation	 can	 weaken	 the	





studied	 example	 is	 the	HAT	 TIP60	 that	 is	 probably	 recruited	 as	 part	 of	 the	Nucleosome	
acetyltransferase	of	H4	(NuA4)	complex.	The	recruitment	of	this	complex	is	not	sufficient	
to	trigger	its	activation	as	only	the	local	transient	release	of	the	heterochromatin	1	protein	








H4K16ac	mark	mediates	 the	 effective	 accrual	 of	 the	 DSB	 repair	 proteins	MDC1,	 53BP1,	
BRCA1	and	RAD51	and	promotes	efficient	HR	(Doyon	and	Cote,	2004;	Murr	et	al.,	2006).	
	 In	addition	 to	HR,	histone	acetylation	also	plays	an	 important	 role	during	NHEJ.	
The	recruitment	of	CBP	and	p300	to	DSBs	induces	the	acetylation	of	a	number	of	H3	(K18)	








HMGN1.	 Depletion	 of	 HMGN1	 resulted	 in	 decreased	 ATM-autophosphorylation	 upon	
2012).	 RNF4	 promotes	 the	 efficient	 assembly	 of	 ubiquitin	 conjugates	 at	 DSBs	 and	 that	






	 In	 conclusion,	 DNA	 damage	 triggers	 a	 SUMOylation	 wave	 that	 leads	 to	 the	
modification	of	various	DSB	repair	proteins.	 It	 recently	has	been	proposed,	that	only	the	











MOF	 (or	MYST1)	 is	 the	major	 HAT	 that	 catalyses	 H4K16	 acetylation	 and	 its	 loss	 causes	
reduced	H4K16ac	levels	and	defects	in	IR-induced	DSB	signaling	and	repair	(Li	et	al.,	2010a;	
Sharma	et	al.,	2010).	In	more	detail,	MOF	depletion	does	not	affect	γH2AX	formation,	but	



















SET	 domain	 and	 can	 either	 mono-,	 di-	 or	 tri-methylate	 histones.	 Proteins	 harbouring	 a	
chromo	or	a	tudor	domain	are	able	to	bind	to	these	methyl	moieties.	Similar	to	other	PTMs,	
histone	methylation	is	a	reversible	process	due	to	the	activity	of	histone	demethylases.	
	 Condensed	 chromatin	 displays	 high	 levels	 of	 H3K9	 trimethylation	 (H3K9me3)	
rendering	the	DNA	inaccessible	for	repair	proteins	and	transcriptionally	inactive.	The	histone	
methyltransferase	SUV39H	establishes	the	H3K9me3	mark,	to	which	HP1	directly	binds	(via	
its	 chromodomains)	and	contributes	 to	 the	maintenance	of	heterochromatin	 (Cheutin	et	









































	 Alternatively,	 it	 has	 been	 suggested	 that	 53BP1	 assembles	 onto	 H4K20me2	
established	 in	 a	DNA	damage-independent	 fashion,	 since	H4K20me2	 is	 a	 very	 abundant	
histone	mark.	This	would	argue	against	the	involvement	of	these	methyltransferases	within	
the	 DSB	 response	 and	 proposes	 that	 H4K20me2	 could	 rather	 represent	 an	 additional	











H3K36,	which	 is	 generated	 upon	DSB	 induction	 by	 the	methyltransferase	Metnase	 (also	





to	 a	 target	 is	 termed	 PARylation	 for	 Poly(ADP-ribose)ylation.	 These	 polymers	 can	 be	
conjugated	 onto	 a	 glutamate,	 aspartate	 or	 lysine	 residue	 of	 an	 acceptor	 protein.	 PAR	 is	
catalysed	by	poly(ADP-ribose)	polymerases	(PARPs)	that	belong	to	a	17	members	counting	
PARP	 superfamily,	which	 is	 further	 divided	 into	 four	 groups	 dependent	 on	 their	 domain	
architecture.	One	 subfamily	 is	 formed	by	 the	DNA-dependent	 PARPs:	 PARP1,	 PARP2	and	
PARP3	 (Schreiber	 et	 al.,	 2006).	 These	 PARPs	 form	 the	most	 relevant	 group	 for	 the	work	
presented	in	this	thesis	as	they	have	been	implicated	in	the	DDR	(Pines	et	al.,	2013).	PAR-
chain	 synthesis	 is	mediated	 by	 PARP,	 but	 PAR-chains	 have	 a	 short	 turnover	 time	 due	 to	
their	 rapid	 degradation	 by	 poly(ADP-ribose)	 glycohydrolase	 (PARG).	 PARG	 functions	 in	 a	
1
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to	 the	 rapid	 recruitment	 of	 PAR-binding	 proteins	 to	 DNA	 lesions.	 Interestingly,	 H4K16ac	
inhibits	H4K16	PARylation	by	PARP1	and	thus	provides	another	indication	for	the	existence	
of	 functional	 crosstalk	 between	 the	 different	 histone	 tail	 modifications	 (Messner	 et	 al.,	








chaperone	 APLF,	 which	 incorporates	 the	 histone	 variant	 MacroH2A1.1	 at	 sites	 of	 DNA	
damage	(Mehrotra	et	al.,	2011).	Both	macroH2A1.1	and	APLF	bind	to	PAR-chains	through	a	
macrodomain	and	PAR-binding	zinc	finger	domain,	respectively	(Ahel	et	al.,	2008;	Timinszky	




	 The	 chromodomain	 helicase	 DNA-binding	 protein	 CHD4	 is	 the	 ATPase	 subunit	
of	the	NuRD	complex	and	its	recruitment	to	DNA	damage	has	been	shown	to	be	partially	
dependent	on	PARP.	Remarkably,	CHD4	 can	bind	 to	PAR	 in	 vitro,	despite	 the	 lack	of	 any	
known	PAR-binding	 consensus	 sites	or	PAR	binding	domains	 (Polo	et	 al.,	 2010).	Another	
example	 is	 the	 chromatin	 remodeler	 SMARCA5	 (or	 SNF2h),	 which	 is	 also	 recruited	 in	
a	 partially	 PARP-dependent	 manner.	 Upon	 DSB-induction,	 RNF168	 gets	 PARylated	 and	
interacts	with	SMARCA5	 in	a	PAR-dependent	 fashion,	contributing	to	 its	accrual	 to	DSBs.	
On	 the	other	hand,	 SMARCA5	 supports	RNF168	 recruitment	 to	DSBs,	 thereby	 regulating	
the	 RNF168-driven	 ubiquitin	 cascade	 (Smeenk	 et	 al.,	 2013).	 Hence,	 the	 distribution	 of	






























PTM crosstalk shapes epigenetic environment of DSBs
From	the	previous	sections	on	PTMs	one	might	start	wondering,	why	there	are	so	many	
different	PTMs	and	how	 they	 relate	 to	each	other	during	 the	 response	 to	DNA	damage.	
PTMs	 alter	 protein	 interactions	 and	 influence	 their	 translocation	 or	 degradation	 and	
therefore	provide	opportunities	to	regulate	and	control	the	activities	of	distinct	proteins	like	
those	involved	in	the	DDR.	Since	there	are	several	different	PTMs	that	can	influence	protein	
















described	 in	 yeast,	 the	 sucrose	 nonfermenting	 (SNF2)	 family	 of	 chromatin	 remodelers	
comprises	 an	 ATPase	 catalytical	 subunit	 as	 well	 as	 a	 helicase	 domain.	 The	 SNF2	 family	
members	 are	 further	 categorized	 into	 four	 subgroups,	 each	 group	 containing	 different	
additional	 functional	 domains	 (Fig.	 7),	 which	will	 be	 addressed	 per	 group	 below.	 These	
ATPases	often	form	the	catalytic	subunit	of	multi-subunit	complexes,	in	which	they	assemble	



















	 SWI/SNF	 has	 been	 implicated	 in	 the	 DSB	 response:	 a	 positive	 feedback	 loop	
has	 been	 described	 for	 γH2AX	 formation	 at	 DSBs,	 constituting	 the	 rapid	 and	 transient	
phosphorylation	of	BRG1	on	Ser-721	by	activated	ATM.	This	stimulates	the	binding	of	BRG1	
through	 its	 bromodomain	 to	 acetylated	 H3	 in	 chromatin	 comprising	 γH2AX-containing	
nucleosomes	and	the	phosphorylation	of	H2AX	by	ATM	through	the	remodeling	activity	of	












































































































	 The	nucleosome	 remodeler	CHD3	possess	 a	 small	 SIM	domain,	which	mediates	
its	binding	to	SUMOylated	KAP1	within	undamaged	heterochromatin.	Upon	DSB	induction,	
however,	 KAP1	 becomes	 phosphorylated	 by	 ATM	 and	 this	 modification	 interferes	 with	
the	SIM-SUMO	interaction	between	CHD3	and	KAP1.	This	results	in	the	dispersal	of	CHD3	
from	 heterochromatin	 surrounding	 DSBs,	 local	 chromatin	 relaxation	 and	 subsequently	










	 The	 chromatin	 remodeler	 ALC1,	 often	 referred	 to	 as	 Chromodomain	 Helicase	
DNA	binding	protein	1	like	(CHD1L),	is	related	to	the	CHD	family,	but	contains	a	C-terminal	





















































The	 yeast	 Snf2-related	 chromatin	 remodeler	 FUN30	 forms	 a	 homodimer	 in	 cells	 and	
its	 ATPase	 activity	 is	 stimulated	by	 the	 presence	of	DNA	 (Awad	 et	 al.,	 2010).	 Fun30	has	









As	 described	 in	 the	 previous	 paragraphs,	 the	 DNA	 damage-mediated	 posttranslational	
modifications	of	chromatin	and	chromatin-associated	proteins	are	crucial	for	the	efficient	









on	 the	organismal	 level	 their	 loss	 can	cause	embryonic	 lethality,	neurodegeneration	and	






over	 the	 last	 decades,	 novel	 factors,	 which	 often	 include	 chromatin	 modifiers,	 are	 still	













display	a	 typical	 facial	 appearance,	 growth	 retardation,	microcephaly,	 immunodeficiency,	




(Staples	 et	 al.,	 2008).	 The	 phenotypic	 manifestation	 varies	 in	 severity	 with	 the	 type	 of	
mutation	and	 accordingly	with	 the	 residual	 amount	of	 functional	ATM	kinase	present	 in	
cells	(Verhagen	et	al.,	2012).	Finally,	mutations	in	the	E3	ubiquitin	ligase	RNF168	involved	in	
the	ubiquitin-dependent	signaling	of	DSBs	can	give	rise	to	a	human	disease.	Patients	with	
either	homozygous	or	 compound	heterozygous	mutations	 in	RNF168	suffer	 from	RIDDLE	
syndrome	 and	 display	 immunodeficiency,	 radiosensitivity,	 learning	 difficulties,	 as	well	 as	
dysmorphic	features	(Devgan	et	al.,	2011;	Stewart	et	al.,	2009).	




induced	DNA	breaks.	 The	first	 patient	with	 classical	 severe	 combined	 immunodeficiency	
(SCID),	comprising	defective	precursor	B-cell	development	and	IR	sensitivity,	was	described	
in	2009	(van	der	Burg	et	al.,	2009).	Mutations	in	Artemis	and	members	of	the	LIG4-XRCC4-










































In	 the	 last	 few	 decades	 scientists	 tried	 to	 gain	more	 detailed	 knowledge	 on	 the	 events	
taking	place	during	the	DDR	with	the	purpose	to	better	diagnose	and	subsequently	develop	
treatments	for	DDR	-associated	diseases.	To	improve	the	current	treatment	opportunities	
of	 for	 instance	 cancer,	mechanistic	 insights	 in	 the	organization	of	 the	DDR	are	exploited	
by	means	of	developing	small	molecule	inhibitors	for	targeted	cancer	therapies.	This	form	
of	 patient	 treatment	 is	 tailored	according	 to	 the	 genetic	 alterations	 in	 their	 tumor	 cells,	
which	often	have	defects	in	one	or	more	DDR	pathway(s).	Consequently,	the	tumor	cells	are	
increasingly	reliant	on	the	remaining	DDR	pathways	to	restore	damaged	DNA.	The	concept	








of	PARP	appeared	 to	have	clinical	 impact	on	 the	 treatment	of	 cancers	 lacking	 functional	
HR.	 The	 best	 studied	 example	 represents	 BRCA1/2-deficient	 (breast	 and	ovarian)	 cancer	
cells,	which	proved	highly	sensitive	to	PARP	 inhibitors.	The	current	view	 is	 that	 inhibitor-
inactivated	PARP	becomes	trapped	at	single-strand	DNA	breaks,	which	are	converted	into	
deleterious	DSBs	upon	DNA	replication.	Repair	of	these	DSBs	normally	requires	HR	(Helleday,	





for	 BRCA1/2-deficient	 cancer	 patients	 (Feng	 et	 al.,	 2015)	 and	 this	 inhibitor	was	 recently	
approved	for	clinical	use.	
	 Promising	 candidates	 for	 this	 PARP-dependent	 synthetic	 lethality	 approach	

















to	 PARP	 inhibition.	 Interestingly,	 numerous	 cancer	 cell	 lines	with	 decreased	or	 excessive	
expression	of	one	of	these	DUBs	exist	as	published	in	the	COSMIC	database.	As	such,	these	
tumors	may	display	defects	in	HR	and	sensitivity	towards	PARP	inhibitors.	However,	since	
USP37	 depletion	 only	 results	 in	 moderate	 PARP	 sensitivity	 (Typas	 et	 al.,	 2015)	 patient	
benefits	could	be	modest	with	regard	to	tumor	cell	death.	 In	this	respect	 it	 is	 interesting	
to	note	 that	USP26-deficient	cells	are	almost	as	 sensitive	 to	PARP	 inhibitor	 treatment	as	
BRCA1/2-deficient	cells	(Typas	et	al.,	2015),	suggesting	that	targeting	USP26-defects	rather	
than	USP37-defects	by	using	PARP	inhibitor	treatment	may	be	a	more	promising	strategy.		
	 Remarkably,	 also	 aberrant	 levels	 of	 epigenetic	 chromatin	 modifications	 have	
been	 linked	 to	 the	 development	 and	 maintenance	 of	 cancer.	 These	 (primarily	 histone)	
modifications	 can	 determine	 phenotypic	 characteristics	 of	 diseases	 in	 a	 manner	 that	 is	
independent	of	the	patient’s	genotype.	The	reversible	nature	of	such	epigenetic	alterations	













of	 histones	 and	 non-histone	 proteins	 are	 maintained,	 which	 promote	 transcriptionally	
active	DNA.	The	latter	can	lead	to	the	restoration	of	gene	expression	of	silenced	genes	and	



























consequences	 of	 (the	 identified)	mutations	 in	 cancer	 cells.	 Since	 a	 significant	 portion	of	
such	mutations	have	been	found	in	histone	modifiers	and	chromatin	remodelers	involved	




remodeler	 causes	 complete	 loss	 of	 gene	 activity	 in	 tumor	 tissue	 remains	 questionable	
and	 requires	 further	 investigation.	 Eventually,	 this	 knowledge	 will	 contribute	 to	 our	
understanding	of	 the	DDR	and	could	explain	 the	cause	of	diseases	arising	 from	aberrant	



















Chapter 1	 comprises	 a	 general	 introduction	and	 reviews	 the	 current	 knowledge	on	DDR	
pathways,	in	particular	pathways	that	respond	to	DSBs	and	the	role	of	chromatin	modifying	
enzymes	therein.	In	Chapter 2,	I	introduce	the	set-up	of	a	siRNA-based	screening	approach	
that	 I	 used	 to	 identify	 novel	 chromatin	 regulators	 involved	 in	 the	 DSB	 response.	 This	
screen	 identified	 the	histone	methyltransferase	EHMT1	as	a	negative	 regulator	of	53BP1	
recruitment	to	sites	of	DNA	breaks	and	presents	the	first	evidence	for	a	role	in	DSB	repair	by	
HR	and	NHEJ.	Chapter 3	addresses	the	role	of	the	Remodeling	and	spacing	factor	1	(RSF1)	
during	DSB	 repair	 via	NHEJ.	 RSF1	deposits	 the	 centromeric	 proteins	 CENP-S	 and	CENP-X	
at	DSBs.	These	factors	subsequently	promote	the	recruitment	of	XRCC4	and	consequently	
efficient	NHEJ.	Additionally,	the	DNA	damage-dependent	SUMOylation	of	RSF1	is	presented	
in Chapter 4.	 The	 so	 far	obtained	data	 suggests	 that	 SUMOylated	RSF1	 regulates	XRCC4	
recruitment	 and	 possibly	 NHEJ.	 In	 Chapter 5	 I	 show	 that	 ZBTB24,	 which	 is	 mutated	 in	
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DNA	double-strand	 breaks	 (DSBs)	 occur	 on	 a	 daily	 basis	when	 both	 strands	 of	 the	DNA	
duplex	are	broken.	This	type	of	lesions	is	highly	toxic	to	cells	and	can	be	induced	by	various	
endogenous	 and	exogenous	 sources.	 If	 not	 repaired	 accurately,	DSBs	 can	 cause	 genome	
rearrangements	or	even	cell	death.	Cells	respond	to	DSBs	by	activating	a	complex	signaling	
network	 that	coordinates	 the	recruitment	of	 repair	proteins,	chromatin	organization	and	
cell	 cycle	progression	 in	order	 to	provide	time	 for	DNA	 repair	 in	a	permissive	 chromatin	
environment.	
	 Upon	 DSB	 induction,	 a	 series	 of	 chromatin	modifications	 are	 initiated	with	 the	
Ataxia	telangiectasia	mutated	(ATM)-dependent	phosphorylation	of	the	histone	H2A	variant	































Moreover,	 the	 structure	 and	 composition	 of	 chromatin	 can	 also	 be	 changed	 by	 ATP-
dependent	chromatin	remodeling	enzymes	such	as	the	ATPases	Chromodomain-helicase-
DNA-binding	 protein	 4	 (CHD4)	 and	 SWI/SNF-related	 matrix-associated	 actin-dependent	




























































factor	53BP1	 into	 ionizing	radiation	(IR)-induced	foci,	which	occurs	during	the	 later	steps	
of	 the	 response	 to	 DSBs.	 Genome-wide	 screens	with	 a	 comparable	 read-out	 have	 been	
performed	before	(Doil	et	al.,	2009;	Paulsen	et	al.,	2009),	however	so	far	did	not	lead	to	the	
identification	of	chromatin	modifiers.	Moreover,	such	screens	often	miss	hits	for	instance	




EHMT1	 knockdown	 cells.	 Interestingly,	we	 revealed	 that	 EHMT1	 is	 rapidly	 recruited	 and	
promotes	DSB	 repair	 via	 both	major	 pathways,	 non-homologous	 end-joining	 (NHEJ)	 and	




siRNA screen identifies novel chromatin regulators involved in the DSB response
In	order	to	identify	novel	chromatin	regulators	involved	in	the	response	to	DSBs,	we	carried	
out	 a	 siRNA	 screen	 using	 the	 Dhamacon	 Epigenetics	 SMARTpool	 library	 complemented	
with	 a	 custom	 made	 SMARTpool	 library	 comprising	 epigenetic	 modifiers	 containing	 a	
chromo-,	bromo-	or	SANT	domain,	as	well	as	SNF2-related	genes	(Table	S1A).	U2OS	cells	




foci/nucleus	was	determined	 in	duplicate	upon	knockdown	of	 all	 227	 targets.	 To	 control	
for	 siRNA	 transfection	 efficiency,	 we	 included	 a	 siRNA	 SMARTpool	 directed	 against	 the	
essential	 KIF11	 gene	 in	 each	 plate,	 whose	 knockdown	 induces	 cell	 killing	 by	 generating	
mitotic	spindle	catastrophes	(Weil	et	al.,	2002).	Indeed,	the	knockdown	of	KIF11	resulted	
in	a	~	90%	reduction	 in	cell	viability	 (Fig.	S1).	Further	controls	per	plate	 included	siRNAs	



























































































Exposure to 2 Gy of ionizing radiation
Fixation after 1 h
Immuno-co-staining with
γH2AX and 53BP1 
antibodies
3 days cultivation
High-throughput imaging and 
γH2AX and 53BP1 foci analysis 
Identification of chromatin regulators that affect 
















































































































































1 10 11 1298765432





Figure 1. RNAi screen identifies EHMT1 as a regulator of 53BP1 accumulation to DSBs. (A)	Schematic	of	siRNA	
screen	performed	to	identify	novel	chromatin	regulators	involved	in	the	DDR.	(B	and	C)	Scatter	plot	of	124	Z-scores	








































































siRNAs	 per	 target	within	 the	 same	 experimental	 set-up	 as	 described	 above	 (Fig.	 1A,D,E;	










EHMT1 regulates 53BP1 recruitment into foci 
To	define	whether	the	siRNA	screen	approach	 indeed	 identified	novel	 factors	 involved	 in	
the	 DDR,	 we	 focused	 on	 the	 histone-lysine	 N-methyltransferase	 1	 (EHMT1,	 also	 named	
GLP).	 EHMT1	 is	 a	 closely	 related	 paralog	 of	 EHMT2	 (also	 G9a),	 both	 being	mammalian	
lysine	 methyltransferases	 (KMTs)	 that	 mainly	 facilitate	 H3K9	 mono-	 and	 dimethylation	
(H3K9me1/2)	 in	 euchromatin	 as	 well	 as	 the	 methylation	 of	 non-histone	 substrates.	
Although	EHMT1	and	EHMT2	can	 form	homomeric	 complexes,	 they	predominantly	exist	




global	H3K9me1/2	 levels	 (Tachibana	et	al.,	2002;	Tachibana	et	al.,	2005).	 Importantly,	no	
additive	effect	was	measured	in	double	knockout	ES	cells,	 indicating	a	cooperative	rather	
















loss	 of	 function	mutations	 in	 the	 EHMT1	 gene	or	 submicroscopic	 deletions	 of	 the	 distal	
long	chromosome	arm	9q	lead	to	haploinsufficiency	of	EHMT1	causing	Kleefstra	syndrome	
(KS)	(previously	9q	subtelomeric	deletion	syndrome).	KS-patients	mainly	display	intellectual	
disability,	 childhood	hypotonia	 and	 characteristic	 facial	 anomalies	 (Kleefstra	 et	 al.,	 1993;	
Kleefstra	et	al.,	2012;	Nillesen	et	al.,	2011).	Finally,	EHMT1	as	well	as	EHMT2	have	been	
found	 to	 be	 overexpressed	 in	 various	 cancers	 (Guan	 et	 al.,	 2014;	 Huang	 et	 al.,	 2010).	
Concerning	these	phenotypes	and	the	detected	increase	in	53BP1	foci	formation	upon	IR	
exposure	in	our	siRNA	screen,	we	started	a	follow-up	study	addressing	the	role	of	EHMT1	
during	 the	 response	 to	 DSBs.	 First,	 we	 used	 two	 siRNAs	 against	 EHMT1	which	 reduced	
53BP1	focus	formation	in	the	deconvolution	screen	to	forwardly	transfect	U2OS	cells	on	18	
Figure 2. Depletion of EHMT1 leads to an increase in 53BP1 foci formation upon ionizing radiation (IR). (A)	U2OS	
cells	were	treated	with	the	indicated	siRNAs.	48	hours	later	cells	were	either	left	untreated	or	were	exposed	to	
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EHMT1 is rapidly recruited to DNA DSBs
Having	 identified	 EHMT1	 as	 a	 novel	 factor	 that	 controls	 53BP1	 recruitment	 during	 the	
DSB	 response,	we	wondered	whether	EHMT1	 itself	 is	 recruited	 to	 sites	of	DNA	damage.	
2
59
EHMT1 promotes DSB repair via Non-homologous end joining (NHEJ) and Homologous 
Recombination (HR)
In	mammals,	two	major	pathways	have	evolved	to	repair	DSBs.	The	main	pathway	is	called	
Non-homologous	 end-joining	 (NHEJ)	 and	 simply	 re-ligates	 the	 broken	 DNA	 ends	 back	





use	 of	 two	well-established	 reporter	 assays	 to	monitor	 DSB	 repair	 efficiency	 in	 EHMT1-
depleted	Hek293T	cells.	The	EJ5-GFP	NHEJ	reporter	consists	of	a	GFP	gene,	which	is	parted	
from	its	promoter	due	to	an	insertion	of	a	Puromycine	gene	that	 is	flanked	by	two	I-SceI	











et	 al.,	 2006).	 As	 expected,	 depletion	 of	 RNF8	 and	 BRCA2	 lead	 to	 a	 severe	 reduction	 in	
NHEJ	and	HR	efficiency,	respectively	(Hu	et	al.,	2014;	Roy	et	al.,	2012).	Surprisingly,	upon	




Therefore,	 we	 locally	 introduced	 DNA	 damage	with	 a	Multi-photon	 (MP)	 laser	 in	 U2OS	
cells	 transiently	expressing	GFP-tagged	mouse	EHMT1	 (Ehmt1),	 since	mouse	and	human	





U2OS	 2-6-3	 cells	 to	 study	whether	 EHMT1	 is	 recruited	 to	 site-specific	DSBs.	 Those	 cells	
contain	an	array	of	lactose	operator	(LacO)	repeats	and	express	instable	FokI	nuclease	fused	


























































































































































































































state	 in	 the	 vicinity	 of	 DSBs	 to	 promote	 their	 signaling	 and	 repair	 as	 part	 of	 the	 DSB	







siRNA Screen for novel chromatin regulators




candidate	 to	 screen	 for,	 as	 several	 distinct	 chromatin	modifications	 are	 required	 for	 and	
contribute	to	its	accrual	at	DSBs.	
	 We	obtained	a	 long	 list	 of	 possible	 chromatin	 regulators	 affecting	either	γH2AX	
and/or	53BP1	accrual	to	IR-induced	foci	from	the	primary	screen.	Among	those	hits,	known	
regulators of γH2AX	were	 found	 such	 as	 BAZ1B	 (WSTF),	 which	 is	 involved	 in	 the	 global	
phosphorylation	of	H2AX	on	Y142	 (Xiao	et	 al.,	 2009),	 a	mark	 that	needs	 to	be	 removed	
upon	 damage	 induction	 for	 proper	MDC1-binding	 to	 γH2AX	 at	 S139	 (Cook	 et	 al.,	 2009;	













study.	 Its	 regulatory	effect	on	53BP1	accrual	 to	DSBs	was	 successfully	 validated	during	a	
second	IR-induced	foci	experiment,	where	another	format	and	different	siRNA	transfection	
method	was	 used	 (Fig.	 2A,B).	 This	 thus	 shows	 the	 ability	 of	 our	 screening	 approach	 to	
identify	 novel	 factors	 involved	 in	 the	 DSB	 response.	 However,	 potential	 hits	 might	 also	



































































as	 selection	 criteria,	 which	 led	 to	 the	 confirmation	 of	 EHMT1	 as	 a	 hit,	 but	 excluded	 its	
related	heterodimer-partner	 EHMT2	 from	 the	hit	 list	 (Table	1B)	 (Tachibana	et	 al.,	 2005).	
Interestingly,	EHMT2	would	have	been	a	hit	under	the	threshold	of	1x	the	standard	deviation	







EHMT1 recruitment to DSBs
Although	EHMT1	was	 identified	as	a	negative	regulator	of	53BP1	accrual	 into	 IR-induced	
foci,	we	 found	 that	γH2AX	 formation	 remained	unaffected	 in	 EHMT1-depleted	 cells	 (Fig.	




into	the	numerous	events	of	 the	DDR,	 the	recruitment	of	other	 important	DSB	response	
factors	such	as	MDC1,	RNF8	or	RNF168	to	 IR-induced	 foci	or	 laser-induced	DNA	damage	
should	be	monitored	in	the	absence	of	EHMT1.	Moreover,	the	recruitment	of	several	DSB	
response	factors	is	highly	dependent	on	the	phosphorylation	activity	of	ATM	on	serine	(S)	




of	 poly(ADP-ribose)	 polymerase	 1	 (PARP1),	which	 attaches	 poly(ADP-ribose)	 chains	 onto	
itself	 and	 other	 target	 proteins	 upon	 DSB	 induction	 (Bekker-Jensen	 and	Mailand,	 2010;	
Smeenk	et	al.,	2013).	Since	the	recruitment	of	the	histone	tri-methylase	SUV39H	was	found	
to	be	PARP-dependent	(Ayrapetov	et	al.,	2014),	 it	would	be	 interesting	to	 investigate	the	
contribution	of	PARP	to	EHMT1	recruitment	in	cells	depleted	from	PARP	or	treated	with	an	
PARP	inhibitor.		 	




generally	 described	 to	mono-	 and	 dimethylate	 H3K9	within	 euchromatin,	 together	with	
EHMT2	(Tachibana	et	al.,	2005).	Since	di-	and	trimethylation	of	H3K9	was	shown	to	locally	
increase	upon	DSB	 induction	 (Ayrapetov	et	al.,	2014;	Khurana	et	al.,	2014),	 the	question	
arises	 whether	 EHMT1/2	 contribute	 to	 establish	 H3K9me2	 at	 DSBs.	 For	 the	 binding	 of	
oligomerized	53BP1	at	DSBs,	RNF168-ubiquitylated	H2AK15	(Fradet-Turcotte	et	al.,	2013)	
















	 To	 investigate	 this	 hypothesis	 experimentally,	 one	 could	 use	 ChIP	 to	 examine	
whether	a	 local	decrease	 in	H3K9	methylation	 levels	at	DSBs	can	be	detected	 in	EHMT1-





and	EHMT2	was	 found	 to	 form	a	multimeric	 complex	with	 SUV39H	and	 the	histone	di-/
trimethyltransferase	 SETDB1	 (Fritsch	et	 al.,	 2010),	 the	 combined	action	of	 these	histone	











































































Potential consequences of EHMT1 overexpression
Where	 the	 depletion	 of	 EHMT1	 leads	 to	 an	 increase	 in	 53BP1	 recruitment	 to	 DSBs,	
its	 overexpression	 might	 actively	 abrogate	 the	 response	 to	 DSBs	 by	 promoting	 H3K9	




for	 at	 least	 1	 h	 at	 the	 site	 of	 DNA	 damage	 (Fig.	 3A).	 Interestingly,	 upon	 a	more	 closely	




reflecting	the	extent	 to	which	 factors	spread	 into	the	damaged	chromatin	compartment,	
should	be	determined	 in	time	after	DNA	damage	 induction	by	 laser	micro-irradiation	 for	
EHMT1	and	53BP1.	If	this	theory	holds,	53BP1	accrual	would	be	clearly	decreased	and	less	
expanded	upon	excessive	EHMT1	expression.	Additional	research	however	needs	to	point	
out whether that is the case.
























cells	 treated	 without	 or	 with	 an	 inhibitor	 for	 EHMT1/EHMT2	 (UNC0638).	 Interestingly,	
amongst	others	the	DNA	repair	factors	DNA	ligase	1	(LIG1),	DNA-dependent	protein	kinase	
catalytic	subunit	(DNA-PKcs)	and	the	chromatin	remodeler	SMARCA5	have	been	identified	
as	methylation-candidate	 targets	 of	 EHMT1/EHMT2	 (Moore	 et	 al.,	 2013).	 Future	 studies	
need	to	reveal	the	role	of	EHMT1/EHMT2-dependent	methylation	of	these	factors	during	
the	 response	 to	DSBs.	However,	 there	 is	 also	a	possibility	 that	EHMT1	might	exert	a	 yet	





















EHMT1 involved in intellectual disability syndrome and cancer






































































HEK293T	 cells	 were	 grown	 in	 DMEM	 (Gibco)	 containing	 10%	 FCS	 (Bodinco	 BV)	 and	 1%	









transfection	 reagent	 (QIAGEN)	 to	 each	 well	 according	 to	manufacturer	 instructions	 and	
secondly	U2OS	cells	in	DMEM	(Gibco)	containing	10%	FCS	(Bodinco	BV).	Cells	were	cultivated	















	 	 	 µ	-	mean	of	Luc	per	plate,	






Transfections and RNAi interference
siRNA	and	plasmid	transfections	were	performed	using	Lipofectamine	RNAiMAX	(Invitrogen)	















1.1	Gy/min).	 In	U2OS	263	cells,	DSBs	were	 induced	 throughout	 the	addition	of	Shield	 [1	
µM]	(Clontech)	and	4-Hydroxytamoxifen	[300	nM]	to	the	growth	media	(Guan	et	al.,	2014;	
Shanbhag	et	al.,	2010)	to	induce	nuclear	expression	of	the	mCherry-LacR-FokI	fusion	that	










































































































EHMT1	 (1:500,	 #B0422,	 R&D	 Systems),	 α-Tubulin	 (1:1000,	 #T6199	 clone	 DM1A,	 Sigma),	
Histone	H3K9me2	(1:500,	#1220,	Abcam)	and	Histone	H3	(1:1000,	#1791,	Abcam).	
Homologous	recombination	and	Non-homologous	end-joining	repair	assay	
HEK293	cell	 lines	containing	a	stably	 integrated	copy	of	 the	DR-GFP	or	EJ5-GFP	reporter,	
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Figure S1. Knockdown efficiency confirmed with KIF11 knockdown.	U2OS	cells	were	reversely	transfected	with	
the	indicated	siRNAs	and	fixed	after	3	days	of	cultivation.	DNA	was	stained	with	DAPI	to	indicate	cell	nuclei,	images	
were	taken	and	the	percentage	of	surviving	cells	in	control	and	siKIF11	treated	cells	was	estimated	to	10%.
Figure S2. RNAi validation screen for novel regulators of γH2AX and 53BP1.	 Presented	 are	 the	 results	 from	
secondary	validation	screen,	where	four	individual	siRNAs	per	target	were	used	to	validate	another	36	hits	from	
primary	screen	(see	first	12	hits	in	Fig.	1.	D	and	E).	Shown	is	the	average	number	of	γH2AX	(A,C	and	E)	and	53BP1	









































































































































































































































































































































































































































































EHMT1_human MAAAD-AEAVPARGEPQQDCCVKTELLGEETPMAADEGSAEKQAGEAHMAADGETNGSCE 59 
Ehmt1_mouse MAAADAEQAVLAKQETKQDCCMKTELLREDTPMAADEGSTEKQEGETPMAADGETNGSCE 60 
            *****  :** *: * :****:***** *:*********:*** **: ************ 
 
EHMT1_human NSDASSHANAAKHTQDSARVNPQDGTNTLTRIAENGVSERDSEAAKQNHVTADDFVQTSV 119 
Ehmt1_mouse KSGDPSHLNAPKHTQENTRASPQEGTNRVSRVAENGVSERDTEVGKQNHVTADDFMQTSV 120 
            :*   ** ** ****:.:*..**:*** ::*:*********:*..**********:**** 
 
EHMT1_human IGSNGYILNKPALQAQPLRTTSTLASSLPGHAAKTLPGGAGKGRTPSAFPQTPAAPPATL 179 
Ehmt1_mouse IGSNGYFLNKPALQGQPLRTPNILTSSLPGHAAKTLPGGASKCRTLSALPQTPTTAPTVP 180 
            ******:*******.***** . *:***************.* ** **:****:: *:.  
 
EHMT1_human GEGSADTEDRKLPAPGADVKVHRARKTMPKSVVGLHAASKDPREVREARDHKEPKEEINK 239 
Ehmt1_mouse GEGSADTEDRKPTASGTDVRVHRARKTMPKSILGLHAASKDHREV---QDHKEPKEDINR 237 
            ***********  * *:**:***********::******** ***   :*******:**: 
 
EHMT1_human NISDFGRQQLLPPFPSLHQSLPQNQCYMATTKSQTACLPFVLAAAVSRKKKRRMGTYSLV 299 
Ehmt1_mouse NISECGRQQLLPTFPALHQSLPQNQCYMATTKSQTACLPFVLAAAVSRKKKRRMGTYSLV 297 
            ***: ******* **:******************************************** 
 
EHMT1_human PKKKTKVLKQRTVIEMFKSITHSTVGSKGEKDLGASSLHVNGESLEMDSDEDDSEELEED 359 
Ehmt1_mouse PKKKTKVLKQRTVIEMFKSITHSTVGAKGEKALDDSALHVNGESLEMDSEDEDSDELEDD 357 
            **************************:**** *  *:************:::**:***:* 
 
EHMT1_human DGHGAEQAAAFPTEDSRTSKESMSEADRAQKMDGESEEEQESVDTGEEEEGGDESDLSSE 419 
Ehmt1_mouse EDHGAEQAAAFPTEDSRTSKESMSETDRAAKMDGDSEEEQESPDTGEDEDGGDESDLSSE 417 
            : ***********************:*** ****:******* ****:*:********** 
 
EHMT1_human SSIKKKFLKRKGKTDSPWIKPARKRRRRSRKKPSGALGSESYKSSAGSAEQTAPGDSTGY 479 
Ehmt1_mouse SSIKKKFLKRRGKTDSPWIKPARKRRRRSRKKPSSMLGSEACKSSPGSMEQAALGDSAGY 477 
            **********:***********************. ****: *** ** **:* ***:** 
 
EHMT1_human MEVSLDSLDLRVKGILSSQA--EGLANGPDVLETDGLQEVPLCSCRMETPKSREITTLAN 537 
Ehmt1_mouse MEVSLDSLDLRVRGILSSQTENEGLASGPDVLGTDGLQEVPLCSCRMETPKSREISTLAN 537 
            ************:******:  ****.***** **********************:**** 
 
EHMT1_human NQCMATESVDHELGRCTNSVVKYELMRPSNKAPLLVLCEDHRGRMVKHQCCPGCGYFCTA 597 
Ehmt1_mouse NQCMATESVDHELGRCTNSVVKYELMRPSNKAPLLVLCEDHRGRMVKHQCCPGCGYFCTA 597 
            ************************************************************ 
 
EHMT1_human GNFMECQPESSISHRFHKDCASRVNNASYCPHCGEESSKAKEVTIAKADTTSTVTPVPGQ 657 
Ehmt1_mouse GNFMECQPESSISHRFHKDCASRVNNASYCPHCGEEASKAKEVTIAKADTTSTVTLAPGQ 657 
            ************************************:****************** .*** 
 
EHMT1_human EKGSALEGRADTTTGSAAGPPLSEDDKLQGAASHVPEGFDPTGPAGLGRPTPGLSQGPGK 717 
Ehmt1_mouse EKSLAAEGRADTTTGSIAGAPED--ERSQSTAPQAPECFDPAGPAGLVRPTSGLSQGPGK 715 
            **. * ********** ** * .  :: *.:* :.** ***:***** *** ******** 
 
EHMT1_human ETLESALIALDSEKPKKLRFHPKQLYFSARQGELQKVLLMLVDGIDPNFKMEHQNKRSPL 777 
Ehmt1_mouse ETLESALIALDSEKPKKLRFHPKQLYFSARQGELQKVLLMLVDGIDPNFKMEHQSKRSPL 775 
            ******************************************************.***** 
 
EHMT1_human HAAAEAGHVDICHMLVQAGANIDTCSEDQRTPLMEAAENNHLEAVKYLIKAGALVDPKDA 837 
Ehmt1_mouse HAAAEAGHVDICHMLVQAGANIDTCSEDQRTPLMEAAENNHLDAVKYLIKAGAQVDPKDA 835 
            ******************************************:********** ****** 
 
EHMT1_human EGSTCLHLAAKKGHYEVVQYLLSNGQMDVNCQDDGGWTPMIWATEYKHVDLVKLLLSKGS 897 
Ehmt1_mouse EGSTCLHLAAKKGHYDVVQYLLSNGQMDVNCQDDGGWTPMIWATEYKHVELVKLLLSKGS 895 
            ***************:*********************************:********** 
 
EHMT1_human DINIRDNEENICLHWAAFSGCVDIAEILLAAKCDLHAVNIHGDSPLHIAARENRYDCVVL 957 
Ehmt1_mouse DINIRDNEENICLHWAAFSGCVDIAEILLAAKCDLHAVNIHGDSPLHIAARENRYDCVVL 955 
            ************************************************************ 
 
EHMT1_human FLSRDSDVTLKNKEGETPLQCASLNSQVWSALQMSKALQDSAPDRPSPVERIVSRDIARG 1017 
Ehmt1_mouse FLSRDSDVTLKNKEGETPLQCASLSSQVWSALQMSKALRDSAPDKPVAVEKTVSRDIARG 1015 




Figure S3. EHMT1 protein sequence is quiet conserved between mouse and human. 
Entries	Q9H9B1	for	human	EHMT1	and	Q5DW34	for	mouse	Ehmt1	were	aligned	using	the	Uniprot	alignment	tool	
available	at	www.uniprot.org.	The	conserved	amino	acids	are	indicated	by	a	green	asterisk.
EHMT1_human YERIPIPCVNAVDSEPCPSNYKYVSQNCVTSPMNIDRNITHLQYCVCIDDCSSSNCMCGQ 1077 
Ehmt1_mouse YERIPIPCVNAVDSELCPTNYKYVSQNCVTSPMNIDRNITHLQYCVCVDDCSSSTCMCGQ 1075 
*************** **:****************************:******.***** 
EHMT1_human LSMRCWYDKDGRLLPEFNMAEPPLIFECNHACSCWRNCRNRVVQNGLRARLQLYRTRDMG 1137 
Ehmt1_mouse LSMRCWYDKDGRLLPEFNMAEPPLIFECNHACSCWRNCRNRVVQNGLRARLQLYRTQDMG 1135 
********************************************************:*** 
EHMT1_human WGVRSLQDIPPGTFVCEYVGELISDSEADVREEDSYLFDLDNKDGEVYCIDARFYGNVSR 1197 
Ehmt1_mouse WGVRSLQDIPLGTFVCEYVGELISDSEADVREEDSYLFDLDNKDGEVYCIDARFYGNVSR 1195 
********** ************************************************* 
EHMT1_human FINHHCEPNLVPVRVFMAHQDLRFPRIAFFSTRLIEAGEQLGFDYGERFWDIKGKLFSCR 1257 




























































Table S1. List of siRNA screen targets and results
A B
siRNA	 Gene Accession	 Z-score Z-score Average	nr.	of Average	nr.	of
nr. SMARTpools ID Number gH2AX	foci 53BP1	foci nr. single	siRNAs gH2AX	foci 53BP1	foci
1 AOF2 23028 NM_015013 -0,052 -0,616 1 ARID3A-1 34,709 33,431
2 ARID1A 8289 NM_006015 -0,307 1,159 ARID3A-2 35,872 32,983
3 ARID1B 57492 NM_017519 - - ARID3A-3 41,308 38,000
4 ARID2 196528 NM_152641 - - ARID3A-4 45,607 15,583
5 ARID3A 1820 NM_005224 2,348 4,968 2 ARID4B-1 40,113 33,527
6 ARID3B 10620 NM_006465 0,860 3,039 ARID4B-2 48,029 42,216
7 ARID4A 8841 NM_003883 - - ARID4B-3 34,248 31,498
8 ARID4B 51742 NM_016374 -12,181 -0,234 ARID4B-4 37,187 26,017
9 ARID5A 10865 NM_212481 0,649 0,171 3 ARID5B-1 41,248 33,742
10 ARID5B 84159 NM_032199 0,341 -4,214 ARID5B-2 45,036 32,307
11 ASH1L 55870 NM_018489 -2,329 6,283 ARID5B-3 47,079 35,690
12 ATAD2 29028 NM_014109 0,135 0,910 ARID5B-4 43,398 18,636
13 ATRX 546 NM_000489 0,517 0,647 4 ASH1L-1 29,857 34,797
14 BAHCC1 57597 XM_371084 - - ASH1L-2 28,510 28,637
15 BAF53A 86 NM_004301 0,638 -6,061 ASH1L-3 25,773 18,578
16 BAHD1 22893 NM_014952 -1,196 4,796 ASH1L-4 34,499 35,024
17 BAZ1A 11177 NM_013448 -0,145 8,129 5 BAF53A-1 37,320 27,618
18 BAZ1B 9031 NM_032408 -1,548 8,691 BAF53A-2 34,337 10,598
19 BAZ2A 11176 NM_013449 -0,425 9,938 BAF53A-3 41,310 28,172
20 BAZ2B 29994 NM_013450 0,356 0,221 BAF53A-4 37,566 27,899
21 BMI1 648 NM_005180 - - 6 BAHD1-1 39,551 23,547
22 BPTF 2186 NM_182641 - - BAHD1-2 34,254 31,420
23 BRD1 23774 NM_014577 - - BAHD1-3 29,322 29,740
24 BRD2 6046 NM_001113182 2,160 -4,732 BAHD1-4 27,907 27,183
25 BRD3 8019 NM_007371 -0,041 6,962 7 BAZ1A-1 44,008 37,954
26 BRD4 23476 NM_014299 - - BAZ1A-2 46,402 49,354
27 BRD7 29117 NM_013263 - - BAZ1A-3 37,175 36,031
28 BRD8 10902 NM_006696 -4,647 -5,215 BAZ1A-4 41,249 32,503
29 BRD9 65980 NM_023924 0,517 7,887 8 BAZ1B-1 48,752 46,985
30 BRDT 676 NM_207189 - - BAZ1B-2 43,338 32,860
31 BRPF1 7862 NM_001003694 0,712 5,265 BAZ1B-3 48,881 53,982
32 BRPF3 27154 NM_015695 0,139 -4,728 BAZ1B-4 49,071 32,026
33 BRWD1 54014 NM_033656 0,303 8,359 9 BAZ2A-1 43,911 37,987
34 BRWD3 254065 NM_153252 0,327 8,959 BAZ2A-2 46,865 39,910
35 BTG1 694 NM_00173 - - BAZ2A-3 48,140 41,062
36 BTG2 7832 NM_006763 0,315 -1,104 BAZ2A-4 38,701 36,868
37 BTG3 10950 NM_001130914 -0,293 -3,307 10 BRD2-1 42,750 20,686
38 BTG4 54766 NM_017589 0,064 -1,299 BRD2-2 34,069 23,351
39 CARM1 10498 NM_199141 0,681 1,614 BRD2-3 34,466 30,597
40 CBX1 10951 NM_006807 - - BRD2-4 38,406 17,000
41 CBX2 84733 NM_032647 -0,329 3,398 11 BRD9-1 43,541 38,397
42 CBX3 11335 NM_007276 0,883 3,916 BRD9-2 27,618 35,081
43 CBX4 8535 NM_003655 - - BRD9-3 30,567 25,157
44 CBX5 23468 NM_001127321 7,771 2,163 BRD9-4 28,137 27,653
45 CBX6 23466 NM_014292 0,407 6,409 12 BRPF1-1 19,121 10,885
46 CBX7 23492 NM_175709 1,191 9,059 BRPF1-2 30,179 30,455
47 CBX8 57332 NM_020649 - - BRPF1-3 37,980 35,169
48 CECR2 27443 NM_031413	 1,233 2,287 BRPF1-4 27,873 26,217
49 CHC1 1104 NM_001269 - - 13 BRWD1-1 47,821 37,626
50 CHAF1B 8208 NM_005441 1,492 2,167 BRWD1-2 49,041 43,083
51 CHD1 1105 NM_001270 0,085 8,161 BRWD1-3 46,082 42,087
52 CHD1L 9557 NM_004284 - - BRWD1-4 54,512 55,835
53 CHD2 1106 NM_001271 -0,232 7,103 14 BRWD3-1 37,748 35,885
54 CHD3 1107 NM_001005273 0,164 4,039 BRWD3-2 46,638 39,317
55 CHD5 26038 NM_015557 - - BRWD3-3 46,486 35,114
56 CHD6 84181 NM_032221 - - BRWD3-4 48,968 42,493
57 CHD7 55636 XM_098762 - - 15 CBX2-1 44,519 38,029
58 CHD8 57680 NM_020920 0,340 5,956 CBX2-2 44,928 20,631
59 CHD9 80205 NM_025134 1,430 10,656 CBX2-3 45,643 32,665
60 CREBBP 1387 NM_001079846 - - CBX2-4 39,741 24,657
61 DIAPH1 1729 NM_001079812 - - 16 CBX3-1 50,434 33,197
62 DIAPH2 1730 NM_006729 -23,710 -1,904 CBX3-2 43,752 30,588
63 DNAJC1 64215 NM_022365 - - CBX3-3 37,122 23,478
64 DNAJC2 27000 NM_001129887 -1,546 -1,509 CBX3-4 33,044 24,081
65 DNMT1 1786 NM_001379 -0,036 1,320 17 CBX5-1 48,271 38,292
66 DNMT2 1787 NM_004412 1,935 -1,001 CBX5-2 41,808 38,217
67 DNMT3B 1789 NM_006892 -2,630 0,894 CBX5-3 44,553 38,157
68 DNMT3L 29947 NM_013369 - - CBX5-4 50,795 47,493
69 DMAP1 55929 NM_019100 - - 18 CHAF1B-1 48,149 33,236
70 DOT1L 84444 NM_032482 -3,333 2,056 CHAF1B-2 50,627 31,618
71 EHMT1 79813 NM_024757 -0,352 4,070 CHAF1B-3 27,068 26,824
72 EHMT2 10919 NM_006709 0,580 3,274 CHAF1B-4 53,529 32,853
73 EID1 23741 NM_014335 - - 19 CHD2-1 38,172 30,544
74 EID2 163126 NM_153232 -0,710 0,280 CHD2-2 39,159 27,515
75 EID2B 126272 NM_152361 - - CHD2-3 41,335 35,504
76 EID3 49386 NM_001008394 - - CHD2-4 43,432 26,287
77 EP300 2033 NM_001429 - - 20 DIAPH2-1 64,573 49,936
78 EP400 57634 NM_015409 -1,165 -1,402 DIAPH2-2 40,234 34,614
79 EPC1 80314 NM_025209 0,499 1,839 DIAPH2-3 35,143 31,135
80 EPC2 26122 NM_015630 - - DIAPH2-4 34,391 35,518
81 ERCC6 2074 NM_000124 - - 21 EHMT1-1 45,574 45,122
82 ERCC6L 54821 NM_017669 0,243 0,914 EHMT1-2 48,704 46,033
83 ERCC6L2 375748 NM_001010895 0,847 1,765 EHMT1-3 46,625 43,122
84 EZH1 2145 NM_001991 - - EHMT1-4 44,315 32,989
85 EZH2 2146 NM_004456 0,378 2,211 22 EHMT2-1 39,674 37,355
86 GAS41 8089 NM_006530 -3,792 -1,997 EHMT2-2 37,511 32,100
87 H2AFZ 3015 NM_002106 0,145 -0,589 EHMT2-3 47,576 43,129
88 HDAC1 3065 NM_004964 - - EHMT2-4 41,884 36,700
89 HDAC2 3066 NM_001527 - - 23 EZH2-1 39,880 29,526
90 HDAC3 8841 NM_003883 -0,913 0,360 EZH2-2 46,136 40,425
91 HDAC4 9757 NM_006037 0,657 8,444 EZH2-3 48,924 27,246
92 HDAC5 10014 NM_001015053 - - EZH2-4 49,208 36,206
93 HDAC6 10013 NM_006044 0,390 4,665 24 HDAC11-1 31,271 29,743
94 HDAC7 51564 NM_001098416 - - HDAC11-2 29,731 25,594
95 HDAC8 55869 NM_018486 - - HDAC11-3 24,397 19,157
96 HDAC9 9734 NM_014707 - - HDAC11-4 26,088 22,879
97 HDAC10 83933 NM_032019 - - 25 HTLF-1 28,987 20,826
98 HDAC11 79885 NM_001136041 0,416 5,562 HTLF-2 29,363 28,703
99 HELLS 3070 NM_018063 0,669 1,859 HTLF-3 33,097 28,346
100 HLTF 6596 NM_003071 0,812 2,104 HTLF-4 28,550 29,955
101 HTATIP 10524 NM_006388 0,025 6,982 26 ING5-1 24,078 19,351
102 ING1 3621 NM_198217 0,664 0,888 ING5-2 34,031 27,771
103 ING2 3622 NM_001564	 - - ING5-3 30,486 29,216
104 ING3 54556 NM_019071 - - ING5-4 20,234 24,502
105 ING5 84289 NM_032329 0,238 2,097 27 JARID1C-1 25,482 29,813
106 JARID1A 5927 NM_001042603 - - JARID1C-2 27,112 25,785
107 JARID1B 10765 NM_006618 0,099 1,086 JARID1C-3 36,700 27,412
108 JARID1C 8242 NM_004187 1,144 6,477 JARID1C-4 29,350 27,726
109 JARID1D 8284 NM_004653 - - 28 JMJD2A-1 16,118 29,191
110 JARID2 3720 NM_004973 - - JMJD2A-2 31,051 34,878
111 JMJD1A 55818 NM_018433 -0,656 -1,535 JMJD2A-3 22,855 21,087
112 JMJD1B 51780 NM_016604 - - JMJD2A-4 38,854 16,947
Table S1. List of siRNA screen gene targets and results.	(A)	List	of	227	gene	targets	and	positive	(siLUC)	and	negative	
(siRNF8)	controls.	Indicated	are	gene	symbols,	Gene	IDs,	Accession	numbers	and	the	obtained	Z-scores	calculated	
from	 the	average	amount	of	γH2AX	or	53BP1	 foci	 determined	during	 the	first	 siRNA	 screen.	Blue	 indicates	 an	
increase	and	green	a	decrease	in	the	average	foci	number/nucleus.	Gray	specifies	the	validation	selected	targets.	




            A                               B 
2
77
113 JMJD1C 221037 NM_004241 - - 29 MECP2-1 29,996 25,534
114 JMJD2A 9682 NM_014663 0,053 2,317 MECP2-2 43,504 29,313
115 JMJD2B 23030 NM_015015 - - MECP2-3 35,965 22,877
116 JMJD2C 23081 NM_015061 - - MECP2-4 46,336 36,664
117 JMJD2D 55693 NM_018039 - - 30 MYST2-1 38,398 34,566
118 JMJD3 23135 NM_001080424 0,144 -0,616 MYST2-2 40,433 41,996
119 JMJD4 65094 NM_023007 - - MYST2-3 48,390 47,312
120 JMJD5 79831 NM_024773 - - MYST2-4 58,962 56,350
121 KAT2A 2648 NM_021078 - - 31 MYST3-1 47,404 41,053
122 KAT2B 8850 NM_003884 - - MYST3-2 43,238 36,808
123 LRCH4 4034 NM_002319	 0,369 1,860 MYST3-3 42,828 34,410
124 Luciferase -0,024 0,188 MYST3-4 50,200 44,705
125 LOC33012 - - 32 PBRM1-1 36,131 24,594
126 MBD1 4152 NM_002384 - - PBRM1-2 39,934 28,288
127 MBD2 8932 NM_003927 -8,576 -1,711 PBRM1-3 37,933 29,673
128 MBD3 53615 NM_003926 - - PBRM1-4 42,264 30,588
129 MBD4 8930 NM_003925 - - 33 RUNX2-1 48,417 45,783
130 MBD5 55777 NM_018328 - - RUNX2-2 42,341 31,484
131 MBD6 114785 NM_052897 -14,592 0,393 RUNX2-3 54,035 38,037
132 MEAF6 	64769 NM_022756 -0,084 -0,593 RUNX2-4 45,251 18,002
133 MECP2 4204 NM_001110792 6,108 0,646 34 RUNX3-1 45,730 32,427
134 METTL5 29081 NM_014168 -0,181 -0,030 RUNX3-2 41,724 34,769
135 MLL 4297 NM_005933 - - RUNX3-3 49,802 38,162
136 MLL2 8085 NM_003482 - - RUNX3-4 48,719 28,175
137 MLL3 58508 NM_170606 - - 35 RUVBL1-1 31,084 28,982
138 MLL4 9757 NM_014727 - - RUVBL1-2 30,966 27,084
139 MLL5 55904 NM_018682 - - RUVBL1-3 36,389 36,962
140 MORF4 10933 NM_006791 -1,942 -0,272 RUVBL1-4 20,497 21,611
141 MORF4L1 10934 NM_006792 -12,662 2,971 36 SAP18-1 30,051 21,053
142 MSL3 10943 NM_006800 - - SAP18-2 45,632 35,004
143 MYBL2 	4605 NM_002466 - - SAP18-3 38,001 36,388
144 MYSM1 114803 NM_001085487 - - SAP18-4 28,637 19,251
145 MYST1 84148 NM_032188 - - 37 SDS3-1 27,482 25,971
146 MYST2 11143 NM_007067	 7,458 2,752 SDS3-2 26,137 27,110
147 MYST3 7994 NM_006766 10,389 2,813 SDS3-3 23,145 25,753
148 MYST4 23522 NM_012330 - - SDS3-4 22,319 23,255
149 NCOR1 9611 NM_006311 0,357 0,593 38 SET7-1 31,671 24,693
150 NCOR2 9612 NM_006312 - - SET7-2 29,397 30,115
151 OR11H2 79334 NM_001197287 2,360 0,601 SET7-3 21,860 23,444
152 PBRM1 55193 NM_018165 0,661 -5,779 SET7-4 20,093 26,192
153 PCGF1 84759 NM_032673 -0,116 -0,822 39 SIN3B-1 31,613 34,431
154 PCGF2 7703 NM_007144 - - SIN3B-2 27,615 30,182
155 PCGF3 10336 NM_006315 - - SIN3B-3 34,242 31,382
156 PCGF5 84333 NM_032373 0,228 -0,011 SIN3B-4 27,409 30,489
157 PCGF6 84108 NM_001011663 - - 40 SMAD1-1 49,333 40,716
158 PHF19 26147 NM_001009936 - - SMAD1-2 44,636 41,325
159 PTDSR 23210 NM_015167	 - - SMAD1-3 45,448 37,746
160 RAD21 5885 NM_006265 0,721 0,601 SMAD1-4 45,260 27,640
161 RAD54B 	25788 NM_012415 1,193 1,645 41 SMAD4-1 39,672 34,932
162 RAD54L 8438 NM_003579 0,885 1,652 SMAD4-2 40,632 46,858
163 RCOR1 23186 NM_015156 - - SMAD4-3 38,128 32,007
164 RCOR2 283248 NM_173587 -1,438 0,010 SMAD4-4 39,416 35,117
165 RCOR3 55758 NM_018254 0,429 1,679 42 SMAD5-1 43,368 33,552
166 RERE 473 NM_001042681 - - SMAD5-2 36,655 27,726
167 RNF8 9025 NM_003958	 0,720 -25,492 SMAD5-3 40,625 34,702
168 RNF2 	6045 NM_007212 - - SMAD5-4 34,178 30,364
169 RUNX2 860 NM_001015051 -2,247 -0,661 43 SMARCA4-1 45,851 28,184
170 RUNX3 864 NM_001031680 -0,328 2,131 SMARCA4-2 41,750 33,136
171 RUVBL1 8607 NM_003707 -4,117 -1,698 SMARCA4-3 43,027 39,069
172 RUVBL2 10856 NM_006666 - - SMARCA4-4 48,007 41,378
173 SAP18 10284 NM_005870 -19,393 -0,976 44 SMARCAD1-1 42,035 33,727
174 SAP30 8819 NM_003864 0,298 0,421 SMARCAD1-2 41,820 26,656
175 SCML2 10389 NM_006089 - - SMARCAD1-3 47,700 32,960
176 SDS3 64426 NM_022491 -3,815 -0,325 SMARCAD1-4 44,607 24,154
177 SET7 80854 NM_030648 - - * 45 SMARCAL1-1 38,758 35,131
178 SETD1A 9739 NM_014712 0,491 0,437 SMARCAL1-2 45,404 32,260
179 SETD1B 23067 NM_015048	 -1,258 -0,511 SMARCAL1-3 37,424 24,474
180 SETD2 29072 NM_014159 -0,812 -0,383 SMARCAL1-4 42,449 37,733
181 SETD4 54093 NM_017438 0,456 -1,283 46 SMARCC2-1 35,750 36,560
182 SETD7 80854 NM_030648 -1,982 0,777 SMARCC2-2 41,507 34,079
183 SETD8 387893 NM_020382 - - SMARCC2-3 46,748 37,802
184 SHPRH 257218 NM_173082 0,377 -0,089 SMARCC2-4 48,262 39,778
185 SIN3A 25942 NM_015477 - - 47 SP100-1 43,653 39,158
186 SIN3B 23309 NM_015260 3,442 4,329 SP100-2 48,938 45,393
187 SMAD1 4086 NM_001003688 1,946 4,277 SP100-3 44,175 38,094
188 SMAD2 4087 NM_001003652 - - SP100-4 40,679 35,287
189 SMAD3 4088 NM_005902 - - 48 TRIM33-1 36,470 18,962
190 SMAD4 4089 NM_005359 0,926 2,254 TRIM33-2 38,833 33,239
191 SMAD5 4090 NM_001001419 -4,744 -3,551 TRIM33-3 47,287 32,415
192 SMAD6 4091 NM_005585 - - TRIM33-4 43,421 35,873
193 SMAD7 4092 NM_005904 - -
194 SMAD9 4093 NM_001127217 - -
195 SMARCA1 6594 NM_003069 - -
196 SMARCA2 6595 NM_003070 - -
197 SMARCA4 6597 NM_001128844 -2,566 -1,001
198 SMARCA5 8467 NM_003601 -6,963 -0,911
199 SMARCAD1 56916 NM_020159 1,213 2,067
200 SMARCAL1 50485 NM_001127207 3,211 0,074
201 SMARCC1 6599 NM_003074 - -
202 SMARCC2 6601 NM_001130420 -0,559 3,506
203 SMC1A 8243 NM_006306 - -
204 SMURF1 57154 NM_020429 - -
205 SMURF2 64750 NM_022739 - -
206 SMYD1 150572 NM_198274 - -
207 SMYD2 56950 NM_020197 -8,556 -0,848
208 SMYD3 64754 NM_022743 - -
209 SMYD4 114826 NM_052928 - -
210 SMYD5 10322 NM_006062 - -
211 SP100 6672 NM_003113 -0,587 4,373
212 SP110 3431 NM_080424 - -
213 SP140L 93349 NM_138402 -1,378 0,070
214 SUPT7L 9913 NM_014860 - -
215 SUV39H1 6839 NM_003173 - -
216 SUV39H2 79723 NM_024670 - -
217 TADA2A 6871 NM_001488 1,094 1,783
218 TADA2B 93624 NM_152293 - -
219 TAF1 6872 NM_004606 1,425 5,945
220 TAF3 83860 NM_031923 - -
221 TAF8 129685 NM_138572 1,287 8,499
222 TERF1 7013 NM_017489 0,168 1,330
223 TERF2 7014 NM_005652 0,831 1,565
224 TRIM28 10155 NM_005762 - -
225 TRIM33 51592 NM_015906 0,437 7,458 Increase	in	average	number	of	foci/nucleus
226 TRIM66 9866 XM_084529 - - Decrease	in	average	number	of	foci/nucleus
227 TRRAP 8295 NM_003496 -2,941 1,017 Hits	selected	for	validation	screen
228 VPS72 6944 NM_005997 1,563 1,852 Hit





































































The	cellular	 response	to	 ionizing	radiation	 (IR)-induced	DNA	double-strand	breaks	 (DSBs)	
in	 native	 chromatin	 requires	 a	 tight	 coordination	 between	 the	 activities	 of	 DNA	 repair	
machineries	and	factors	that	modulate	chromatin	structure.	SMARCA5	is	an	ATPase	of	the	
SNF2	family	of	chromatin	remodeling	factors	that	has	recently	been	implicated	in	the	DSB	









while	 SMARCA5	was	 not	 required	 for	 these	 events.	Mechanistically,	 we	 uncovered	 that	
CENP-S	and	CENP-X,	upon	their	incorporation	by	RSF1,	promote	assembly	of	the	NHEJ	factor	








Chromosomal	 DNA	 double-strand	 breaks	 (DSBs),	which	 can	 arise	 after	 exposure	 of	 cells	
to	 ionizing	 radiation	 (IR)	 or	 as	 a	 consequence	 of	 DNA	 replication	 stress,	 form	 a	 major	
threat	to	genome	stability.	Their	inefficient	or	inaccurate	repair	can	result	in	chromosome	
rearrangements	and	translocations,	which	may	result	in	cancer	development	or	cell	death	
(Jackson	 and	Bartek,	 2009).	 To	 circumvent	 the	 deleterious	 effects	 of	DSBs,	 cells	 activate	
the	 DNA	 damage	 response	 (DDR),	 which	 comprises	 events	 that	 lead	 to	 detection	 and	
repair	 of	 these	 lesions,	 as	 well	 as	 a	 delay	 in	 cell	 cycle	 progression	 (Ciccia	 and	 Elledge,	
2010;	 Jackson	and	Bartek,	2009).	DSB	 repair	 involves	 two	dedicated	pathways	known	as	
non-homologous	end-joining	(NHEJ)	and	homologous	recombination	(HR)	(Chapman	et	al.,	
2012).	While	NHEJ	re-joins	the	ends	of	a	DSB	in	an	error-free	or	error-prone	manner	and	




structure	 and	 function.	 Several	 proteins	 involved	 in	 modulating	 chromatin	 structure,	
including	histone-modifying	enzymes	and	ATP-dependent	chromatin	remodeling	complexes	
are	critically	important	for	DSB	repair	(Luijsterburg	and	van,	2011;	Smeenk	and	van,	2013).	
A	 key	modification	 that	occurs	 throughout	DSB-associated	 chromatin	 is	 the	ATM	kinase-
dependent	 phosphorylation	 of	 histone	 H2A	 variant	 H2AX	 (γH2AX).	 This	 γH2AX	 histone	
mark	then	leads	to	the	recruitment	of	two	distinct	ubiquitin	E3	ligases,	RNF8	and	RNF168,	
which	 are	 responsible	 for	 the	ubiquitylation	of	 damaged	 chromatin	and	 the	 subsequent	
accumulation	 of	 BRCA1	 through	 its	 ubiquitin-binding	 partner	 RAP80	 (Doil	 et	 al.,	 2009;	










marks	 and	 distinct	 chromatin	 remodeling	 enzymes	 in	 coordinating	 signaling	 and	 repair	
activities	within	damaged	chromatin	compartments.
Interestingly,	while	CHD4	is	unique	to	the	NuRD	chromatin	remodeling	complex,	SMARCA5	




































































RNF168-dependent	 ubiquitin	 signaling	 of	 DSBs,	 it	 promotes	 the	 repair	 of	 DSBs	 by	 NHEJ	
and	HR.	Mechanistically,	we	show	that	RSF1	promotes	 the	deposition	of	 the	centromere	






RSF1 protects cells against DNA damage
The	ATPase	SMARCA5	forms	distinct	chromatin	remodeling	complexes	with	the	chromatin	
assembly	 factor	 ACF1,	 the	 histone-fold	 proteins	 CHRAC15/CHRCA17	 and	 the	 remodeling	
and	 spacing	 factor	 RSF1	 (Wang	 et	 al.,	 2007).	 We	 and	 others	 have	 recently	 implicated	
SMARCA5	 in	 the	 signaling	 and	 repair	 of	 DSBs	 (Lan	 et	 al.,	 2010;	 Nakamura	 et	 al.,	 2011;	
Smeenk	et	al.,	2013).	However,	while	the	available	data	suggest	that	ACF1	and	CHRAC15/
CHARCA17	 assist	 in	modulating	 SMARCA5	 activity,	 the	 role	 of	 RSF1	 in	 the	DNA	 damage	
response	(DDR)	remains	unclear.	Here	we	set	out	 to	study	the	role	of	 this	protein	 in	 the	
DDR	by	first	addressing	whether	RSF1	protects	human	cells	against	the	toxic	consequences	
of	ionizing	radiation	(IR)-induced	DSBs.	To	this	end,	we	transfected	human	VH10-SV40	cells	






RSF1 is recruited to DNA double-strand breaks



















































































































Helfricht et al., Figure 1
E









































































SMARCA5, but not RSF1, regulates the ubiquitin-dependent accumulation of BRCA1 at 
DSBs
Next,	we	sought	 to	unravel	how	RSF1	regulates	 the	DSB	response.	We	recently	 reported	
that	SMARCA5	regulates	the	ubiquitin-dependent	accumulation	of	BRCA1	at	DSBs	(Smeenk	
et	al.,	2013).	This	process	is	triggered	by	the	MDC1-depedendent	recruitment	of	the	RNF8	






































































































Figure 2. SMARCA5, but not RSF1, associates with RNF168 to regulate the ubiquitin-dependent accumulation 




















































RSF1 promotes the assembly of CENP-X and CENP-S at damaged chromatin






























































Figure 3. RSF1 regulates DSB repair by homologous recombination and non-homologous end-joining.	 (A)	





































































































































































































































































































Helfricht et al., Figure 4


































































seven	other	 components	 and	 is	 required	 to	protect	 cells	 against	 the	 cytotoxic	 effects	 of	
agents	that	induce	DNA	inter-strand	crosslinks	(ICLs)	(Kottemann	and	Smogorzewska,	2013).	
Interestingly,	CENP-S	and	CENP-X	are	required	for	the	loading	of	FANCM	at	ICLs,	suggesting	
that	these	factors	play	a	role	 in	 ICL	repair	 (Singh	et	al.,	2010;	Yan	et	al.,	2010).	However,	





proteins	 and	 observed	 recruitment	 of	GFP-tagged	 CENP-S	 and	 CENP-X	 to	 such	 damaged	
areas	 (Fig.	 S5).	 Having	 established	 that	 CENP-S	 and	 CENP-X	 accumulate	 at	 sites	 of	 DNA	
damage	 we	 then	 asked	 whether	 this	 event	 requires	 RSF1.	 Indeed,	 we	 found	 that	 RSF1	













assemble	 at	 damaged	 chromatin	 in	 an	 RSF1-dependent	manner,	 while	 SMARCA5	 is	 not	
involved	in	the	loading	of	these	proteins.	We	infer	that	CENP-S	and	CENP-X	may	be	involved	
in	regulating	RSF1-dependent	DSB	repair	events.
CENP-S and CENP-X promote NHEJ, but not HR
We	next	addressed	whether	we	could	functionally	link	the	role	of	RSF1	in	promoting	DSB	




























































































































































Helfricht et al., Figure 5
B
Figure 5. CENP-S and CENP-X promote 
NHEJ, but not HR. (A)	HEK293T	cells	were	
treated	 with	 the	 indicated	 siRNAs	 and	
48	 h	 later	 transfected	with	 either	 a	GFP-
CENP-S	 or	GFP-CENP-X	 expression	 vector.	
Twenty-four	 h	 later	 cells	 were	 subjected	
to	 western	 blot	 analysis	 to	 show	 the	
knockdown	 efficiency	 for	 the	 indicated	
siRNAs.	 (B)	 HEK293T	 cells	 containing	 the	
HR	 reporter	 DR-GFP	 were	 transfected	
with	 the	 indicated	 siRNAs	 and	 48	 h	 later	
transfected	 with	 an	 I-SceI	 expression	
vector	(pCBASce).	Forty-eight	h	 later	cells	
were	 analyzed	 for	 GFP	 expression	 by	
flow	cytometry.	The	mean	+/-	s.e.m.	of	3	
experiments	is	shown.	(C)	As	in	(B),	except	
that	 cells	 containing	 the	 NHEJ	 reporter	
EJ5-GFP	were	used.























































































































































































































Here	we	uncover	novel	 functions	 for	 the	spacing	and	remodeling	 factor	1	 (RSF1)	protein	






dispensable	 for	 the	 function	of	 RSF1	 in	HR,	 suggesting	 an	 alternative	pathway	 for	 RSF1-
dependent	regulation	of	HR,	which	remains	to	be	elucidated	but	may	involve	the	reported	
functional	interaction	between	RSF1	and	cyclin	proteins	involved	in	DSB	repair	(Jirawatnotai	
et	al.,	 2011).	Thus,	RSF1	 is	a	 critical	 factor	 involved	 in	 the	efficient	execution	of	 the	 two	
major	pathways	of	DSB	repair.
SMARCA5, but not RSF1 is linked to RNF168-dependent signaling of DSBs
While	 it	 is	 evident	 from	our	 studies	 that	RSF1	 regulates	DSB	 repair,	we	did	 not	 uncover	
a	role	for	this	protein	 in	the	ubiquitin-dependent	BRCA1	response	pathway.	This	result	 is	
surprising	given	that	we	have	previously	shown	that	the	RSF1-associated	ATPase	SMARCA5	
directly	 interacts	 with	 ubiquitin	 ligase	 RNF168	 and	 is	 essential	 for	 the	 DNA	 damage-




Figure 6. RSF1, CENP-S and CENP-X load XRCC4 onto damaged chromatin.	 (A)	 U2OS	 cells	 were	 treated	with	











































































CENP-S and CENP-X: Novel factors involved in DSB repair
We	found	that	RSF1	promotes	DSB	repair	by	both	NHEJ	and	HR.	Our	data	suggest	that	RSF1	
regulates	 NHEJ	 by	 recruiting	 CENP-S	 and	 CENP-X	 to	 DSB-associated	 chromatin,	which	 in	
turn	promotes	assembly	of	the	XRCC4-LigIV	complex.	It	is	currently	not	clear	whether	RSF1	
promotes	CENP-S/CENP-X	assembly	 through	 recruiting	CENP-A,	or	whether	RSF1	directly	
loads	 CENP-S/CENP-X	 onto	 damaged	 chromatin.	 In	 addition,	 how	 CENP-S	 and	 CENP-X	
assembly	 contributes	 to	 XRCC4	 binding	 at	 DSB	 sites	 remains	 to	 be	 elucidated.	 Previous	
studies	demonstrated	that	CENP-S	and	CENP-X	form	a	compact	tetramer	that	can	bind	DNA	
and	resembles	H3-H4	tetramers	found	in	histone	octamers	(Nishino	et	al.,	2012;	Tao	et	al.,	
2012).	CENP-S	and	CENP-X	 localize	 to	centromeres	where	 they	promote	 the	assembly	of	
kinetochore	proteins	(Amano	et	al.,	2009;	Foltz	et	al.,	2006).	Consequently,	 loss	of	either	








CENP proteins, chromatin structure and DSB repair
Analogous	to	their	function	at	ICLs,	it	is	possible	that	these	CENP	proteins	may	also	target	
FANCM	to	DSBs	 sites,	 although	 it	 is	 currently	unclear	whether	FANCM	 is	 involved	 in	 the	
IR-induced	DSB	response.	On	the	other	hand,	our	results	suggest	that	the	CENP-S/CENP-X	
complex	may	functionally	interact	with	factors	other	than	FANCM,	such	as	the	NHEJ	factor	
XRCC4.	To	 this	end,	 it	would	be	 interesting	 to	 investigate	whether	XRCC4,	either	directly	





to	DNA	nucleosome-free	 regions	 (Nishino	 et	 al.,	 2012;	 Tao	 et	 al.,	 2012),	 including	 those	
that	 are	 in	 close	proximity	 to	DSBs.	 The	binding	of	 CENP	proteins	 to	DNA	may	enhance	
the	binding	of	DNA	repair	 factors	such	as	XRCC4,	which	possess	DNA-binding	properties,	


















al.,	 2005).	 It	would	be	of	 interest	 to	 study	 if	 higher	 levels	of	RSF1	 in	 such	 tumors	 affect	







candidate	 for	 PARP	 inhibitor-based	 cancer	 treatment	 (Helleday,	 2011).	 In	 summary,	 our	














































































































of γH2AX,	 GFP-RSF1,	 and	mCherry-LacR	 fused	 to	 either	 Fok1	 or	 Fok1D450A	 using	 Zeiss	
AxioImager	M2	and	D2	widefield	fluorescence	microscopes.
Laser micro-irradiation





generated	with	 a	Mira	modelocked	 Ti:Sapphire	 laser	 (λ	 =	 800	 nm,	 pulselength	 =	 200	 fs,	
repetition	 rate	=	76	MHz,	output	power	=	80	mW).	Typically,	 an	average	of	75	cells	was	





















(Zeiss)	 and	 an	 HXP	 120	metal-halide	 lamp	 used	 for	 excitation.	 Fluorescent	 probes	were	














(Inucleoplasm	 −	 Ibackground)	 –	 1).	 The	 accumulation	 in	 the	 control	 cells	 transfected	
with	 siLuc	 within	 each	 experiment	was	 normalized	 to	 100%.	 Images	 obtained	 from	 live	





































































Immunofluoresecent	 labeling	 of	 γH2AX,	 RSF1,	MDC1,	 FK2,	 BRCA1,	 CENP-S,	 CENP-X,	 and	
XRCC4	was	performed	as	described	previously	 (Luijsterburg	et	al.,	2012a;	 Luijsterburg	et	
al.,	 2012b;	 Smeenk	et	 al.,	 2010;	 Smeenk	et	 al.,	 2013).	 Briefly,	 cells	were	 grown	on	glass	














NaCl,	 0.5%	NP-40,	 1	mM	 EDTA)	 supplemented	with	 protease	 and	 phosphatase	 inhibitor	
















RNA isolation, cDNA synthesis, and quantitative PCR
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Helfricht et al., Figure S1
Figure S1. Analysis of spontaneous MDC1, conjugated ubiquitin and BRCA1 in unchallenged SMARCA5 and RSF1 
knockdown cells.	(A)	U2OS	cells	were	transfected	with	the	indicated	siRNAs.	After	48	h	cells	were	exposed	to	2Gy	
IR	or	left	untreated,	and	1	h	later	immunostained	for	MDC1,	conjugated	ubiquitin	(FK2)	or	BRCA1.	Representative	



















































































Helfricht et al., Figure S2
A
B


















































Helfricht et al., Figure S3
Figure S3. Knockdown of RSF1, SMARCA5, CENP-S or CENP-X does not affect cell cycle progression.	HEK293T	
cells	 containing	 the	DR-GFP	 reporter	 system	were	 transfected	with	 the	 indicated	 siRNAs.	After	48	h	 cells	were	
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Helfricht et al., Figure S5
Figure S4. Analysis of CENP-A and GFP-CENP-A recruitment to sites of DNA damage.	(A)	U2OS	cells	were	subjected	
to	multiphoton	laser	irradiation	and	immunostained	for	MDC1	and	endogenous	CENP-A	at	10	min	after	irradiation.	
Scale	bar,	 10	μm.	 (B)	As	 in	A,	 except	 that	U2OS	cells	 stably	expressing	GFP-CENP-A	were	used.	Representative	
images	are	shown	for	the	indicated	time-points.	Arrows	indicate	micro-irradiated	areas.
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Figure S6. Recruitment of SMARCA5 and RSF1 to sites of DNA damage is mutually independent. (A)	 U2OS	


































































































































































































































Helfricht et al., Figure S7
A
B











































































to	 form	 the	 RSF	 complex	 together	 with	 the	 chromatin	 remodelling	 ATPase	 SWI/SNF-
related	matrix-associated	actin-dependent	regulator	of	chromatin	subfamily	A	member	5	




type	 1	 susceptibility	 protein	 (BRCA1).	 Moreover,	 SMARCA5	 is	 required	 for	 the	 proper	
execution	of	 the	 two	major	DSB	 repair	pathways	 i.e.	nonhomologous	end-joining	 (NHEJ)	
and	homologous	recombination	(HR)	(Lan	et	al.,	2010;	Smeenk	et	al.,	2013).	
More	recently,	we	and	others	have	shown	a	role	for	RSF1	in	the	cellular	response	to	DNA	
damage.	RSF1	 is	 recruited	 to	DSBs	 in	an	Ataxia	 telangiectasia	mutated	 (ATM)-dependent	






and	 Lowndes,	 2014).	 Thus,	 RSF1	 contributes	 to	 a	 permissive	 chromatin	 state	 to	 allow	
efficient	DNA	repair	by	at	least	two	mechanisms.	
Proteins	in	the	DNA	damage	response	(DDR)	are	extensively	regulated	by	post-translational	










downstream	of	 the	 SUMOylated	 lysine	 (Hendriks	 et	 al.,	 2014;	Matic	et	 al.,	 2010).	Other	
SUMOylation	motifs	include	the	inverted	consensus	motif	[(ED)xKx(≠ED)]	(E:	glutamic	acid;	
D:	aspartic	acid,	K:	lysine)	and	a	hydrophobic	cluster	motif	(Matic	et	al.,	2010).	





In	human	cells,	3	different	modifiers	are	distinguished,	SUMO-1,	 -2	and	 -3.	 SUMO-2	and	
SUMO-3	 are	 virtually	 identical	 and	 are	 also	 the	most	 abundant	 SUMO	 family	members	
(Saitoh	 and	 Hinchey,	 2000).	 Furthermore,	 SUMO-2	 and	 SUMO-3	 contain	 an	 internal	












































substrates.	 PIAS4-mediated	 SUMOylation	 plays	 a	 crucial	 role	 during	 the	 ubiquitylation-
dependent	signalling	of	DSBs.	Notably,	the	SUMOylation	of	HERC2	facilitates	the	interaction	
of	HERC2	with	RNF8,	and	the	assembly	of	UBC13	with	RNF8	thereby	promoting	DNA	damage-





al.,	 2011).	 On	 the	 contrary,	MDC1-SUMOylation	 on	 lysine	 1840	 by	 PIAS4	 is	 required	 for	
its	 removal	 from	DNA	 lesions	 through	 the	 SUMO-dependent	 recruitment	 of	 the	 SUMO-




































transfected	 parental	 HeLa	 cells	 or	 HeLa	 cells	 stably	 expressing	His6-SUMO-2	with	 either	
a	control	plasmid	or	a	plasmid	encoding	GFP-RSF1	and	performed	a	His-pulldown	(PD)	to	
enrich	for	SUMO	conjugates.	Consistent	with	our	previous	results,	we	could	detect	a	strong	
SUMOylation	 signal	 for	 GFP-RSF1,	 but	 not	 in	 control	 PD	 samples	 (Fig.	 1B).	 SUMOylated	
full-length	GFP-RSF1	appeared	in	a	typical	SUMO	ladder-type	of	signal	above	the	marked	
GFP-RSF1	band	(*).	However	additional	lower	molecular	weight	SUMOylation	bands	were	
detected	 on	 the	 immunoblot	 before	 and	 after	 His-PD,	 which	 suggest	 that	 ectopically	
expressed	GFP-RSF1	got	partially	degraded	in	the	absence	of	DNA	damage	(Fig.	1B).	
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SUMOylation of the RSF1 21KR mutant is abrogated
RSF1	 is	 a	 protein	with	 two	 functional	 domains,	 a	 DNA	 binding	 homeobox	 and	Different	
Transcription	factors	(DDT)	domain	at	the	N-terminus	facilitating	DNA	binding,	and	a	PhD-




to	 replace	 21	 lysines	 (K)	 for	 arginines	 (R).	 Arginine	 has	 been	 selected	 as	 a	 replacement	














The RSF1 21KR mutant is recruited to laser tracks
RSF1	was	shown	to	be	recruited	to	DSBs	in	a	manner	dependent	on	ATM	(Helfricht	et	al.,	
2013;	Min	et	al.,	2014;	Pessina	and	Lowndes,	2014).	To	investigate	whether	SUMOylation	
of	RSF1	plays	a	role	 in	 its	 recruitment	to	DSBs,	we	 inflicted	DNA	damage	by	 laser	micro-
irradiation	 in	U2OS	 cells	 transiently	 expressing	 either	GFP-RSF1	wt	 or	 the	 21KR	mutant.	




XRCC4 accumulation is hampered in the RSF1 21KR mutant
Since	 we	 have	 shown	 that	 RSF1	 promotes	 NHEJ	 repair	 by	 loading	 of	 XRCC4	 onto	 DSB-
containing	chromatin	(Helfricht	et	al.,	2013),	it	is	an	obvious	question	whether	the	RSF1	21KR	
mutant	is	still	capable	to	promote	XRCC4	loading	onto	chromatin.	We	therefore	generated	






-RSF1	wt	 and	mCherry-LacR-	 21KR	 to	 the	 array	 and	 subsequently	monitored	GFP-XRCC4	
accumulation	(Fig.	3A).	XRCC4	did	not	accumulate	at	the	LacO	array	in	the	absence	of	RSF1,	
as	has	been	shown	 in	chapter	3	Fig.	6.	But	XRCC4	clearly	assembled	at	RSF1	wt	covered	
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Chapter IV - Figure 2 
Figure 2. The RSF1 21KR mutant does not get SUMOylated. (A)	Overview	of	full-length	human	RSF1	amino	acid	(aa)	
sequence.	21	K	to	R	mutation	positions	are	indicated	by	asterisks.	(B)	U2OS	cells	stably	expressing	His-SUMO-2	or	
parental	control	cells	were	either	mock	treated	or	transfected	with	the	indicated	plasmids.	24	h	after	transfection,	





































































































Chapter IV - Figure 3 
DISCUSSION
SUMOylation	 is	a	post-translational	modification	(PTM)	that	can	change	the	stability	of	a	







mutations	 and	was	 deficient	 in	 RSF1	 SUMOylation.	While	 this	mutant	was	 still	 recruited	
to	laser-induced	DNA	damage	(Fig.	2C,D)	with	similar	kinetics	as	RSF1	wt,	its	ability	to	load	
XRCC4	was	highly	decreased	(Fig.	3A,B).	
The RSF1 21KR mutant
Recently,	 several	 SUMO	acceptor	 lysines	 had	been	 found	 in	 RSF1	 (Hendriks	 et	 al.,	 2014;	
Hendriks	et	al.,	2015;	Matic	et	al.,	2010),	hence	we	generated	several	RSF1	SUMO	mutants.	
In	contrast	 to	the	21KR	mutant,	 the	RSF1	K294K	and	6KR	mutants	did	not	show	reduced	





way	 for	 the	disruption	of	 SUMOylation	 sites	 that	 leaves	 the	PTM-acceptor	 lysines	 intact,	
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The RSF1 21KR mutant might be unable to recruit XRCC4
We	observed	a	clear	decrease	 in	XRCC4	accumulation	to	the	targeted	RSF1	21KR	mutant	
compared	to	RSF1	wt	in	LacO	array-containing	U2OS	2-6-3	cells	(Fig.	3).	As	this	recruitment	


















	 It	 is	 furthermore	 noteworthy	 that	 SUMOylation-deficient	 mutant	 proteins	
frequently	 lack	 severe	 phenotypes	 (Sacher	 et	 al.,	 2006;	 Silver	 et	 al.,	 2011).	 Accordingly,	




































Jentsch,	 2012).	Which	 phenotypes	 are	 associated	with	 SUMOylation	 deficient	 RSF1	 and	
whether	RSF1	contributes	to	the	stability	of	protein	interactions	during	DSB	repair	however	
remain	to	be	investigated.
Identification of a SUMO E3 ligase for RSF1
Another	 unaddressed	 point	 is	 the	 identity	 of	 a	 SUMO	 E3	 ligase	 responsible	 for	 RSF1	
SUMOylation	 upon	 DNA-damage	 induction.	 PIAS1	 and	 PIAS4	 are	 likely	 candidates	 to	






Potential strategies for future functional studies
Efforts	to	generate	experimental	data	to	elucidate	a	possible	function	of	RSF1	SUMOlyation	
in	the	DDR	were	 inconclusive.	Expression	of	a	siRNA-resistant	version	of	RSF1	wt	did	not	
complement	 the	 knockdown-induced	 reduction	 of	 XRCC4	 recruitment	 to	DSB-containing	
laser	tracks	(Fig.	S2).	This	could	have	had	several	reasons,	one	being	inappropriate	expression	
levels	of	RSF1.	Not	only	does	the	depletion	of	RSF1	leads	to	defects	in	the	response	to	DNA	
damage,	 the	overexpression	of	RSF1	actually	 induces	DNA	damage	 (i.e.	γH2AX),	 thereby	
initiating	cell	growth	arrest	and	apoptosis	 (Sheu	et	al.,	2010).	For	such	complementation	
approaches,	near-endogenous	expression	levels	of	RSF1	wt	and	21KR	mutant	are	therefore	
vital	 and	 further	 investigations	 are	 required	 to	 proof	 the	 functionality	 of	 tagged	 RSF1	
and	 the	 importance	of	 RSF1	 SUMOylation	when	 compared	 to	RSF1	 21KR	mutant	 during	
complementation	experiments.	





for	 efficient	HR	 (Helfricht	 et	 al.,	 2013;	Min	 et	 al.,	 2014).	 This	 study	 so	 far	 however	 only	
focused	on	the	possible	involvement	of	RSF1	SUMOylation	during	NHEJ,	which	was	based	
on	 former	 results	 (Helfricht	 et	 al.,	 2013).	 But	RSF1	has	 also	 been	 suggested	 to	 promote	
the	recruitment	of	the	HR	factors	RPA	and	RAD51	to	laser-induced	DSBs	(Min	et	al.,	2014).	
Whether	SUMOylation	of	RSF1	plays	a	 role	 in	 the	HR	pathway	however	 requires	 further	
investigation.	Thus	additional	efforts	have	to	be	made	in	order	to	dissect	the	role	of	RSF1	



























Transfections and RNAi interference
siRNA	and	plasmid	transfections	were	performed	using	Lipofectamine	RNAiMAX	(Invitrogen)	









in	 four	pellet	volumes	of	 lysis	buffer	 (1%	SDS,	0.5%	NP-40	 in	PBS,	 including	phosphatase	
and	 protease	 inhibitors).	 70	mM	 Chloroacetamide	 was	 added	 freshly	 to	 Flag-IP	 lysates.	












































including	 EDTA	 (Roche;	 1	 tablet	 per	 10	ml	 buffer)),	 	 including	 3	 tube	 changes.	 The	 Flag-
SUMO-2	conjugates	were	eventually	eluted	with	one	bead	volume	of	5%	SDS	and	1	mM	Flag	
M2	epitope	peptide	in	wash	buffer.
Purification of His-SUMO conjugates
U2OS	 cells	 stably	 expressing	His-SUMO-2	were	 rinsed	with	 and	 collected	 in	 icecold	 PBS.	
To	prepare	 input	samples,	small	aliquots	of	cells	were	 lysed	 in	1x	LDS	sample	buffer.	For	
cell	 lysis,	 Guanidinium	 lysis	 buffer	 (6	 M	 guanidinium-HCl,	 0.1	 M	 Na2HPO4/NaH2PO4,	
0.01	M	Tris/HCl,	pH	8.0	and	competing	 imidazole)	was	added	to	the	cell	pellet,	 followed	
by	 sonication	 to	 reduce	 the	 viscosity.	 The	 protein	 concentration	 of	 these	 lysates	 was	
subsequently	 determined	 using	 the	 BCA	 kit	 to	 equalize	 the	 samples.	 The	 His-SUMO-2	












washed	 in	 ice-cold	 PBS,	 followed	 by	 lysis	 in	 EBC	 buffer	 (50	mM	 Tris	 (pH	 7.5),	 150	mM	












et	 al.,	 2004)),	 GFP	 (1:5000,	 #290,	 Abcam).	 Immunofluorescence	 analysis	was	 performed	

















laser	 (Micropoint	 Ablation	 Laser	 System;	 Photonic	 Instruments,	 Inc)	 was	 used	 for	 DNA-
damage	induction.	The	pulsed	nitrogen	laser	(16	Hz,	364	nm)	was	thereby	directly	coupled	to	
the	epifluorescence	path	of	the	microscope	and	focused	through	a	Leica	40×	HCX	PLAN	APO	
1.25–0.75	 oil-immersion	 objective.	 To	 strictly	 induce	 localized	 sub-nuclear	DNA	damage,	
the	laser	output	power	was	set	to	78	and	2	iterations	per	pixel	were	applied	with	the	Andor	
software.	 Cells	were	 incubated	 for	 10	minutes	 at	 37	 °C	 and	 subsequently	 fixed	with	 4%	
formaldehyde	before	immunostaining.	
Immunofluorescent labeling
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Chapter IV - Figure S1 
U2OS


































































Chapter IV - Figure S2 




WB	analysis	 for	 endogenous	RSF1.	 (B)	U2OS	 cells	were	
transiently transfected with constructs encoding either 
GFP,	 GFP-RSF1	 wt	 or	 GFP-RSF1	 21KR.	 Cells	 were	 mock	
treated	or	exposed	to	4	Gy	of	IR	and	lysed.	GFP(-tagged)	
proteins	were	purified	and	analysed	by	immunoblotting	
using	 anti	 GFP	 and	 SUMO-2/3	 antibody.	 The	 asteriks	
indicate	full-length	GFP-RSF1.	
Figure S2. Exogenous RSF1 wt fails to complement the XRCC4 recruitment defect of U2OS cells depleted from 
endogenous RSF1.	(A)	U2OS	cells	were	treated	with	siLuc	or	siRSF1-3	for	48	h	and	were	subsequently	transfected	
























































Chapter IV - Figure S1 
U2OS




























PDSM ≠ ExK or KxE
Tabel S1. List of SUMO target sites mutated in RSF1 
21KR.	 (A)	Listed	are	 identified	SUMO	target	sites	and	
additional	 inverted	 motifs,	 (¹Hendriks	 et	 al.,	 2014).	
Blue:	 Lysine	 fitting	 the	 Phosphorylation-dependent	
SUMOylation	motif	 (PDSM)	 [KxExx(pS)P],	 Red:	 SUMO	




Tabel S2. List of described phosphorylation and 
acetylation target sites found in RSF1. 
www.phosphosite.org.	
Yellow:	 ATM-/ATR	 phosphorylation	 target	 sites	
(¹Matsuoka	et	al.,	2007,	²Choudhary	et	al.,	2009).
Tabel S2
Phosphorylation sites1 Acetylation sites2
















































































The	 autosomal	 recessive	 immunodeficiency,	 centromeric	 instability	 and	 facial	 anomalies	




immunoglobulin	 class-switch	 recombination	 and	 consequently	 impairs	 immunoglobulin	
production	 and	 subtype	balance.	Mechanistically,	we	 found	 that	 ZBTB24	associates	with	
poly(ADP-ribose)	polymerase	1	(PARP1)	and	stimulates	auto-poly(ADP-ribosyl)ation	of	this	


































of	 switched	memory	B	cells	and	an	 increased	proportion	of	 immature	B	cells	have	been	
reported	 (Blanco-Betancourt	et	al.	2004),	 suggesting	a	defect	 in	 the	final	 stages	of	B-cell	
differentiation.	A	key	step	in	B-cell	maturation	is	isotype	switching	of	immunoglobulins	(Ig)	
through	 class-switch	 recombination	 (CSR).	 Effective	 CSR	 heavily	 relies	 on	 the	 controlled	
formation	 and	 correct	 repair	 of	 DNA	 double-strand	 breaks	 (DSB)	 induced	 by	 Activation-
Induced	 (Cytidine)	 Deaminase	 (AID)	 at	 conserved	 motifs	 within	 the	 switch	 (S)	 regions,	
which	are	upstream	from	gene	segments	that	encode	distinct	constant	regions	of	antibody	
heavy	chains	(Alt	et	al.	2013).	Upon	break	formation,	two	switch	regions	are	rejoined	by	








2013).	 In	 the	 absence	 of	 this	 classical	 (c-)NHEJ	mechanism,	 effective	 CSR	 is	 significantly	
impaired	but	not	absent,	as	DSB	repair	is	carried	out	by	alternative	NHEJ	(a-NHEJ).	a-NHEJ	
is	 a	 poorly	 characterized	process	 dependent	 on	 poly(ADP-ribose)	 polymerase	 1	 (PARP1),	
X-ray	repair	cross-complementing	protein	1	(XRCC1)	and	DNA	ligase	1	and	3	(LIG1	and	LIG3)	
(Audebert	et	al.	2004;	Paul	et	al.	2013;	Lu	et	al.	2016).	






































primary	 cause	 of	 immunodeficiency	 in	 patients	 (Woodbine	 et	 al.	 2014).	 Considering	 the	







ICF2 patients display features of defective CSR
The	 immunodeficiency	 in	 ICF2	 syndrome	 is	 characterized	 by	 a	 reduction	 or	 even	 an	
absence	of	immunoglobulins	(Igs)	(hypo-	or	agammaglobulinemia)	and	decreased	numbers	
of	 switched	memory	B	 cells,	while	 normal	 levels	 of	 total	 B	 cells	 are	 observed	 (de	Greef	





(Fig.	 1A).	Of	 note,	 total	 numbers	 of	 CD4+	 T	 cells,	 as	well	 as	 naive,	 central	memory	 and	
CD27+CD28+	 early	 antigen	 experienced	CD4+	 T	 cells	were	 increased	when	 compared	 to	
age-matched	controls,	while	those	for	CD8+	T	cells	were	normal	(Fig.	S1).	
These	findings	could	suggest	a	defect	in	V(D)J	recombination	or	class-switch	recombination	
(CSR),	which	are	processes	 that	 are	 critical	 for	B-cell	 development	and	ultimately	define	
antibody	 production	 and	 diversification.	 We	 therefore	 first	 examined	 the	 combinatorial	
diversity	of	VDJ	usage	and	composition	of	the	junctional	region	during	V(D)J	recombination	
by	sequencing	 immunoglobulin	heavy	chain	gene	rearrangements	 in	B	cells	derived	from	













by	an	 increase	 in	relative	 IgG3	expression	 in	 ICF2	patients	 (Fig.	1D).	Together,	 these	data	
show	 that	 the	 absence	 or	 reduction	 of	 Igs	 in	 combination	 with	 changes	 in	 the	 relative	
abundance	of	Ig	subclasses	in	ICF2	patients	is	most	likely	caused	by	impaired	CSR.	
Loss of ZBTB24 resembles NHEJ-deficiency in CSR 


















Figure 1. Defective CSR in ICF2 patients due to loss of ZBTB24-dependent NHEJ. (A)	Number	of	cells	within	the	
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of	 sequential	 switching	 (Sm-Sg3-Sg2;	 9%),	which	 is	 rarely	 observed	 in	 controls	 (2%),	 but	
frequently	seen	in	NHEJ-defective	cells	such	as	Artemis-	or	DNA-PKcs-deficient	cells	(Du	et	
al.	 2008;	Bjorkman	et	 al.	 2015).	 Thus,	 the	 altered	CSR	patterns	 in	 ICF2	patient	 cells	 and	
their	resemblance	to	those	observed	in	several	known	NHEJ-deficient	patients	suggest	that	
ZBTB24	might	be	a	novel	NHEJ	factor	involved	in	CSR.




from	 the	GFP	 gene	 by	 a	 puromycin-resistance	 gene	 that	 is	 flanked	 by	 I-SceI	 recognition	








Table 1: Characterization of CSR junctionsa 
Study 
subjects Perfectly matched short homology 
No. of 
junctions 






insertions 1-3 bp 4-6 bp 7-9 bp ≥ 10 bp  
Sµ-Sα        
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a. Statistical analysis was performed by χ2 test and significant changes are indicated in bold. *p<0.05, 
**p<0.01, ***p<0.001 
b. Previously published CSR junctions from Lig4-deficient patients (Pan-Hammarström et al., 2005) 
c. Previously published CSR junctions from Artemis-deficient patients (Du et al., 2008) 
d. Previously published Sµ-Sα junctions from children controls (Du et al., 2008; Enervald et al., 2013) 
e. Previously published Sµ-Sγ junctions from children controls (Du et al., 2008) 
 




























































































































































































































































































































deficient	 for	 the	c-NHEJ	 factor	LIG4	 (Table	1),	 suggesting	a	 role	 for	ZBTB24	 in	c-NHEJ.	To	
provide	further	support	for	this,	we	used	a	plasmid	integration	assay	to	specifically	study	the	
role	of	ZBTB24	in	c-NHEJ.	In	this	assay,	a	linearized	plasmid	encoding	GFP	and	a	Neomycin-
selection	marker	 is	 transfected	 into	U2OS	cells.	 Survival	of	G418-resistant	 colonies	 relies	



















ZBTB24 interacts with PARP1 in a PARylation-dependent manner
To	assess	how	ZBTB24	affects	NHEJ,	we	aimed	to	identify	its	interaction	partners	using	an	
unbiased,	quantitative	proteomics	approach.	We	expressed	GFP-ZBTB24	or	GFP	 (control)	





3A	and	Table	S3).	To	explore	 this	 further,	we	performed	 the	 reciprocal	experiment	using	
cells	expressing	GFP-PARP1.	This	screen	identified	21	proteins	that	were	at	least	two-fold	
enriched	 over	 control	 cells	 (Table	 S4).	 Remarkably,	 not	 only	 did	 we	 find	 several	 known	
PARP1-interactors	such	as	XRCC1,	LIG3	and	DNA	polymerase	beta	(POLB)	(Pines	et	al.	2013),	
also	ZBTB24	was	among	the	top	hits	of	this	screen	(Fig.	3B	and	Table	S4).	To	confirm	the	
ZBTB24-PARP1	 interactions,	 we	 performed	 co-immunoprecipitation	 (co-IP)	 experiments	


































































   










































































Helfricht et al., Figure 3
Figure	3.	PARP1	 interacts	with	ZBTB24	 in	a	PARylation-dependent	manner	and	 recruits	ZBTB24	 to	 sites	of	DNA	
damage.	 (A)	 Schematic	 representation	of	 SILAC-based	mass	 spectrometry	 (MS)	 approach.	GFP-	 or	GFP-ZBTB24	






















































PARP1 recruits ZBTB24 to sites of DNA damage
PARP1	binds	to	both	single-	and	double-strand	breaks,	where	it	promotes	the	assembly	of	





with	 PARPi	 (Fig.	 3F-G),	 demonstrating	 its	 dependency	 on	 PARylation.	 Furthermore,	 the	
accumulation	of	ZBTB24	at	DNA	damage	tracks	was	rapid	but	transient,	reaching	maximum	








mediated	 depletion	 of	 PARG	 (Fig.	 S6A).	 Under	 these	 conditions,	we	 observed	 enhanced	
and	more	persistent	accumulation	of	ZBTB24	at	sites	of	damage	(Fig.	S6B-C).	 In	contrast,	





The ZNF of ZBTB24 binds PAR to promote PARP1-dependent ZBTB24 recruitment 
Three	conserved	domains	can	be	identified	in	ZBTB24:	an	N-terminal	BTB	domain	(amino	
acids	9-132),	a	 small	AT-hook	DNA-binding	domain	 (amino	acids	159-171)	and	8	 tandem	
C2H2	 zinc-finger	 (ZNF)	 motifs	 (amino	 acids	 294-512)	 (Fig.	 4A).	 To	 dissect	 the	 relevance	
of	 these	 domains	 for	 ZBTB24’s	 interaction	with	 PARP1	 and	 localization	 to	 DNA	 damage,	
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domain),	 could	bind	 to	PAR	chains	 (Fig.	4D).	 In	concordance,	 co-IP	experiments	 revealed	
an	 interaction	between	PARP1	and	GFP-ZNF,	 but	 not	GFP-ΔZNF	 (Fig.	 4E).	 Together	 these	
results	suggest	that	the	ZNF	of	ZBTB24	is	a	novel	PAR-binding	domain	that	mediates	ZBTB24	
recruitment	to	DNA	damage	through	interactions	with	PARylated	PARP1.	
ZBTB24 promotes PAR synthesis and protects PAR chains 
Considering	 that	 ZBTB24	 efficiently	 associates	 with	 PARP1-generated	 PAR	 chains,	 we	
wondered	whether	ZBTB24	could	be	involved	in	regulating	the	steady-state	levels	of	such	
chains	 in	response	to	DNA	damage.	To	examine	this	possibility,	we	monitored	global	PAR	
levels	by	western	blot	 analysis	 in	 cells	 exposed	 to	 IR.	While	hardly	 any	PARylation	 could	
be	observed	 in	mock-treated	cells,	exposure	to	 IR	triggered	robust	DNA	damage-induced	












Another	non-mutually	exclusive	possibility	 is	 that	ZBTB24	binding	 to	PAR	chains	protects	
such	chains	 from	efficient	hydrolysis	by	 the	PARP1	antagonist	PARG	 (Fig.	5D).	 To	explore	
this	possibility,	we	allowed	PARP1-dependent	synthesis	of	PAR	in	our	in	vitro	system	and,	












XRCC4/DNA	 ligase	4	 (LIG4)	complex	 (Alt	et	al.	2013).	 Interestingly,	 recent	 in	vitro	studies	
5
137






























+ + + + + + +
- - -
- - - - - - +













+ + + + + +
- -
- - - - - +






































































































































































































































the	 recruitment	 of	 GFP-XRCC4	 to	 damaged	 DNA	 in	 U2OS	 cells	 that	 were	 either	 treated	







Given	 ZBTB24’s	 role	 in	 NHEJ,	 its	 interaction	 with	 PARP1	 and	 its	 stimulatory	 effect	 on	
PARylation,	we	addressed	whether	it	affects	the	PARP1-dependent	assembly	of	XRCC4/LIG4	



























ZBTB24 is required for CSR, a process defective in ICF2 patients 







































































































































































































































































































Figure 6. ZBTB24 and PARP1 promote XRCC4/LIG4 assembly at DNA damage sites. (A)	U2OS	stably	expressing	
GFP-XRCC4	were	 treated	with	DMSO	 (Mock)	 or	 PARPi	 and	 subjected	 to	 laser	micro-irradiation.	 Representative	




cells	used	 to	 locally	 induce	multiple	DSBs	upon	 tethering	of	 the	FokI	endonuclease.	 (I)	Accumulation	of	XRCC4	






















































are	 not	 bound	 by	 PARP1	due	 to	 their	 processing	 by	 the	 structure-specific	 endonuclease	
Artemis	(Alt	et	al.	2013),	which	could	rule	out	a	function	for	PARP1	and	most	likely	ZBTB24	
in	V(D)J	recombination	and	would	be	in	agreement	with	our	observations.	However,	PARP1	
seems	 to	 have	 affinity	 for	 AID-induced	 breaks	 in	mice,	 where	 it	 promotes	 CSR	 through	
a-NHEJ	 (Robert	 et	 al.	 2009).	Whether	 it	 also	modulates	 CSR	 in	 humans	 remains	 elusive,	
mainly	because	patients	with	loss-of-function	mutations	in	PARP1	have	not	been	reported	
yet.




this	 does	 not	 exclude	 a	 stimulatory	 role	 for	 PARP1	 in	 c-NHEJ.	 Indeed,	 several	 studies	
reported	that	the	loss	of	PARP1	activity	modulates	the	c-NHEJ-dependent	re-joining	of	DSBs	
in	hamster,	mouse	and	human	cells	(Veuger	et	al.	2003;	Mitchell	et	al.	2009).	Our	results	
corroborate	and	extend	 these	observations	and	 further	 support	 a	 role	 for	PARP1	 in	DSB	
repair	through	c-NHEJ.							
	 Our	work	identifies	ZBTB24	as	an	effector	of	PARP1-dependent	c-NHEJ.	However,	
the	 c-NHEJ-specific	 phenotypes,	 such	 as	 impaired	 random	plasmid	 integration	 or	 XRCC4	









The C2H2 ZNF of ZBTB24 binds PAR chains
Four	 structurally	 distinct	protein	motifs	have	been	 characterized	 to	mediate	 interactions	
with	PAR	chains:	1)	a	consensus	of	eighth	interspersed	basic	and	hydrophobic	amino	acid	
residues,	 2)	macro	 domains	 containing	 a	 conserved	 ligand-binding	 pocket,	 3)	 the	WWE	
domain	that	recognizes	iso-ADP-ribose,	which	is	the	smallest	internal	structural	unit	of	PAR,	










studies	 on	 these	 DNA	 damage-associated	 ZNF-containing	 proteins	 may	 reveal,	 whether	
they	have	evolved	as	general	PAR-binding	proteins	with	specialized	functions	in	the	PARP-
dependent	DDRs.	







catalytic	domain	 to	 induce	auto-PARylation	 (Langelier	et	al.	2012).	One	possibility	 is	 that	
ZBTB24	by	binding	to	PARP1	stimulates	these	intramolecular	interactions	and	conformational	










with	 PARP1-associated	 PAR	 chains.	 This	 may	 sterically	 hinder	 PARG	 from	 attacking	 PAR	






















































Sera	and	PBMC	were	obtained	after	 informed	consent	 from	 two	 ICF2	patients	 that	have	
been	described	previously	(patients	49	and	55;(Weemaes	et	al.	2013))	and	one	novel	ICF2	
patient	(p67)	carrying	the	same	recessive	mutation	as	patient	49.
Lymphocyte phenotyping and Ig production analysis
PBMC	 from	 patients	 and	 healthy	 individuals	 were	 stained	 with	 fluorochrome-labelled	
antibodies	against	cell	 surface	antigens.	Stimulated	PBMC	were	analyzed	 for	 IgG	and	 IgA	
production	by	sandwich	ELISA	(see	Supplemental	Material).







Cell lines, chemicals, plasmids and transfections
Human	 cells	 (see	 Supplemental	 Material)	 were	 cultured	 in	 DMEM,	 supplemented	 with	
antibiotics	and	10%	fetal	calf	serum.	PARP	inhibitor	(KU-0058948)	was	used	at	a	concentration	







Immunoprecipitation for mass spectrometry and PAR-binding assay
GFP-tagged	 ZBTB24	 and	 PARP1	 were	 immunoprecipitated,	 trypsinized,	 desalted	 and	
analyzed	on	a	Q-Exactive	Orbitrap	mass	spectrometer	(Thermo	Scientific,	Germany)	coupled	
to	an	EASY-nanoLC	1000	system	(Proxeon,	Odense,	Denmark).	GFP-ZBTB24	and	derivatives	
were	 immunoprecipitated,	 separated	 by	 SDS-PAGE	 and	 incubated	 with	 radioactive	 PAR.	
Radioactivity	was	detected	by	a	phosphor-imager	screen.
PARP1 activation and PAR protection 
PARP1	activation	and	PAR	protection	assays	were	done	as	described	(Shah	et	al.	2011),	using	
purified	GST	or	GST-ZBTB24	proteins	(see	Supplemental	Material).
Laser micro-irradiation and FokI assays
Laser	micro-irradiation	was	performed	by	UV-A	micro-irradiation	of	BrdU-sensitized	cells	or	
by	multi-photon	(MP)	 irradiation	using	a	titanium-sapphire	 laser	were	done	as	described	
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Isolation of peripheral blood mononuclear cells and phenotyping of lymphocytes
Peripheral	blood	mononuclear	cells	(PBMC)	were	obtained	from	patients,	family	members	
and	 healthy	 donors	 by	 Ficoll	 density	 gradient	 separation.	 PBMC	 were	 stored	 in	 liquid	




F(ab’)2)	 (DAKO);	CD45RA	(#MEM-56)	 (Invitrogen	Life	Technologies).	DAPI	 (4’,6-diamidino-
2-phenylindole)	 was	 added	 to	 discriminate	 between	 live	 and	 dead	 cells.	 Samples	 were	
analyzed	on	a	BD	Biosciences	LSR	II	flowcytometer	with	DIVA	software.
In vitro B-cell stimulation and analysis of IgG and IgA production
PBMC	 (0.25	 x	 106/well)	 were	 cultured	 in	 a	 flatbottom	 96-well	 plate	 in	 AIM-V	 medium	
supplemented	with	5%	FCS	ultra-low	IgG,	penicillin/streptomycin	(100	IU/mL/100	mg/mL;	
Life	 Technologies),	 0.05	mg/mL	 transferrin	 and	 5	mg/mL	 insulin	 (Sigma-Aldrich).	 Added	










(3’Cγ-CH1	 (Tiller	 et	 al.,	 2008)).	 The	primers	were	 adapted	 for	 454	 sequencing	by	 adding	
the	forward	A	or	reverse	B	adaptor,	the	‘TCAG’	key	and	multiplex	identifier	(MID)	adaptor.	
PCR	products	were	purified	by	 gel	 extraction	 (Qiagen)	 and	Agencourt	AMPure	XP	beads	
(Beckman	Coulter).	DNA	concentration	was	measured	using	the	Quant-it	Picogreen	dsDNA	














Sequencing of switch recombination junctions
Amplification,	cloning	and	sequencing	of	the	Sm-Sa	or	Sm-Sg	fragments	derived	from	PBMC	
was	performed	using	a	previously	described	PCR	strategy	(Pan-Hammarstrom	et	al.	2005).	




U2OS,	 HEK293,	 HEK293T	 and	 VH10-SV40-immortalized	 fibroblast	 cells	 were	 grown	 in	








The	 full-length	 cDNA	of	 human	 ZBTB24	was	 obtained	by	RT-PCR	 and	flanking	 restriction	
sites	for	conventional	cloning	(BglII/SalI)	were	introduced	using	a	nested	PCR	on	the	cDNA.	
The	obtained	PCR	product	was	 subsequently	 cloned	 into	 pEGFP-C1	 and	pEGFP-N1	 (both	
Clontech)	using	the	BglII	and	SalI	restriction	sites.	The	GST-ZBTB24	expression	vector	was	
generated	by	 cloning	 the	ZBTB24	ORF	 from	pEGFP-C1-ZBTB24	as	a	BglII/	 EcoRI	 fragment	
into	BamHI/EcoRI-digested	pGEX-6p-3	(GE	Healthcare).	The	Myc-ZBTB24	expression	vector	
was	obtained	by	exchanging	GFP,	using	the	AgeI	and	BglII	restriction	sites,	for	a	single	Myc	
tag	 (EQKLISEEDL)	 by	oligo	 annealing	 in	 the	pEGFP-ZBTB24	 construct.	Deletion	 constructs	
were	generated	by	amplifying	the	specified	regions	using	internal	primers	containing	BglII	




An	 IRES-Puro	 cassette	was	 amplified	 by	 PCR	 and	 inserted	 into	 EGFP-C1	 (Addgene).	 	 The	




Transfections and RNA interference
siRNA	and	plasmid	transfections	were	performed	using	Lipofectamine	RNAiMAX	(Invitrogen),	
Lipofectamine	2000	(Invitrogen),	and	JetPEI	(Polyplus	Transfection),	respectively,	according	










































Non-homologous end-joining assay 










cells	was	 used	 to	 determine	 transfection	 efficiency,	 as	measured	 by	 the	 amount	 of	GFP	













VH10-SV40	 cells	 were	 transfected	 with	 siRNAs,	 trypsinized,	 seeded	 at	 low	 density,	 and	
exposed	to	IR	at	indicated	doses.	Seven	days	later	cells	were	washed	with	0.9%	NaCl	and	
stained	with	methylene	 blue.	 Colonies	 of	more	 than	 10	 cells	were	 counted	 and	 relative	
survival	compared	to	the	untreated	sample	was	calculated.
RNA expression analysis by RT-qPCR and RNA sequencing 
Gene	 expression	 analysis	 using	 quantitative	 realtime	 PCR	 was	 carried	 out	 as	 described	
before	(Helfricht	et	al.	2013).	Briefly,	RNA	isolation	was	done	using	the	miRNeasy	minikit	
(Qiagen)	and	 subsequently	polydT	primed	cDNA	was	generated	using	 the	RevertAid	first	
strand	 cDNA	 synthesis	 kit	 (Thermo	 scientific)	 according	 to	 manufacturer’s	 instructions.	
Realtime	 qPCR	was	 performed	 in	 duplicate	 on	 the	 CFX96/384	 system	 using	 SYBR	 green	
master	mix	(Bio-Rad).	Primers,	which	are	listed	in	Table	5S,	were	designed	using	Primer3Plus	
software	(http://primer3plus.com).	Relative	expression	levels	were	obtained	with	the	CFX	




























followed	 by	 overnight	 digestion	 using	 2.5	 µg	 trypsin	 at	 37°C	 under	 constant	 shaking.	
Peptides	of	the	H	and	L	precipitates	were	mixed	and	desalted	using	a	Sep-Pak	tC18	cartridge	
by	washing	with	0.1	%	acetic	acid.	Finally,	peptides	were	eluted	with	0.1	%	acetic	acid/60	
%	 acetonitrile	 and	 lyophilized.	 Samples	were	 analyzed	 by	 nanoscale	 LC-MS/MS	using	 an	







































































10%	FCS	and	pen/strep.	Cells	were	placed	 in	 a	Chamlide	TC-A	 live-cell	 imaging	 chamber	
before	 imaging	 and	were	 kept	 at	 37°C.	 DSB-containing	 tracks	 (1	 or	 1.5	 μm	width)	were	

























(Zeiss)	 and	 an	 HXP	 120	metal-halide	 lamp	 used	 for	 excitation.	 Fluorescent	 probes	were	
5
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relative	 to	 the	 protein	 level	 in	 the	 nucleoplasm	 was	 calculated	 as	 follows:	 ((Idamage	 −	
Ibackground)/(Inucleoplasm	 −	 Ibackground)	 –	 1).	 The	 accumulation	 in	 the	 control	 cells	
transfected	with	siLUC	within	each	experiment	was	normalized	to	100%.	Images	obtained	
from	 live	 cell	 imaging	 after	 multi-photon	 micro-irradiation	 were	 analyzed	 using	 LAS-AF	
software.	Fluorescence	intensities	were	subtracted	by	the	pre-bleach	values	and	normalized	
to	 the	 first	 data	 point,	 which	 was	 set	 to	 0,	 to	 obtain	 relative	 fluorescence	 units	 (RFU).	




GFP	 (1:1000,	 #11814460001,	 Roche),	 PARP1	 (1:1000,	 #9542,	 Cell	 Signaling,	 Alexis),	Myc	
(1:1000,	9E10,	SC-40,	Santa	Cruz),	γH2AX	(1:1000,	#07-164,	Millipore),	α-Tubulin	(Sigma),	
DNA-PKcs	(1:500,	ab1832,	Abcam),	LIG4	(1:1000,	#80514,	Abcam),	XRCC4	(1:500,	gift	from	
Mauro	Modesti),	 Histone	 H3	 (1:2000,	 #1791,	 Abcam),	 GST	 (1:2000,	 Amersham),	 PARP1	
(1:1000,	#9542S,	Cell	Signaling),	PARP2	(1:500,	#C3956,	Sigma),	PAR	(1:1000,	#4336-BPC-
100,	Trevigen;	used	 in	 Fig.	5A-B)	and	PAR	monoclonal	10H,	which	was	purified	 from	 the	

























































Analysis of protein PARylation
Cells	were	washed	with	 ice-cold	PBS	 supplemented	with	PARG	 inhibitor	 (PARGi;	 400	nM	
Tannic	acid),	scraped	in	a	small	volume	of	PBS	with	PARGi	and	transferred	to	low	binding	
tubes,	 followed	 by	 high	 speed	 centrifugation	 at	 4°C.	 Cells	were	 lysed	 in	 RIPA	 buffer	 (10	
mM	Tris-HCl	 (pH	8),	1%	Triton	X-100,	0.1%	deoxycholate,	0.1%	SDS,	100	µM	Tannic	acid)	
supplemented	 with	 protease	 and	 phosphatase	 inhibitor	 cocktails	 (Roche)	 comprising	 a	
NaCl-concentration	 of	 450	 mM.	 After	 centrifugation,	 cleared	 lysates	 were	 subjected	 to	
immunoprecipitation	with	GFP	Trap	beads	(Chromotek)	for	2	hours	on	a	rotating	wheel	in	




















buffer	 (20-30	 ml	 25	 mM	 Tris	 7.5,	 192	 mM	 glycine,	 5	 %	 β-mercaptoethanol,	 0.1%	 SDS)	
followed	by	protein	transfer	to	a	nitrocellulose	membrane	at	4°C.	Membrane	were	rinsed	
three	times	with	TST	buffer	(10	mM	Tris	pH	7.5,	150	mM	NaCl,	0.05	%	Tween)	and	incubated	
in	20	ml	 TST	buffer	 supplemented	with	250	nM	 radioactive	PAR	polymer	on	a	 shaker	at	
room	temperature	for	1	h,	followed	by	three	washes	with	TST	and	one	wash	with	TST	buffer	
containing	500	mM	NaCl.	After	a	final	wash	with	regular	TST,	membranes	were	dried	and	












PAR protection assays 
To	examine	the	effect	of	ZBTB24	on	PAR	protection,	PARP1	activation	reactions	were	carried	
out	in	a	15	µl	assay	volume	with	4	pmol	of	PARP1,	3	µg	of	activated	and	100	µM	unlabeled	
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* * ** ** ns ns ns
A B
Figure S1. T-cell differentiation in ICF2 patients	(related	to	Fig.	1).	Absolute	numbers	(per	μL)	of	the	peripheral	
blood	CD3+CD4+	T-cell	subset	(A)	and	CD3+CD8+	T-cell	subset	(B)	and	the	indicated	differentiation	stages	in	both	




































































































































































































































































Figure S2. Combinational diversity 
and junction characteristics of IgH 
rearrangements (related	 to	 Fig.	
1).	 Heatmaps	 showing	 the	 relative	
frequency	 of	 the	 combinational	
diversity	of	(A)	VH	and	JH	genes	or	(B)	
DH	and	JH	genes	of	unique	productive	
IgH	 rearrangements	 (defined	 by	 the	
unique	 combination	 of	 VH,	 DH,	 JH	
and	 nucleotide	 sequences	 of	 CDR3)	
amplified	 from	control	 (n=4789)	and	
ICF2	 patients	 ICF2-49	 (n=757),	 IFC2-
55	 (n=3723)	 and	 ICF2-67	 (n=1663).	
(C)	 The	 ICF2	 patients	 display	
normal	 numbers	 of	 deletions	 and	
N-nucleotides	 compared	 to	 control	
(n=12),	 in	 contrast	 to	 XRCC4-	 and	
LIG4-deficient	patients	(n=7)	(Murray	
et	 al.	 2015),	 who	 display	 increased	
numbers	of	deletions	and	decreased	















































































































































































Genes involved in 
DSB repair (based on GO):
Helfricht et al., Supplemental Figure 4
siRNA transfection
RNA sequencing analysis
No overlap between ZBTB24-regulated





















Helfricht et al., Supplemental Figure 5
GFP-NLS GFP-ZBTB24
GFP-ZBTB24GFP-NLSGFP-PARP1
Figure S5. ZBTB24 interacts with histone 
H3 (related	 to	 Fig.	 3).	 (A)	 U2OS	 cells	
transiently	 expressing	 GFP-ZBTB24	 or	 GFP-
NLS	were	either	treated	with	DMSO	(Mock)	
or	 with	 PARPi.	 WCEs	 were	 subjected	 to	
GFP-IP	 followed	 by	 western	 blot	 analysis	
of	 the	 indicated	 proteins.	 (B)	 U2OS	 cells	
transfected	 with	 the	 indicated	 GFP-tagged	



















































































Helfricht et al., Supplemental Figure 6
Figure S6. PARG-dependent turnover of PAR chains modulates the accumulation of ZBTB24 at sites of DNA 
damage	(related	to	Fig.	3).	(A)	Western	blot	analysis	showing	total	PAR	levels	in	U2OS	cells	transfected	with	the	
indicated	siRNAs	and	transiently	expressing	GFP-ZBTB24.	Tubulin	is	loading	control.	(B)	GFP-ZBTB24	accumulation	
as	monitored	at	 the	 indicated	time	points	after	 laser	micro-irradiation	 in	cells	 from	A.	 (C)	Quantification	of	 the	








































   












   















































Figure S7. The ZNF domain of ZBTB24 accumulates at sites of DNA damage in a PARP-dependent manner (related	














































Helfricht et al., Supplemental Figure 8









   
   




   
   



































































Supplemental Table 1: Serum Ig isoptype concentrations at first analysis 
 



























6 1.45 3.16-11.48 n.d.  n.d.  
24 n.d.  <0.04 0.63-2.51 <0.06 0.23-1.23 
ICF2-P67 9 <0.33 3.16-11.48 <0.04 0.47-2.04 <0.07 0.13-0.69 
 
The range of age-dependent normal values (g/L) represents the 5th and 95th 










































Supplemental Table 2: List of ZBTB24-regulated genes identified by RNA-seq
HEK293T cells were transfected with siRNAs against Luciferase or ZBTB24 (siZBTB24-8, siZBTB24-9 or siZBTB24-10) and subjected
to RNA-seq. Genes whose expression was affected following treatment with each of the siRNAs against ZBTB24 are shown.  
Ensembl.Gene.ID Associated Gene Name Fold Change log2 Fold Change pval padj
ENSG00000100292 HMOX1 0,242319408 -2,045018134 2,83908E-05 0,018667905
ENSG00000005102 MEOX1 0,323998217 -1,625942223 3,65729E-07 0,001132639
ENSG00000145721 LIX1 0,340926569 -1,552467058 1,61882E-05 0,014854462
ENSG00000230171 RPL22P18 0,356349218 -1,488636337 2,18977E-05 0,016693086
ENSG00000248979 LAMTOR3P2 0,398942805 -1,325746168 6,25567E-05 0,029242879
ENSG00000232027 RP11-275F13.3 0,406609005 -1,298285928 3,71884E-05 0,021937162
ENSG00000271113 RP11-159H10.4 0,416214274 -1,264601652 5,0755E-07 0,00147939
ENSG00000112365 ZBTB24 0,421111515 -1,24772577 1,88817E-20 9,35608E-16
ENSG00000120675 DNAJC15 0,4545578 -1,137464341 4,32056E-05 0,023526151
ENSG00000213480 RP11-364P2.2 0,484195745 -1,046337694 5,86427E-09 4,37278E-05
ENSG00000256940 RP11-783K16.5 0,52099793 -0,940650455 0,000116923 0,04316744
ENSG00000236015 AC011290.5 0,52630168 -0,926038095 0,000000287 0,001016514
ENSG00000224274 ENSAP1 0,53524199 -0,901736796 2,67935E-05 0,018439527
ENSG00000165507 C10orf10 0,54564478 -0,873966047 1,02742E-08 6,36372E-05
ENSG00000254910 RP11-326C3.7 0,548888257 -0,86541562 0,000138315 0,045997476
ENSG00000220494 YAP1P1 0,558208854 -0,841123087 7,82227E-05 0,033340721
ENSG00000130066 SAT1 0,564614975 -0,824660701 2,14387E-05 0,016598569
ENSG00000260563 RP13-516M14.1 0,566027439 -0,821056104 1,48213E-06 0,002937647
ENSG00000247095 MIR210HG 0,571981543 -0,805959501 5,76607E-05 0,028288584
ENSG00000236182 RP11-297K7.1 0,575450831 -0,797235432 2,43288E-05 0,01753826
ENSG00000225770 AC092933.3 0,582534838 -0,779583763 6,17736E-09 4,37278E-05
ENSG00000167733 HSD11B1L 0,583448174 -0,777323583 2,78074E-05 0,018620084
ENSG00000143847 PPFIA4 0,584092594 -0,775731004 5,41691E-07 0,001491185
ENSG00000145293 ENOPH1 0,585854597 -0,771385448 2,87203E-07 0,001016514
ENSG00000229083 PSMA6P2 0,590486762 -0,760023378 0,00006528 0,029950838
ENSG00000230224 PHBP9 0,603938741 -0,727525875 0,000117608 0,04316744
ENSG00000186897 C1QL4 0,614348374 -0,702871109 9,62855E-05 0,038168359
ENSG00000254506 RP11-748H22.1 0,619001977 -0,691984077 4,62144E-05 0,024532999
ENSG00000232380 ZDHHC20P4 0,622162252 -0,684637229 1,60488E-05 0,014854462
ENSG00000176788 BASP1 0,623449344 -0,681655752 2,44221E-05 0,01753826
ENSG00000228986 RP13-228J13.8 0,624530743 -0,679155504 2,96195E-06 0,00456816
ENSG00000244153 WWP1P1 0,625151169 -0,677723003 9,31647E-07 0,002098365
ENSG00000142227 EMP3 0,626777792 -0,673974032 0,000001602 0,00305313
ENSG00000139921 TMX1 0,628377 -0,670297719 7,83921E-07 0,001849717
ENSG00000213290 PGK1P2 0,634386151 -0,656566818 4,91773E-05 0,024846568
ENSG00000237801 AMDP1 0,639994148 -0,643869382 5,45822E-06 0,006596589
ENSG00000131389 SLC6A6 0,64229385 -0,638694612 0,000000987 0,002126309
ENSG00000090054 SPTLC1 0,646719963 -0,628786952 4,71065E-06 0,005835434
ENSG00000230870 FBXW11P1 0,648540377 -0,624731698 0,000112513 0,042558399
ENSG00000236686 BZW1P1 0,651711446 -0,617694761 0,000151113 0,048621906
ENSG00000121966 CXCR4 0,65512456 -0,610158861 4,04265E-06 0,00527151
ENSG00000272520 CTD-2044J15.2 0,656889602 -0,606277165 0,000123013 0,043717729
ENSG00000122203 KIAA1191 0,663631161 -0,591546464 1,96077E-05 0,015596156
ENSG00000198406 BZW1P2 0,663736204 -0,591318126 3,52198E-05 0,021453568
ENSG00000254406 RP11-215D10.1 0,664082175 -0,59056632 1,89685E-05 0,015596156
ENSG00000266282 UBL5P2 0,664657609 -0,589316752 4,38366E-06 0,005569605
ENSG00000254682 RP11-660L16.2 0,665024554 -0,588520486 6,34857E-05 0,029399819
ENSG00000248015 AC005329.7 0,665050876 -0,588463385 0,000075332 0,03274365
ENSG00000169242 EFNA1 0,669841996 -0,578107265 4,08778E-05 0,022802697
ENSG00000141425 RPRD1A 0,672548701 -0,572289355 5,72511E-07 0,001493079
ENSG00000231549 USMG5P1 0,676331869 -0,564196759 2,63535E-05 0,018392137
ENSG00000232801 SDCBPP3 0,679462884 -0,55753335 0,000125842 0,04390957
ENSG00000214121 TDPX2 0,680475654 -0,555384548 1,98292E-05 0,015596156
ENSG00000261612 SUB1P3 0,683524585 -0,548934866 0,000137557 0,045997476
ENSG00000160408 ST6GALNAC6 0,688644251 -0,538169207 6,91152E-05 0,030853386
ENSG00000173674 EIF1AX 0,689250253 -0,536900202 6,15708E-05 0,029240244
ENSG00000249286 CTD-2210P15.2 0,693848208 -0,527308014 0,000114945 0,042824457
ENSG00000258445 RP11-307P22.1 0,693964876 -0,52706545 9,03382E-05 0,036994623
ENSG00000103449 SALL1 0,69616196 -0,522505111 5,27786E-05 0,026152313
ENSG00000270553 RP11-15E18.5 0,69719548 -0,520364879 0,000139701 0,046148875
ENSG00000157514 TSC22D3 0,697842351 -0,51902694 0,000029906 0,018998379
ENSG00000180730 SHISA2 0,698902817 -0,516836234 0,000121026 0,043514535
ENSG00000110218 PANX1 0,700723706 -0,513082391 0,00012818 0,044107264
ENSG00000221988 PPT2 0,701357405 -0,511778279 0,000124609 0,043790708
ENSG00000213409 RP11-658F2.3 0,701489017 -0,511507579 0,000111999 0,042558399
ENSG00000213684 LDHBP2 0,708015124 -0,498147917 0,000100621 0,038952261
ENSG00000006831 ADIPOR2 0,708029432 -0,498118763 8,82767E-05 0,036757985
ENSG00000130522 JUND 0,711466486 -0,491132295 2,95435E-05 0,018998379
ENSG00000257923 CUX1 1,365449977 0,449376462 0,000158375 0,049957002
ENSG00000133059 DSTYK 1,375898777 0,460374336 0,000123519 0,043717729
ENSG00000142156 COL6A1 1,38834809 0,473369329 0,000126719 0,04390957
ENSG00000116260 QSOX1 1,395197484 0,480469343 0,000121035 0,043514535
ENSG00000130363 RSPH3 1,42211213 0,508035222 0,000130535 0,044607681
ENSG00000196562 SULF2 1,422165478 0,508089341 0,000092847 0,037403769
ENSG00000183741 CBX6 1,425280114 0,511245483 1,41245E-05 0,01398908
ENSG00000241360 PDXP 1,425722878 0,511693588 0,000159295 0,049957002
Tabel S2: List of ZBTB24-regulated genes identified by RNA-seq
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Proteins with increased (SILAC ratio H/L  ≥ 4) enrichment with at least 2 unique peptides
Protein names Gene names Fasta headers Peptides Ratio H/L
Zinc finger and BTB domain-containing protein 24 ZBTB24 >sp|O43167|ZBT24_HUMAN Zinc finger and BTB domain-containing protein 24 OS=Homo sapiens GN=ZBTB24 PE=1 SV=2;>sp|O43167-2|ZBT24_HUMAN Isoform 2 of Zinc finger and BTB domain-containing protein 24 OS=Homo sapiens GN=ZBTB2430 13,94
Zinc finger and BTB domain-containing protein 11 ZBTB11 >sp|O95625|ZBT11_HUMAN Zinc finger and BTB domain-containing protein 11 OS=Homo sapiens GN=ZBTB11 PE=1 SV=2;>tr|C9J2L2|C9J2L2_HUMAN Zinc finger and BTB domain-containing protein 11 OS=Homo sapiens GN=ZBTB11 PE=2 SV=12 11,32
Heat shock 70 kDa protein 1A/1B HSPA1A >sp|P08107|HSP71_HUMAN Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5;>sp|P08107-2|HSP71_HUMAN Isoform 2 of Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A;>tr|E7EP94|E7EP94_HUMAN Heat shock 70 kDa protein 1A/1B OS=Homo sapie25 7,57
60S ribosome subunit biogenesis protein NIP7 homolog NIP7 >sp|Q9Y221|NIP7_HUMAN 60S ribosome subunit biogenesis protein NIP7 homolog OS=Homo sapiens GN=NIP7 PE=1 SV=1;>sp|Q9Y221-2|NIP7_HUMAN Isoform 2 of 60S ribosome subunit biogenesis protein NIP7 homolog OS=Homo sapiens GN=NIP7;>tr|J3QRD6|J3QRD6_HUMAN 60S ribos4 7,31
Pentatricopeptide repeat domain-containing protein 3, mitochondrial PTCD3 >sp|Q96EY7|PTCD3_HUMAN Pentatricopeptide repeat domain-containing protein 3, mitochondrial OS=Homo sapiens GN=PTCD3 PE=1 SV=311 7,22
Probable rRNA-processing protein EBP2 EBNA1BP2 >sp|Q99848|EBP2_HUMAN Probable rRNA-processing protein EBP2 OS=Homo sapiens GN=EBNA1BP2 PE=1 SV=2;>tr|H7C2Q8|H7C2Q8_HUMAN EBNA1 binding protein 2, isoform CRA_d OS=Homo sapiens GN=EBNA1BP2 PE=2 SV=19 7,06
Phospholipase DDHD1 DDHD1 >sp|Q8NEL9|DDHD1_HUMAN Phospholipase DDHD1 OS=Homo sapiens GN=DDHD1 PE=1 SV=2;>sp|Q8NEL9-2|DDHD1_HUMAN Isoform 2 of Phospholipase DDHD1 OS=Homo sapiens GN=DDHD1;>sp|Q8NEL9-4|DDHD1_HUMAN Isoform 4 of Phospholipase DDHD1 OS=Homo sapiens GN=DDHD1;>sp|Q8NEL9-322 6,98
Nucleolar complex protein 3 homolog NOC3L >tr|F5H677|F5H677_HUMAN Nucleolar complex protein 3 homolog OS=Homo sapiens GN=NOC3L PE=2 SV=1;>sp|Q8WTT2|NOC3L_HUMAN Nucleolar complex protein 3 homolog OS=Homo sapiens GN=NOC3L PE=1 SV=1;>tr|A6NJZ9|A6NJZ9_HUMAN Nucleolar complex protein 3 homolog OS=Homo2 6,81
Guanine nucleotide-binding protein-like 3 GNL3 >sp|Q9BVP2-2|GNL3_HUMAN Isoform 2 of Guanine nucleotide-binding protein-like 3 OS=Homo sapiens GN=GNL3;>sp|Q9BVP2|GNL3_HUMAN Guanine nucleotide-binding protein-like 3 OS=Homo sapiens GN=GNL3 PE=1 SV=25 6,79
ATP-dependent RNA helicase DDX54 DDX54 >sp|Q8TDD1|DDX54_HUMAN ATP-dependent RNA helicase DDX54 OS=Homo sapiens GN=DDX54 PE=1 SV=2;>sp|Q8TDD1-2|DDX54_HUMAN Isoform 2 of ATP-dependent RNA helicase DDX54 OS=Homo sapiens GN=DDX544 6,65
Putative ribosomal RNA methyltransferase NOP2 NOP2 >sp|P46087-2|NOP2_HUMAN Isoform 2 of Putative ribosomal RNA methyltransferase NOP2 OS=Homo sapiens GN=NOP2;>sp|P46087|NOP2_HUMAN Putative ribosomal RNA methyltransferase NOP2 OS=Homo sapiens GN=NOP2 PE=1 SV=2;>sp|P46087-4|NOP2_HUMAN Isoform 4 of Putative r11 6,36
Ribosome production factor 2 homolog RPF2 >sp|Q9H7B2|RPF2_HUMAN Ribosome production factor 2 homolog OS=Homo sapiens GN=RPF2 PE=1 SV=2;>tr|Q5VXN0|Q5VXN0_HUMAN Ribosome production factor 2 homolog (Fragment) OS=Homo sapiens GN=RPF2 PE=2 SV=12 6,34
28S ribosomal protein S29, mitochondrial DAP3 >sp|P51398-2|RT29_HUMAN Isoform 2 of 28S ribosomal protein S29, mitochondrial OS=Homo sapiens GN=DAP3;>sp|P51398|RT29_HUMAN 28S ribosomal protein S29, mitochondrial OS=Homo sapiens GN=DAP3 PE=1 SV=1;>sp|P51398-3|RT29_HUMAN Isoform 3 of 28S ribosomal protei11 6,23
Pumilio domain-containing protein KIAA0020 KIAA0020 >sp|Q15397|K0020_HUMAN Pumilio domain-containing protein KIAA0020 OS=Homo sapiens GN=KIAA0020 PE=1 SV=37 6,22
Putative helicase MOV-10 MOV10 >tr|Q5JR04|Q5JR04_HUMAN Mov10, Moloney leukemia virus 10, homolog (Mouse), isoform CRA_a OS=Homo sapiens GN=MOV10 PE=2 SV=1;>sp|Q9HCE1|MOV10_HUMAN Putative helicase MOV-10 OS=Homo sapiens GN=MOV10 PE=1 SV=2;>sp|Q9HCE1-2|MOV10_HUMAN Isoform 2 of Putative he2 6,21
ATP-dependent RNA helicase DDX24 DDX24 >tr|F5GYL3|F5GYL3_HUMAN ATP-dependent RNA helicase DDX24 OS=Homo sapiens GN=DDX24 PE=2 SV=1;>sp|Q9GZR7-2|DDX24_HUMAN Isoform 2 of ATP-dependent RNA helicase DDX24 OS=Homo sapiens GN=DDX24;>tr|G3V529|G3V529_HUMAN ATP-dependent RNA helicase DDX24 OS=Homo sap2 6,04
SHC SH2 domain-binding protein 1 SHCBP1 >sp|Q8NEM2|SHCBP_HUMAN SHC SH2 domain-binding protein 1 OS=Homo sapiens GN=SHCBP1 PE=1 SV=32 6,03
Ribosomal L1 domain-containing protein 1 RSL1D1 >sp|O76021|RL1D1_HUMAN Ribosomal L1 domain-containing protein 1 OS=Homo sapiens GN=RSL1D1 PE=1 SV=3;>tr|J3QSV6|J3QSV6_HUMAN Ribosomal L1 domain-containing protein 1 (Fragment) OS=Homo sapiens GN=RSL1D1 PE=2 SV=1;>tr|B4DJ58|B4DJ58_HUMAN Ribosomal L1 domain-15 6,00
Histone H3.2;Histone H3.1;Histone H3;Histone H3.1t;Histone H3.3;Histone H3.3C HIST2H3A;HIST1H3A;H3F3B;H3F3A;HIST3H3;H3F3C>sp|Q71DI3|H32_HUMAN Histone H3.2 OS=Homo sapiens GN=HIST2H3A PE=1 SV=3;>sp|P68431|H31_HUMAN Histone H3.1 OS=Homo sapiens GN=HIST1H3A PE=1 SV=2;>tr|K7EMV3|K7EMV3_HUMAN Histone H3 OS=Homo sapiens GN=H3F3B PE=2 SV=1;>tr|B4DEB1|B4DEB1_HUMAN Histone H3 OS=Homo7 5,98
Ribosome biogenesis protein BRX1 homolog BRIX1 >sp|Q8TDN6|BRX1_HUMAN Ribosome biogenesis protein BRX1 homolog OS=Homo sapiens GN=BRIX1 PE=1 SV=25 5,97
Ankyrin repeat domain-containing protein 17;Ankyrin repeat and KH domain-containing protein 1ANKRD17;ANKHD1 >sp|O75179-6|ANR17_HUMAN Isoform 6 of Ankyrin repeat domain-containing protein 17 OS=Homo sapiens GN=ANKRD17;>tr|H0YM23|H0YM23_HUMAN Ankyrin repeat domain-containing protein 17 (Fragment) OS=Homo sapiens GN=ANKRD17 PE=4 SV=1;>tr|E7EUV3|E7EUV3_HUMAN Ankyrin4 5,86
Serine/threonine-protein phosphatase 6 regulatory subunit 3 PPP6R3 >tr|H7BXH2|H7BXH2_HUMAN Serine/threonine-protein phosphatase 6 regulatory subunit 3 OS=Homo sapiens GN=PPP6R3 PE=2 SV=1;>tr|E9PKF6|E9PKF6_HUMAN Serine/threonine-protein phosphatase 6 regulatory subunit 3 OS=Homo sapiens GN=PPP6R3 PE=2 SV=1;>sp|Q5H9R7-6|PP66 5,84
Histone H2A.V;Histone H2A.Z;Histone H2A H2AFV;H2AFZ >sp|Q71UI9|H2AV_HUMAN Histone H2A.V OS=Homo sapiens GN=H2AFV PE=1 SV=3;>sp|P0C0S5|H2AZ_HUMAN Histone H2A.Z OS=Homo sapiens GN=H2AFZ PE=1 SV=2;>sp|Q71UI9-3|H2AV_HUMAN Isoform 3 of Histone H2A.V OS=Homo sapiens GN=H2AFV;>sp|Q71UI9-4|H2AV_HUMAN Isoform 4 of H3 5,83
Core histone macro-H2A.1 H2AFY >sp|O75367-2|H2AY_HUMAN Isoform 1 of Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY;>sp|O75367-3|H2AY_HUMAN Isoform 3 of Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY;>sp|O75367|H2AY_HUMAN Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY PE=1 SV=48 5,83
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 PLOD3 >sp|O60568|PLOD3_HUMAN Procollagen-lysine,2-oxoglutarate 5-dioxygenase 3 OS=Homo sapiens GN=PLOD3 PE=1 SV=16 5,73
Histone H2B type 1-L;Histone H2B type 1-N;Histone H2B type 1-H;Histone H2B type 1-C/E/F/G/I;Histone H2B type 1-D;Histone H2B type F-S;Histone H2B type 1-K;Histone H2B type 1-M;Histone H2B type 2-F;Histone H2BHIST1H2BL;HIST1H2BN;HIST1H2BH;HIST1H2BC;HIST1H2BD; FS;HIST1 2BK;HIST1H2BM;HIST2H2BF>sp|Q99880|H2B1L_HUMAN Histone H2B type 1-L OS= omo sapiens GN=HIST1H2BL PE=1 SV=3;>sp|Q99877|H2B1N_HUMAN Histone H2B type 1-N OS=Homo sapiens GN=HIST1H2BN PE=1 SV=3;>sp|Q93079|H2B1H_HUMAN Histone H2B type 1-H OS=Homo sapiens GN=HIST1H2BH PE=1 SV=3;>sp|P627 5,72
RRP12-like protein RRP12 >sp|Q5JTH9-2|RRP12_HUMAN Isoform 2 of RRP12-like protein OS=Homo sapiens GN=RRP12;>sp|Q5JTH9-3|RRP12_HUMAN Isoform 3 of RRP12-like protein OS=Homo sapiens GN=RRP12;>sp|Q5JTH9|RRP12_HUMAN RRP12-like protein OS=Homo sapiens GN=RRP12 PE=1 SV=2;>tr|F5H456|F5H46 5,69
Protein mago nashi homolog 2;Protein mago nashi homolog MAGOHB;MAGOH >tr|A6NEC0|A6NEC0_HUMAN Protein mago nashi homolog 2 OS=Homo sapiens GN=MAGOHB PE=2 SV=1;>sp|Q96A72|MGN2_HUMAN Protein mago nashi homolog 2 OS=Homo sapiens GN=MAGOHB PE=1 SV=1;>tr|B1ARP8|B1ARP8_HUMAN Mago-nashi homolog, proliferation-associated (Drosophila3 5,66
Cytoskeleton-associated protein 4 CKAP4 >sp|Q07065|CKAP4_HUMAN Cytoskeleton-associated protein 4 OS=Homo sapiens GN=CKAP4 PE=1 SV=222 5,63
Methylosome protein 50 WDR77 >tr|B4DP38|B4DP38_HUMAN Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=2 SV=1;>sp|Q9BQA1|MEP50_HUMAN Methylosome protein 50 OS=Homo sapiens GN=WDR77 PE=1 SV=1;>tr|H0Y711|H0Y711_HUMAN Methylosome protein 50 (Fragment) OS=Homo sapiens GN=WDR77 PE=4 SV=12 5,59
Histone H1.1;Histone H1t HIST1H1A;HIST1H1T >sp|Q02539|H11_HUMAN Histone H1.1 OS=Homo sapiens GN=HIST1H1A PE=1 SV=3;>sp|P22492|H1T_HUMAN Histone H1t OS=Homo sapiens GN=HIST1H1T PE=2 SV=46 5,59
Histone H1.4;Histone H1.2;Histone H1.3 HIST1H1E;HIST1H1C;HIST1H1D >sp|P10412|H14_HUMAN Histone H1.4 OS=Homo sapiens GN=HIST1H1E PE=1 SV=2;>sp|P16403|H12_HUMAN Histone H1.2 OS=Homo sapiens GN=HIST1H1C PE=1 SV=2;>sp|P16402|H13_HUMAN Histone H1.3 OS=Homo sapiens GN=HIST1H1D PE=1 SV=29 5,59
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 PLOD1 >sp|Q02809|PLOD1_HUMAN Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 OS=Homo sapiens GN=PLOD1 PE=1 SV=2;>tr|B4DR87|B4DR87_HUMAN Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 OS=Homo sapiens GN=PLOD1 PE=2 SV=114 5,58
mRNA turnover protein 4 homolog MRTO4 >sp|Q9UKD2|MRT4_HUMAN mRNA turnover protein 4 homolog OS=Homo sapiens GN=MRTO4 PE=1 SV=22 5,57
Protein KRI1 homolog KRI1 >tr|H0YFD2|H0YFD2_HUMAN Protein KRI1 homolog (Fragment) OS=Homo sapiens GN=KRI1 PE=4 SV=1;>sp|Q8N9T8|KRI1_HUMAN Protein KRI1 homolog OS=Homo sapiens GN=KRI1 PE=1 SV=3;>tr|D3YTE0|D3YTE0_HUMAN Protein KRI1 homolog OS=Homo sapiens GN=KRI1 PE=2 SV=12 5,56
Histone H4 HIST1H4A >sp|P62805|H4_HUMAN Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=211 5,52
Tripartite motif-containing protein 58 TRIM58 >sp|Q8NG06|TRI58_HUMAN Tripartite motif-containing protein 58 OS=Homo sapiens GN=TRIM58 PE=2 SV=23 5,52
Ribonucleases P/MRP protein subunit POP1 POP1 >sp|Q99575|POP1_HUMAN Ribonucleases P/MRP protein subunit POP1 OS=Homo sapiens GN=POP1 PE=1 SV=22 5,48
Growth arrest and DNA damage-inducible proteins-interacting protein 1 GADD45GIP1 >sp|Q8TAE8|G45IP_HUMAN Growth arrest and DNA damage-inducible proteins-interacting protein 1 OS=Homo sapiens GN=GADD45GIP1 PE=1 SV=12 5,45
BAG family molecular chaperone regulator 2 BAG2 >sp|O95816|BAG2_HUMAN BAG family molecular chaperone regulator 2 OS=Homo sapiens GN=BAG2 PE=1 SV=1;>tr|B4DXE2|B4DXE2_HUMAN BAG family molecular chaperone regulator 2 OS=Homo sapiens GN=BAG2 PE=2 SV=1;>tr|A2A296|A2A296_HUMAN BAG family molecular chaperone r3 5,45
Protein SET SET >sp|Q01105-3|SET_HUMAN Isoform 3 of Protein SET OS=Homo sapiens GN=SET;>sp|Q01105-4|SET_HUMAN Isoform 4 of Protein SET OS=Homo sapiens GN=SET;>sp|Q01105-2|SET_HUMAN Isoform 2 of Protein SET OS=Homo sapiens GN=SET;>sp|Q01105|SET_HUMAN Protein SET OS=Homo sa2 5,43
Ribosome biogenesis regulatory protein homolog RRS1 >sp|Q15050|RRS1_HUMAN Ribosome biogenesis regulatory protein homolog OS=Homo sapiens GN=RRS1 PE=1 SV=22 5,41
Nucleolar protein 16 NOP16 >tr|D6RIC3|D6RIC3_HUMAN Nucleolar protein 16 OS=Homo sapiens GN=NOP16 PE=2 SV=1;>sp|Q9Y3C1|NOP16_HUMAN Nucleolar protein 16 OS=Homo sapiens GN=NOP16 PE=1 SV=2;>sp|Q9Y3C1-2|NOP16_HUMAN Isoform 2 of Nucleolar protein 16 OS=Homo sapiens GN=NOP162 5,39
E3 ubiquitin-protein ligase HERC2 HERC2 >sp|O95714|HERC2_HUMAN E3 ubiquitin-protein ligase HERC2 OS=Homo sapiens GN=HERC2 PE=1 SV=22 5,39
Heat shock cognate 71 kDa protein HSPA8 >sp|P11142|HSP7C_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1;>tr|E9PKE3|E9PKE3_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=2 SV=1;>sp|P11142-2|HSP7C_HUMAN Isoform 2 of Heat shock cognate 71 kDa protein27 5,36
Bystin BYSL >sp|Q13895|BYST_HUMAN Bystin OS=Homo sapiens GN=BYSL PE=1 SV=3;>tr|F8WBL2|F8WBL2_HUMAN Bystin OS=Homo sapiens GN=BYSL PE=2 SV=17 5,36
Importin subunit alpha-3 KPNA3 >sp|O00505|IMA4_HUMAN Importin subunit alpha-4 OS=Homo sapiens GN=KPNA3 PE=1 SV=23 5,33
YTH domain-containing protein 1 YTHDC1 >sp|Q96MU7-2|YTDC1_HUMAN Isoform 2 of YTH domain-containing protein 1 OS=Homo sapiens GN=YTHDC1;>sp|Q96MU7|YTDC1_HUMAN YTH domain-containing protein 1 OS=Homo sapiens GN=YTHDC1 PE=1 SV=3;>tr|J3QR07|J3QR07_HUMAN YTH domain-containing protein 1 OS=Homo sapie3 5,32
pre-rRNA processing protein FTSJ3 FTSJ3 >sp|Q8IY81|SPB1_HUMAN pre-rRNA processing protein FTSJ3 OS=Homo sapiens GN=FTSJ3 PE=1 SV=210 5,29
Histone H2B type 2-E;Histone H2B type 1-O;Histone H2B type 1-J;Histone H2B type 3-B;Histone H2B type 1-BHIST2H2BE;HIST1H2BO;HIST1H2BJ;HIST3H2BB;HIST1H2BB>sp|Q16778|H2B2E_HUMAN Histone H2B type 2-E OS=Homo sapiens GN=HIST2H2BE PE=1 SV=3;>sp|P23527|H2B1O_HUMAN Histone H2B type 1-O OS=Homo sapiens GN=HIST1H2BO PE=1 SV=3;>sp|P06899|H2B1J_HUMAN Histone H2B type 1-J OS=Homo sapiens GN=HIST1H2BJ PE=1 SV=3;>sp|Q8N7 5,28
Periodic tryptophan protein 1 homolog PWP1 >tr|B4DJV5|B4DJV5_HUMAN Periodic tryptophan protein 1 homolog OS=Homo sapiens GN=PWP1 PE=2 SV=1;>sp|Q13610|PWP1_HUMAN Periodic tryptophan protein 1 homolog OS=Homo sapiens GN=PWP1 PE=1 SV=14 5,28
Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1 >sp|P63244|GBLP_HUMAN Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens GN=GNB2L1 PE=1 SV=3;>tr|D6RAC2|D6RAC2_HUMAN Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens GN=GNB2L1 PE=2 SV=1;>tr|J3KPE3|J3KPE3_HUMAN 11 5,27
Metastasis-associated protein MTA2 MTA2;DKFZp686F2281 >sp|O94776|MTA2_HUMAN Metastasis-associated protein MTA2 OS=Homo sapiens GN=MTA2 PE=1 SV=1;>tr|Q68DB1|Q68DB1_HUMAN Metastasis-associated protein MTA2 OS=Homo sapiens GN=DKFZp686F2281 PE=2 SV=17 5,26
Melanoma-associated antigen B2 MAGEB2 >sp|O15479|MAGB2_HUMAN Melanoma-associated antigen B2 OS=Homo sapiens GN=MAGEB2 PE=1 SV=32 5,25
Poly [ADP-ribose] polymerase 1 PARP1 >sp|P09874|PARP1_HUMAN Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=47 5,23
Prolow-density lipoprotein receptor-related protein 1;Low-density lipoprotein receptor-related protein 1 85 kDa subunit;Low-density lipoprotein receptor-related protein 1 515 kDa subunit;Low-density lipoprotein receptor-related protein 1 intracellular domainLRP1 >sp|Q07954|LRP1_HUMAN Prolow-density lipoprotein recep or-related protein 1 OS=Homo sap ens GN=LRP1 PE=1 SV=27 5,23
DnaJ homolog subfamily C member 9 DNAJC9 >sp|Q8WXX5|DNJC9_HUMAN DnaJ homolog subfamily C member 9 OS=Homo sapiens GN=DNAJC9 PE=1 SV=12 5,15
Histone H2A type 2-B HIST2H2AB >sp|Q8IUE6|H2A2B_HUMAN Histone H2A type 2-B OS=Homo sapiens GN=HIST2H2AB PE=1 SV=34 5,13
Serine/threonine-protein kinase Nek7;Serine/threonine-protein kinase Nek6 NEK7;NEK6 >sp|Q8TDX7|NEK7_HUMAN Serine/threonine-protein kinase Nek7 OS=Homo sapiens GN=NEK7 PE=1 SV=1;>tr|F5H3U7|F5H3U7_HUMAN Serine/threonine-protein kinase Nek7 (Fragment) OS=Homo sapiens GN=NEK7 PE=2 SV=1;>tr|F8WAG2|F8WAG2_HUMAN Serine/threonine-protein kinase N2 5,08
Probable ubiquitin carboxyl-terminal hydrolase FAF-X USP9X >sp|Q93008-1|USP9X_HUMAN Isoform 2 of Probable ubiquitin carboxyl-terminal hydrolase FAF-X OS=Homo sapiens GN=USP9X;>sp|Q93008|USP9X_HUMAN Probable ubiquitin carboxyl-terminal hydrolase FAF-X OS=Homo sapiens GN=USP9X PE=1 SV=321 5,08
Histone H2A type 1-J;Histone H2A type 1-H;Histone H2A.J;Histone H2A type 2-C;Histone H2A type 2-A;Histone H2A type 1;Histone H2A type 1-D;Histone H2A;Histone H2A type 1-C;Histone H2A type 3;Histone H2A type 1-B/E;Histone H2A type 1-AHIST1H2AJ;HIST1 2AH;H2AFJ;HIST2H2AC; IST2H2AA3; IST1H2AG; IST1H2AD;HIST H2AC;HIST3H2A;HIST1H2AB;HIST1H2AA>sp|Q99878|H2A J_ UMAN Histone 2A type 1-J O = omo sapien  GN= IST1H2AJ P =1 SV=3;>sp|Q96KK5|H2A1H_HUMAN Histone H2A type 1-H OS=Homo sapiens GN=HIST1H2AH PE=1 SV=3;>sp|Q9BTM1|H2AJ_HUMAN Histone H2A.J OS=Homo sapiens GN=H2AFJ PE=1 SV=1;>sp|Q16777|H2A2C_HU6 5,07
Ankyrin repeat and SAM domain-containing protein 3 ANKS3 >tr|D3DUE4|D3DUE4_HUMAN Ankyrin repeat and SAM domain-containing protein 3 OS=Homo sapiens GN=ANKS3 PE=2 SV=1;>sp|Q6ZW76-2|ANKS3_HUMAN Isoform 2 of Ankyrin repeat and SAM domain-containing protein 3 OS=Homo sapiens GN=ANKS3;>sp|Q6ZW76|ANKS3_HUMAN Ankyrin r3 5,05
Putative ATP-dependent RNA helicase DHX30 DHX30 >sp|Q7L2E3-3|DHX30_HUMAN Isoform 3 of Putative ATP-dependent RNA helicase DHX30 OS=Homo sapiens GN=DHX30;>tr|H7BXY3|H7BXY3_HUMAN Putative ATP-dependent RNA helicase DHX30 OS=Homo sapiens GN=DHX30 PE=2 SV=1;>sp|Q7L2E3|DHX30_HUMAN Putative ATP-dependent RNA 17 5,02
RNA-binding protein 8A RBM8A >sp|Q9Y5S9|RBM8A_HUMAN RNA-binding protein 8A OS=Homo sapiens GN=RBM8A PE=1 SV=1;>sp|Q9Y5S9-2|RBM8A_HUMAN Isoform 2 of RNA-binding protein 8A OS=Homo sapiens GN=RBM8A4 4,99
Chromobox protein homolog 3 CBX3 >sp|Q13185|CBX3_HUMAN Chromobox protein homolog 3 OS=Homo sapiens GN=CBX3 PE=1 SV=4;>tr|S4R2Y4|S4R2Y4_HUMAN Chromobox protein homolog 3 (Fragment) OS=Homo sapiens GN=CBX3 PE=4 SV=12 4,98
Protein AATF AATF >sp|Q9NY61|AATF_HUMAN Protein AATF OS=Homo sapiens GN=AATF PE=1 SV=12 4,97
Eukaryotic initiation factor 4A-III EIF4A3 >sp|P38919|IF4A3_HUMAN Eukaryotic initiation factor 4A-III OS=Homo sapiens GN=EIF4A3 PE=1 SV=48 4,95
Histone-binding protein RBBP4;Histone-binding protein RBBP7 RBBP4;RBBP7 >sp|Q09028-3|RBBP4_HUMAN Isoform 3 of Histone-binding protein RBBP4 OS=Homo sapiens GN=RBBP4;>sp|Q09028|RBBP4_HUMAN Histone-binding protein RBBP4 OS=Homo sapiens GN=RBBP4 PE=1 SV=3;>sp|Q09028-2|RBBP4_HUMAN Isoform 2 of Histone-binding protein RBBP4 OS=Homo6 4,94
RNA-binding protein 34 RBM34 >tr|A2A2V2|A2A2V2_HUMAN RNA-binding protein 34 (Fragment) OS=Homo sapiens GN=RBM34 PE=2 SV=1;>sp|P42696|RBM34_HUMAN RNA-binding protein 34 OS=Homo sapiens GN=RBM34 PE=1 SV=23 4,93
Heterogeneous nuclear ribonucleoproteins C1/C2;Heterogeneous nuclear ribonucleoprotein C-like 1HNRNPC;HNRNPCL1 >tr|G3V4W0|G3V4W0_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2 (Fragment) OS=Homo sapiens GN=HNRNPC PE=2 SV=1;>tr|B4DY08|B4DY08_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNPC PE=2 SV=1;>tr|G3V4C1|G3V4C1_HUMAN Heterog10 4,92
Nucleolar RNA helicase 2 DDX21 >sp|Q9NR30-2|DDX21_HUMAN Isoform 2 of Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21;>sp|Q9NR30|DDX21_HUMAN Nucleolar RNA helicase 2 OS=Homo sapiens GN=DDX21 PE=1 SV=511 4,89
78 kDa glucose-regulated protein HSPA5 >sp|P11021|GRP78_HUMAN 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=223 4,87
Heterogeneous nuclear ribonucleoprotein U HNRNPU >sp|Q00839|HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 SV=6;>sp|Q00839-2|HNRPU_HUMAN Isoform Short of Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU12 4,86
RNA-binding protein NOB1 NOB1 >tr|H3BUR4|H3BUR4_HUMAN RNA-binding protein NOB1 OS=Homo sapiens GN=NOB1 PE=2 SV=1;>sp|Q9ULX3|NOB1_HUMAN RNA-binding protein NOB1 OS=Homo sapiens GN=NOB1 PE=1 SV=13 4,85
Y-box-binding protein 3 YBX3 >sp|P16989-3|YBOX3_HUMAN Isoform 3 of Y-box-binding protein 3 OS=Homo sapiens GN=YBX3;>sp|P16989|YBOX3_HUMAN Y-box-binding protein 3 OS=Homo sapiens GN=YBX3 PE=1 SV=4;>sp|P16989-2|YBOX3_HUMAN Isoform 2 of Y-box-binding protein 3 OS=Homo sapiens GN=YBX39 4,83
Oxysterol-binding protein-related protein 3 OSBPL3 >sp|Q9H4L5-2|OSBL3_HUMAN Isoform 1b of Oxysterol-binding protein-related protein 3 OS=Homo sapiens GN=OSBPL3;>sp|Q9H4L5|OSBL3_HUMAN Oxysterol-binding protein-related protein 3 OS=Homo sapiens GN=OSBPL3 PE=1 SV=1;>sp|Q9H4L5-6|OSBL3_HUMAN Isoform 2b of Oxyst2 4,77
N-acetyltransferase 10 NAT10 >sp|Q9H0A0|NAT10_HUMAN N-acetyltransferase 10 OS=Homo sapiens GN=NAT10 PE=1 SV=2;>tr|E7ESU4|E7ESU4_HUMAN N-acetyltransferase 10 OS=Homo sapiens GN=NAT10 PE=2 SV=18 4,76
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit C ANKRD52 >sp|Q8NB46|ANR52_HUMAN Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit C OS=Homo sapiens GN=ANKRD52 PE=1 SV=34 4,76
Leucine-rich repeat-containing protein 1;Protein scribble homolog LRRC1;SCRIB >sp|Q9BTT6|LRRC1_HUMAN Leucine-rich repeat-containing protein 1 OS=Homo sapiens GN=LRRC1 PE=1 SV=1;>tr|Q5T0G3|Q5T0G3_HUMAN Leucine-rich repeat-containing protein 1 OS=Homo sapiens GN=LRRC1 PE=2 SV=1;>sp|Q9BTT6-2|LRRC1_HUMAN Isoform 2 of Leucine-rich repeat2 4,75
Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A ANKRD28 >sp|O15084-2|ANR28_HUMAN Isoform 2 of Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A OS=Homo sapiens GN=ANKRD28;>sp|O15084|ANR28_HUMAN Serine/threonine-protein phosphatase 6 regulatory ankyrin repeat subunit A OS=Homo sapiens GN3 4,73
Histone H1.0 H1F0 >sp|P07305|H10_HUMAN Histone H1.0 OS=Homo sapiens GN=H1F0 PE=1 SV=3;>sp|P07305-2|H10_HUMAN Isoform 2 of Histone H1.0 OS=Homo sapiens GN=H1F07 4,68
Melanoma-associated antigen C1 MAGEC1 >tr|A0PK03|A0PK03_HUMAN MAGEC1 protein OS=Homo sapiens GN=MAGEC1 PE=2 SV=1;>sp|O60732|MAGC1_HUMAN Melanoma-associated antigen C1 OS=Homo sapiens GN=MAGEC1 PE=1 SV=32 4,68
Dedicator of cytokinesis protein 6 DOCK6 >sp|Q96HP0|DOCK6_HUMAN Dedicator of cytokinesis protein 6 OS=Homo sapiens GN=DOCK6 PE=1 SV=3;>tr|C9IZV6|C9IZV6_HUMAN Dedicator of cytokinesis protein 6 OS=Homo sapiens GN=DOCK6 PE=2 SV=2;>tr|K7ESB7|K7ESB7_HUMAN Dedicator of cytokinesis protein 6 (Fragment)15 4,67
Histone H1x H1FX >sp|Q92522|H1X_HUMAN Histone H1x OS=Homo sapiens GN=H1FX PE=1 SV=13 4,66
Ribosome biogenesis protein BOP1 BOP1;KM-PA-2 >tr|E9PIF8|E9PIF8_HUMAN Ribosome biogenesis protein BOP1 (Fragment) OS=Homo sapiens GN=BOP1 PE=2 SV=1;>tr|Q96Q25|Q96Q25_HUMAN Ribosome biogenesis protein BOP1 OS=Homo sapiens GN=KM-PA-2 PE=2 SV=1;>sp|Q14137|BOP1_HUMAN Ribosome biogenesis protein BOP1 OS=Ho2 4,64
Pinin PNN >sp|Q9H307|PININ_HUMAN Pinin OS=Homo sapiens GN=PNN PE=1 SV=4;>sp|Q9H307-2|PININ_HUMAN Isoform 2 of Pinin OS=Homo sapiens GN=PNN6 4,59
Protein arginine N-methyltransferase 5;Protein arginine N-methyltransferase 5, N-terminally processedPRMT5 >sp|O14744-2|ANM5_HUMAN Isoform 2 of Protein arginine N-methyltransferase 5 OS=Homo sapiens GN=PRMT5;>sp|O14744|ANM5_HUMAN Protein arginine N-methyltransferase 5 OS=Homo sapiens GN=PRMT5 PE=1 SV=4;>tr|B4DV00|B4DV00_HUMAN Protein arginine N-methyltransferas6 4,55
RNA-binding protein PNO1 PNO1 >sp|Q9NRX1|PNO1_HUMAN RNA-binding protein PNO1 OS=Homo sapiens GN=PNO1 PE=1 SV=1;>tr|F8WBJ6|F8WBJ6_HUMAN RNA-binding protein PNO1 OS=Homo sapiens GN=PNO1 PE=2 SV=14 4,54
Protein LTV1 homolog LTV1 >sp|Q96GA3|LTV1_HUMAN Protein LTV1 homolog OS=Homo sapiens GN=LTV1 PE=1 SV=13 4,48
Heterogeneous nuclear ribonucleoprotein M HNRNPM >sp|P52272-2|HNRPM_HUMAN Isoform 2 of Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens GN=HNRNPM;>sp|P52272|HNRPM_HUMAN Heterogeneous nuclear ribonucleoprotein M OS=Homo sapiens GN=HNRNPM PE=1 SV=3;>tr|M0R019|M0R019_HUMAN Heterogeneous nuclear rib6 4,45
Transformer-2 protein homolog beta TRA2B >sp|P62995|TRA2B_HUMAN Transformer-2 protein homolog beta OS=Homo sapiens GN=TRA2B PE=1 SV=1;>sp|P62995-3|TRA2B_HUMAN Isoform 3 of Transformer-2 protein homolog beta OS=Homo sapiens GN=TRA2B;>tr|H7BXF3|H7BXF3_HUMAN Transformer-2 protein homolog beta (Fragm7 4,43
Serine/arginine-rich splicing factor 6;Serine/arginine-rich splicing factor 4 SRSF6;SRSF4 >sp|Q13247-3|SRSF6_HUMAN Isoform SRP55-3 of Serine/arginine-rich splicing factor 6 OS=Homo sapiens GN=SRSF6;>sp|Q13247|SRSF6_HUMAN Serine/arginine-rich splicing factor 6 OS=Homo sapiens GN=SRSF6 PE=1 SV=2;>sp|Q08170|SRSF4_HUMAN Serine/arginine-rich splicin3 4,43






































Tabel S4: Proteins identified as PARP1 interactors by SILAC MS ordered by H/L




Proteins with increased (SILAC ratio H/L  ≥ 2) enrichment with at least 2 unique peptides
Protein names Gene names Fasta headers Peptides Ratio H/L
Zinc finger and BTB domain-containing protein 24 ZBTB24 >sp|O43167|ZBT24_HUMAN Zinc finger and BTB domain-containing protein 24 OS=Homo sapiens GN=ZBTB24 PE=1 SV=2;>sp|O43167-2|ZBT24_HUMAN Isoform 2 of Zinc finger and BTB domain-containing protein 24 OS=Homo sapiens GN=ZBTB242 10,02
Poly [ADP-ribose] polymerase 1 PARP1 >sp|P09874|PARP1_HUMAN Poly [ADP-ribose] polymerase 1 OS=Homo sapiens GN=PARP1 PE=1 SV=468 8,92
DNA polymerase beta POLB >tr|E7EW18|E7EW18_HUMAN DNA polymerase beta (Fragment) OS=Homo sapiens GN=POLB PE=2 SV=1;>sp|P06746|DPOLB_HUMAN DNA polymerase beta OS=Homo sapiens GN=POLB PE=1 SV=3;>tr|E5RIJ0|E5RIJ0_HUMAN DNA polymerase beta OS=Homo sapiens GN=POLB PE=2 SV=1;>tr|H0YBJ0|H3 8,83
Bifunctional polynucleotide phosphatase/kinase;Polynucleotide 3-phosphatase;Polynucleotide 5-hydroxyl-kinasePNKP >tr|M0R3C8|M0R3C8_HUMAN Bifunctional polynucleotide phosphatase/kinase OS=Homo sapiens GN=PNKP PE=2 SV=1;>tr|M0QYH2|M0QYH2_HUMAN Bifunctional polynucleotide phosphatase/kinase OS=Homo sapiens GN=PNKP PE=2 SV=1;>sp|Q96T60|PNKP_HUMAN Bifunctional polynucleot4 7,06
DNA repair protein XRCC1 XRCC1 >tr|F5H8D7|F5H8D7_HUMAN DNA repair protein XRCC1 OS=Homo sapiens GN=XRCC1 PE=2 SV=1;>sp|P18887|XRCC1_HUMAN DNA repair protein XRCC1 OS=Homo sapiens GN=XRCC1 PE=1 SV=25 6,15
DNA ligase 3 LIG3 >sp|P49916|DNLI3_HUMAN DNA ligase 3 OS=Homo sapiens GN=LIG3 PE=1 SV=2;>sp|P49916-2|DNLI3_HUMAN Isoform Beta of DNA ligase 3 OS=Homo sapiens GN=LIG3;>tr|K7ERZ5|K7ERZ5_HUMAN DNA ligase 3 (Fragment) OS=Homo sapiens GN=LIG3 PE=2 SV=120 5,88
Chromodomain-helicase-DNA-binding protein 1-like CHD1L >sp|Q86WJ1-2|CHD1L_HUMAN Isoform 2 of Chromodomain-helicase-DNA-binding protein 1-like OS=Homo sapiens GN=CHD1L;>sp|Q86WJ1|CHD1L_HUMAN Chromodomain-helicase-DNA-binding protein 1-like OS=Homo sapiens GN=CHD1L PE=1 SV=2;>tr|B5MDZ7|B5MDZ7_HUMAN Chromodomain-3 5,85
Core histone macro-H2A.1 H2AFY >sp|O75367-2|H2AY_HUMAN Isoform 1 of Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY;>sp|O75367-3|H2AY_HUMAN Isoform 3 of Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY;>sp|O75367|H2AY_HUMAN Core histone macro-H2A.1 OS=Homo sapiens GN=H2AFY PE=1 SV=45 5,48
Histone H2B type 1-L;Histone H2B type 1-N;Histone H2B type 1-H;Histone H2B type 1-C/E/F/G/I;Histone H2B type 1-D;Histone H2B type F-S;Histone H2B type 1-K;Histone H2B type 1-M;Histone H2B type 2-F;Histone H2BHIST1H2BL;HIST1 N;HIST1H2BH;HIST1H2BC;HI T1H2BD;H2BFS;HIST1H2BK;HIST1H2BM;HIST2H2BF>sp|Q99880|H2B1L_ UMAN istone 2B type 1-L OS= omo sapiens GN=HIST1H BL PE=1 SV=3;>sp|Q99877|H2B1N_HUMAN Histone H2B type 1-N OS=Homo sapiens GN=HIST1H2BN PE=1 SV=3;>sp|Q93079|H2B1H_HUMAN Histone H2B type 1-H OS=Homo sapiens GN=HIST1H2BH PE=1 SV=3;>sp|P625 5,14
Histone H2A.V;Histone H2A.Z;Histone H2A H2AFV;H2AFZ >sp|Q71UI9|H2AV_HUMAN Histone H2A.V OS=Homo sapiens GN=H2AFV PE=1 SV=3;>sp|P0C0S5|H2AZ_HUMAN Histone H2A.Z OS=Homo sapiens GN=H2AFZ PE=1 SV=2;>sp|Q71UI9-3|H2AV_HUMAN Isoform 3 of Histone H2A.V OS=Homo sapiens GN=H2AFV;>sp|Q71UI9-4|H2AV_HUMAN Isoform 4 of H4 5,02
Histone H4 HIST1H4A >sp|P62805|H4_HUMAN Histone H4 OS=Homo sapiens GN=HIST1H4A PE=1 SV=29 4,92
Histone H3.2;Histone H3.1;Histone H3;Histone H3.1t;Histone H3.3;Histone H3.3C HIST2H3A;HIST1H3A;H3F3B;H3F3A;HIST3H3;H3F3C>sp|Q71DI | 2_HUMAN Histone H3.2 OS=Homo sapiens GN=HIST2H3A PE=1 SV=3;>sp|P68431|H31_HUMAN Histone H3.1 OS=Homo sapiens GN=HIST1H3A PE=1 SV=2;>tr|K7EMV3|K7EMV3_HUMAN Histone H3 OS=Homo sapiens GN=H3F3B PE=2 SV=1;>tr|B4DEB1|B4DEB1_HUMAN Histone H3 OS=Homo5 4,83
Histone H2B type 2-E;Histone H2B type 1-O;Histone H2B type 1-J;Histone H2B type 3-B;Histone H2B type 1-BHIST2H2BE;HIST1H2BO;HIST1H2BJ;HIST3H2BB;HIST1H2BB>sp|Q16778|H2B2E_HUMAN Histone H2B type 2-E OS=Homo sapiens GN=HIST2H2BE PE=1 SV=3;>sp|P23527|H2B1O_HUMAN Histone H2B type 1-O OS=Homo sapiens GN=HIST1H2BO PE=1 SV=3;>sp|P06899|H2B1J_HUMAN Histone H2B type 1-J OS=Homo sapiens GN=HIST1H2BJ PE=1 SV=3;>sp|Q8N6 4,74
Histone H2A type 2-B HIST2H2AB >sp|Q8IUE6|H2A2B_HUMAN Histone H2A type 2-B OS=Homo sapiens GN=HIST2H2AB PE=1 SV=33 4,70
Histone H2A type 1-J;Histone H2A type 1-H;Histone H2A.J;Histone H2A type 2-C;Histone H2A type 2-A;Histone H2A type 1;Histone H2A type 1-D;Histone H2A;Histone H2A type 1-C;Histone H2A type 3;Histone H2A type 1-B/E;Histone H2A type 1-AHIST1H2AJ;HIST1H2AH; FJ;HIST2H2AC; IST2H2AA3; IST1H2AG; IST1H2AD;HIST1H2AC;HIST3H2A;HIST1H2AB; IST1H2AA>sp|Q99878|H2A1J_HUMAN Histone 2A type 1-J O =Homo api ns GN= J PE=1 SV=3;>sp|Q96KK5|H2A1H_HUMAN Histone H2A type 1-H OS=Homo sapiens GN=HIST1H2AH PE=1 SV=3;>sp|Q9BTM1|H2AJ_HUMAN Histone H2A.J OS=Homo sapiens GN=H2AFJ PE=1 SV=1;>sp|Q16777|H2A2C_HU4 4,40
Inosine-5-monophosphate dehydrogenase 2 IMPDH2 >tr|H0Y4R1|H0Y4R1_HUMAN Inosine-5-monophosphate dehydrogenase 2 (Fragment) OS=Homo sapiens GN=IMPDH2 PE=3 SV=1;>sp|P12268|IMDH2_HUMAN Inosine-5-monophosphate dehydrogenase 2 OS=Homo sapiens GN=IMPDH2 PE=1 SV=26 4,30
Heat shock 70 kDa protein 1A/1B HSPA1A >sp|P08107|HSP71_HUMAN Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A PE=1 SV=5;>sp|P08107-2|HSP71_HUMAN Isoform 2 of Heat shock 70 kDa protein 1A/1B OS=Homo sapiens GN=HSPA1A;>tr|E7EP94|E7EP94_HUMAN Heat shock 70 kDa protein 1A/1B OS=Homo sapie14 3,51
DNA topoisomerase 2;DNA topoisomerase 2-alpha;DNA topoisomerase 2-beta TOP2B;TOP2A >tr|E9PCY5|E9PCY5_HUMAN DNA topoisomerase 2 (Fragment) OS=Homo sapiens GN=TOP2B PE=2 SV=1;>sp|P11388|TOP2A_HUMAN DNA topoisomerase 2-alpha OS=Homo sapiens GN=TOP2A PE=1 SV=3;>sp|P11388-2|TOP2A_HUMAN Isoform 2 of DNA topoisomerase 2-alpha OS=Homo sapiens GN2 ,99
Ubiquitin-60S ribosomal protein L40;Ubiquitin;60S ribosomal protein L40;Ubiquitin-40S ribosomal protein S27a;Ubiquitin;40S ribosomal protein S27a;Polyubiquitin-B;Ubiquitin;Polyubiquitin-C;UbiquitinUBB;RPS27A;UBC;UBA52;UBBP >tr|J3QS39|J3QS39_HUMAN Ubiquitin (Fragment) OS=Homo sapiens GN=UBB PE=2 SV=1;>tr|J3QTR3|J3QTR3_HUMAN Ubiquitin (Fragment) OS=Homo sapiens GN=RPS27A PE=1 SV=1;>tr|F5H6Q2|F5H6Q2_HUMAN Polyubiquitin-C (Fragment) OS=Homo sapiens GN=UBC PE=2 SV=1;>sp|P62987|RL2 2,83
Heat shock cognate 71 kDa protein HSPA8 >sp|P11142|HSP7C_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1;>tr|E9PKE3|E9PKE3_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=2 SV=1;>sp|P11142-2|HSP7C_HUMAN Isoform 2 of Heat shock cognate 71 kDa protein16 2,76
Nuclease-sensitive element-binding protein 1 YBX1 >sp|P67809|YBOX1_HUMAN Nuclease-sensitive element-binding protein 1 OS=Homo sapiens GN=YBX1 PE=1 SV=3;>tr|H0Y449|H0Y449_HUMAN Nuclease-sensitive element-binding protein 1 (Fragment) OS=Homo sapiens GN=YBX1 PE=4 SV=14 2,33
78 kDa glucose-regulated protein HSPA5 >sp|P11021|GRP78_HUMAN 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=213 2,32
Nucleolin NCL >sp|P19338|NUCL_HUMAN Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3;>tr|H7BY16|H7BY16_HUMAN Nucleolin (Fragment) OS=Homo sapiens GN=NCL PE=2 SV=15 1,94
Heterogeneous nuclear ribonucleoproteins C1/C2;Heterogeneous nuclear ribonucleoprotein C-like 1HNRNPC;HNRNPCL1 >tr|G3V4W0|G3V4W0_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2 (Fragment) OS=Homo sapiens GN=HNRNPC PE=2 SV=1;>tr|B4DY08|B4DY08_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2 OS=Homo sapiens GN=HNRNPC PE=2 SV=1;>tr|G3V4C1|G3V4C1_HUMAN Heterog2 1,94
Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1 >sp|P63244|GBLP_HUMAN Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens GN=GNB2L1 PE=1 SV=3;>tr|D6RAC2|D6RAC2_HUMAN Guanine nucleotide-binding protein subunit beta-2-like 1 OS=Homo sapiens GN=GNB2L1 PE=2 SV=1;>tr|J3KPE3|J3KPE3_HUMAN 4 1,92
Tubulin beta-4B chain TUBB4B >sp|P68371|TBB4B_HUMAN Tubulin beta-4B chain OS=Homo sapiens GN=TUBB4B PE=1 SV=19 1,50
Tubulin alpha-1B chain;Tubulin alpha-1C chain TUBA1B;TUBA1C >sp|P68363|TBA1B_HUMAN Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1;>sp|Q9BQE3|TBA1C_HUMAN Tubulin alpha-1C chain OS=Homo sapiens GN=TUBA1C PE=1 SV=1;>ENSEMBL:ENSBTAP00000016242 (Bos taurus) similar to alpha-tubulin I isoform 1;>tr|F5H5D3|F5H8 1,23
Heterogeneous nuclear ribonucleoprotein U HNRNPU >sp|Q00839|HNRPU_HUMAN Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU PE=1 SV=6;>sp|Q00839-2|HNRPU_HUMAN Isoform Short of Heterogeneous nuclear ribonucleoprotein U OS=Homo sapiens GN=HNRNPU2 1,21
Tubulin beta chain TUBB >tr|Q5JP53|Q5JP53_HUMAN Tubulin beta chain OS=Homo sapiens GN=TUBB PE=2 SV=1;>sp|P07437|TBB5_HUMAN Tubulin beta chain OS=Homo sapiens GN=TUBB PE=1 SV=2;>tr|Q5ST81|Q5ST81_HUMAN Tubulin beta chain OS=Homo sapiens GN=TUBB PE=2 SV=110 1,17
ADP/ATP translocase 3 SLC25A6 >sp|P12236|ADT3_HUMAN ADP/ATP translocase 3 OS=Homo sapiens GN=SLC25A6 PE=1 SV=4;>tr|I7HJJ0|I7HJJ0_HUMAN ADP/ATP translocase 3 (Fragment) OS=Homo sapiens GN=SLC25A6 PE=2 SV=12 1,17
Tubulin alpha-3C/D chain;Tubulin alpha-3E chain TUBA3C;TUBA3E >sp|Q13748|TBA3C_HUMAN Tubulin alpha-3C/D chain OS=Homo sapiens GN=TUBA3C PE=1 SV=3;>sp|Q13748-2|TBA3C_HUMAN Isoform 2 of Tubulin alpha-3C/D chain OS=Homo sapiens GN=TUBA3C;>sp|Q6PEY2|TBA3E_HUMAN Tubulin alpha-3E chain OS=Homo sapiens GN=TUBA3E PE=1 SV=29 1,15
ADP/ATP translocase 2;ADP/ATP translocase 1 SLC25A5;SLC25A4 >sp|P05141|ADT2_HUMAN ADP/ATP translocase 2 OS=Homo sapiens GN=SLC25A5 PE=1 SV=7;>sp|P12235|ADT1_HUMAN ADP/ATP translocase 1 OS=Homo sapiens GN=SLC25A4 PE=1 SV=4;>tr|V9GYG0|V9GYG0_HUMAN ADP/ATP translocase 1 OS=Homo sapiens GN=SLC25A4 PE=3 SV=12 1,13
Pyruvate kinase isozymes M1/M2;Pyruvate kinase PKM;PKM2 >sp|P14618|KPYM_HUMAN Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4;>sp|P14618-3|KPYM_HUMAN Isoform 3 of Pyruvate kinase PKM OS=Homo sapiens GN=PKM;>sp|P14618-2|KPYM_HUMAN Isoform M1 of Pyruvate kinase PKM OS=Homo sapiens GN=PKM;>tr|H3BTN5|H3BTN5_HU6 1,10
Clathrin heavy chain 1 CLTC >sp|Q00610-2|CLH1_HUMAN Isoform 2 of Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC;>sp|Q00610|CLH1_HUMAN Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=52 1,03
Nucleophosmin NPM1 >sp|P06748-2|NPM_HUMAN Isoform 2 of Nucleophosmin OS=Homo sapiens GN=NPM1;>sp|P06748|NPM_HUMAN Nucleophosmin OS=Homo sapiens GN=NPM1 PE=1 SV=2;>sp|P06748-3|NPM_HUMAN Isoform 3 of Nucleophosmin OS=Homo sapiens GN=NPM12 1,03
Galectin-1 LGALS1 >sp|P09382|LEG1_HUMAN Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=22 1,02
Heat shock protein beta-1 HSPB1 >sp|P04792|HSPB1_HUMAN Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=1 SV=2;>tr|F8WE04|F8WE04_HUMAN Heat shock protein beta-1 OS=Homo sapiens GN=HSPB1 PE=2 SV=12 0,97
Vimentin VIM >sp|P08670|VIME_HUMAN Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4;>tr|B0YJC4|B0YJC4_HUMAN Vimentin OS=Homo sapiens GN=VIM PE=2 SV=110 0,91
LanC-like protein 2 LANCL2 >sp|Q9NS86|LANC2_HUMAN LanC-like protein 2 OS=Homo sapiens GN=LANCL2 PE=1 SV=12 0,90
Elongation factor 1-delta EEF1D >sp|P29692-3|EF1D_HUMAN Isoform 3 of Elongation factor 1-delta OS=Homo sapiens GN=EEF1D;>tr|E9PK01|E9PK01_HUMAN Elongation factor 1-delta (Fragment) OS=Homo sapiens GN=EEF1D PE=2 SV=1;>sp|P29692|EF1D_HUMAN Elongation factor 1-delta OS=Homo sapiens GN=EEF1D2 0,86
DNA replication licensing factor MCM3 MCM3 >sp|P25205|MCM3_HUMAN DNA replication licensing factor MCM3 OS=Homo sapiens GN=MCM3 PE=1 SV=3;>tr|B4DWW4|B4DWW4_HUMAN DNA replication licensing factor MCM3 OS=Homo sapiens GN=MCM3 PE=2 SV=1;>tr|J3KQ69|J3KQ69_HUMAN DNA replication licensing factor MCM3 OS=H5 0,83
Annexin A2;Annexin;Putative annexin A2-like protein ANXA2;ANXA2P2 >sp|P07355|ANXA2_HUMAN Annexin A2 OS=Homo sapiens GN=ANXA2 PE=1 SV=2;>sp|P07355-2|ANXA2_HUMAN Isoform 2 of Annexin A2 OS=Homo sapiens GN=ANXA2;>tr|H0YN42|H0YN42_HUMAN Annexin (Fragment) OS=Homo sapiens GN=ANXA2 PE=2 SV=1;>tr|H0YMD0|H0YMD0_HUMAN Annexin (Fr15 0,80
Cystatin-B CSTB >sp|P04080|CYTB_HUMAN Cystatin-B OS=Homo sapiens GN=CSTB PE=1 SV=22 0,80
Filamin-A FLNA >tr|Q5HY54|Q5HY54_HUMAN Filamin-A OS=Homo sapiens GN=FLNA PE=2 SV=1;>sp|P21333-2|FLNA_HUMAN Isoform 2 of Filamin-A OS=Homo sapiens GN=FLNA;>sp|P21333|FLNA_HUMAN Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=42 0,80
ATP-dependent RNA helicase DDX3X;ATP-dependent RNA helicase DDX3Y DDX3X;DDX3Y >sp|O00571-2|DDX3X_HUMAN Isoform 2 of ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X;>sp|O00571|DDX3X_HUMAN ATP-dependent RNA helicase DDX3X OS=Homo sapiens GN=DDX3X PE=1 SV=3;>tr|B4DXX7|B4DXX7_HUMAN Uncharacterized protein OS=Homo sapiens GN=DD3 0,79
Melanoma-associated antigen 4;Melanoma-associated antigen 8 MAGEA4;MAGEA8 >sp|P43358|MAGA4_HUMAN Melanoma-associated antigen 4 OS=Homo sapiens GN=MAGEA4 PE=1 SV=2;>sp|P43361|MAGA8_HUMAN Melanoma-associated antigen 8 OS=Homo sapiens GN=MAGEA8 PE=2 SV=22 0,78
Heterogeneous nuclear ribonucleoprotein H;Heterogeneous nuclear ribonucleoprotein H, N-terminally processedNRNPH1 >sp|P31943|HNRH1_HUMAN Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens GN=HNRNPH1 PE=1 SV=4;>tr|G8JLB6|G8JLB6_HUMAN Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens GN=HNRNPH1 PE=2 SV=1;>tr|E9PCY7|E9PCY7_HUMAN Heterogeneous nuclear ribon3 0,77
Endoplasmic reticulum resident protein 44 ERP44 >sp|Q9BS26|ERP44_HUMAN Endoplasmic reticulum resident protein 44 OS=Homo sapiens GN=ERP44 PE=1 SV=13 0,77
Glyceraldehyde-3-phosphate dehydrogenase GAPDH >sp|P04406-2|G3P_HUMAN Isoform 2 of Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH;>sp|P04406|G3P_HUMAN Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3;>tr|E7EUT5|E7EUT5_HUMAN Glyceraldehyde-3-phosphate dehydr2 0,77
Profilin PFN2 >tr|C9J0J7|C9J0J7_HUMAN Profilin-2 OS=Homo sapiens GN=PFN2 PE=2 SV=1;>sp|P35080-2|PROF2_HUMAN Isoform IIb of Profilin-2 OS=Homo sapiens GN=PFN2;>tr|G5E9Q6|G5E9Q6_HUMAN Profilin OS=Homo sapiens GN=PFN2 PE=2 SV=1;>tr|C9JQ45|C9JQ45_HUMAN Profilin OS=Homo sapi4 0,77
Peroxiredoxin-1 PRDX1 >sp|Q06830|PRDX1_HUMAN Peroxiredoxin-1 OS=Homo sapiens GN=PRDX1 PE=1 SV=19 0,76
Phenylalanine--tRNA ligase beta subunit FARSB >sp|Q9NSD9|SYFB_HUMAN Phenylalanine--tRNA ligase beta subunit OS=Homo sapiens GN=FARSB PE=1 SV=3;>tr|F5H6Y1|F5H6Y1_HUMAN Phenylalanine--tRNA ligase beta subunit OS=Homo sapiens GN=FARSB PE=2 SV=13 0,75
Cysteine and glycine-rich protein 2 CSRP2 >sp|Q16527|CSRP2_HUMAN Cysteine and glycine-rich protein 2 OS=Homo sapiens GN=CSRP2 PE=1 SV=3;>tr|F8VW96|F8VW96_HUMAN Cysteine and glycine-rich protein 2 OS=Homo sapiens GN=CSRP2 PE=2 SV=1;>tr|F8VQR7|F8VQR7_HUMAN Cysteine and glycine-rich protein 2 OS=Homo5 0,74
Probable ATP-dependent RNA helicase DDX17 DDX17 >sp|Q92841-1|DDX17_HUMAN Isoform 2 of Probable ATP-dependent RNA helicase DDX17 OS=Homo sapiens GN=DDX17;>sp|Q92841-3|DDX17_HUMAN Isoform 4 of Probable ATP-dependent RNA helicase DDX17 OS=Homo sapiens GN=DDX17;>sp|Q92841|DDX17_HUMAN Probable ATP-dependent 4 0,74
Filamin-C FLNC >sp|Q14315-2|FLNC_HUMAN Isoform 2 of Filamin-C OS=Homo sapiens GN=FLNC;>sp|Q14315|FLNC_HUMAN Filamin-C OS=Homo sapiens GN=FLNC PE=1 SV=33 0,74
Crk-like protein CRKL >sp|P46109|CRKL_HUMAN Crk-like protein OS=Homo sapiens GN=CRKL PE=1 SV=14 0,72
Putative elongation factor 1-alpha-like 3;Elongation factor 1-alpha 1 EEF1A1P5;EEF1A1 >sp|Q5VTE0|EF1A3_HUMAN Putative elongation factor 1-alpha-like 3 OS=Homo sapiens GN=EEF1A1P5 PE=5 SV=1;>sp|P68104|EF1A1_HUMAN Elongation factor 1-alpha 1 OS=Homo sapiens GN=EEF1A1 PE=1 SV=18 0,72
CTP synthase 1 CTPS1 >sp|P17812|PYRG1_HUMAN CTP synthase 1 OS=Homo sapiens GN=CTPS1 PE=1 SV=2;>tr|B4DR64|B4DR64_HUMAN CTP synthase OS=Homo sapiens GN=CTPS1 PE=2 SV=16 0,72
Heat shock protein HSP 90-beta HSP90AB1 >sp|P08238|HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=45 0,71
Myosin-9 MYH9 >sp|P35579|MYH9_HUMAN Myosin-9 OS=Homo sapiens GN=MYH9 PE=1 SV=4;>sp|P35579-2|MYH9_HUMAN Isoform 2 of Myosin-9 OS=Homo sapiens GN=MYH93 0,68
Probable ATP-dependent RNA helicase DDX5 DDX5 >sp|P17844|DDX5_HUMAN Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens GN=DDX5 PE=1 SV=1;>tr|J3KTA4|J3KTA4_HUMAN Probable ATP-dependent RNA helicase DDX5 OS=Homo sapiens GN=DDX5 PE=2 SV=1;>tr|B4DLW8|B4DLW8_HUMAN Probable ATP-dependent RNA helicase 5 0,65
Actin, cytoplasmic 2;Actin, cytoplasmic 2, N-terminally processed;Actin, cytoplasmic 1;Actin, cytoplasmic 1, N-terminally processed;Actin, alpha skeletal muscle;Actin, alpha cardiac muscle 1;Actin, gamma-enteric smooth muscle;Actin, aortic smooth muscleCTG1;ACTB;ACTA1;ACTC1;ACTG2;ACTA2>sp|P63261|ACTG_HUMAN Actin, cytoplasmic 2 OS=Homo sapi ns GN=ACTG1 PE=1 SV=1;>sp|P60709|ACTB_HUMAN Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1;>P60712 SWISS-PROT:P60712 (Bos taurus) Actin, cytoplasmic 1;>tr|I3L3I0|I3L3I0_HUMAN Actin, cytoplasmi12 0,65
Peptidyl-prolyl cis-trans isomerase A;Peptidyl-prolyl cis-trans isomerase PPIA >sp|P62937|PPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A OS=Homo sapiens GN=PPIA PE=1 SV=2;>tr|F8WE65|F8WE65_HUMAN Peptidyl-prolyl cis-trans isomerase OS=Homo sapiens GN=PPIA PE=2 SV=1;>tr|C9J5S7|C9J5S7_HUMAN Peptidyl-prolyl cis-trans isomerase OS=Homo 2 0,63
Cofilin-1 CFL1 >sp|P23528|COF1_HUMAN Cofilin-1 OS=Homo sapiens GN=CFL1 PE=1 SV=3;>tr|G3V1A4|G3V1A4_HUMAN Cofilin 1 (Non-muscle), isoform CRA_a OS=Homo sapiens GN=CFL1 PE=2 SV=1;>tr|E9PP50|E9PP50_HUMAN Cofilin-1 (Fragment) OS=Homo sapiens GN=CFL1 PE=2 SV=1;>tr|E9PK25|E9PK4 0,62
Histone deacetylase 6 HDAC6 >sp|Q9UBN7|HDAC6_HUMAN Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=1 SV=2;>tr|B4DZH6|B4DZH6_HUMAN Histone deacetylase 6 OS=Homo sapiens GN=HDAC6 PE=2 SV=1;>sp|Q9UBN7-2|HDAC6_HUMAN Isoform 2 of Histone deacetylase 6 OS=Homo sapiens GN=HDAC64 0,61
U2 small nuclear ribonucleoprotein A SNRPA1 >sp|P09661|RU2A_HUMAN U2 small nuclear ribonucleoprotein A OS=Homo sapiens GN=SNRPA1 PE=1 SV=2;>tr|H0YMA0|H0YMA0_HUMAN U2 small nuclear ribonucleoprotein A (Fragment) OS=Homo sapiens GN=SNRPA1 PE=2 SV=1;>tr|H0YLR3|H0YLR3_HUMAN U2 small nuclear ribonucleo5 0,58
Prohibitin-2 PHB2 >tr|F5GY37|F5GY37_HUMAN Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=2 SV=1;>sp|Q99623|PHB2_HUMAN Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=1 SV=2;>tr|J3KPX7|J3KPX7_HUMAN Prohibitin-2 OS=Homo sapiens GN=PHB2 PE=2 SV=1;>tr|F5GWA7|F5GWA7_HUMAN Prohibitin-2 (Fragmen2 0,57
Protein RCC2 RCC2 >sp|Q9P258|RCC2_HUMAN Protein RCC2 OS=Homo sapiens GN=RCC2 PE=1 SV=22 0,50
Ketosamine-3-kinase FN3KRP >tr|I3L2G3|I3L2G3_HUMAN Ketosamine-3-kinase (Fragment) OS=Homo sapiens GN=FN3KRP PE=2 SV=1;>tr|F5H4E4|F5H4E4_HUMAN Ketosamine-3-kinase OS=Homo sapiens GN=FN3KRP PE=2 SV=1;>sp|Q9HA64|KT3K_HUMAN Ketosamine-3-kinase OS=Homo sapiens GN=FN3KRP PE=1 SV=2;>tr|I3L2 0,42
Thioredoxin TXN >sp|P10599-2|THIO_HUMAN Isoform 2 of Thioredoxin OS=Homo sapiens GN=TXN;>sp|P10599|THIO_HUMAN Thioredoxin OS=Homo sapiens GN=TXN PE=1 SV=32 0,41
Heterogeneous nuclear ribonucleoprotein A1;Heterogeneous nuclear ribonucleoprotein A1-like 2HNRNPA1;HNRNPA1L2 >sp|P09651-3|ROA1_HUMAN Isoform 2 of Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens GN=HNRNPA1;>tr|F8W6I7|F8W6I7_HUMAN Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens GN=HNRNPA1 PE=4 SV=2;>sp|P09651-2|ROA1_HUMAN Isoform A1-A of Heter3 0,32
Tubulin beta-3 chain TUBB3 >sp|Q13509|TBB3_HUMAN Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2;>tr|A8K854|A8K854_HUMAN HCG1983504, isoform CRA_f OS=Homo sapiens GN=TUBB3 PE=2 SV=18 0,25
LanC-like protein 1 LANCL1 >tr|E9PHS0|E9PHS0_HUMAN LanC-like protein 1 (Fragment) OS=Homo sapiens GN=LANCL1 PE=2 SV=1;>sp|O43813|LANC1_HUMAN LanC-like protein 1 OS=Homo sapiens GN=LANCL1 PE=1 SV=1;>tr|F8WDS9|F8WDS9_HUMAN LanC-like protein 1 OS=Homo sapiens GN=LANCL1 PE=2 SV=12 0,24
Keratin, type I cytoskeletal 17 KRT17 >sp|Q04695|K1C17_HUMAN Keratin, type I cytoskeletal 17 OS=Homo sapiens GN=KRT17 PE=1 SV=2;>Q04695 SWISS-PROT:Q04695 Tax_Id=9606 Gene_Symbol=KRT17 Keratin, type I cytoskeletal 17;>Q9QWL7 SWISS-PROT:Q9QWL7 Tax_Id=10090 Gene_Symbol=Krt17 Keratin, type I cytos4 0,21
Hornerin HRNR >sp|Q86YZ3|HORN_HUMAN Hornerin OS=Homo sapiens GN=HRNR PE=1 SV=2;>Q86YZ3 SWISS-PROT:Q86YZ3 Tax_Id=9606 Gene_Symbol=HRNR Hornerin5 0,19
Keratin, type II cytoskeletal 5 KRT5 >sp|P13647|K2C5_HUMAN Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3;>P13647 SWISS-PROT:P13647 Tax_Id=9606 Gene_Symbol=KRT5 Keratin, type II cytoskeletal 58 0,11
Keratin, type I cytoskeletal 14 KRT14 >sp|P02533|K1C14_HUMAN Keratin, type I cytoskeletal 14 OS=Homo sapiens GN=KRT14 PE=1 SV=4;>P02533 SWISS-PROT:P02533 Tax_Id=9606 Gene_Symbol=KRT14 Keratin, type I cytoskeletal 14;>Q6IFX2 SWISS-PROT:Q6IFX2 Tax_Id=10090 Gene_Symbol=Krt42 Keratin, type I cytos10 0,09
Keratin, type II cytoskeletal 6C;Keratin, type II cytoskeletal 6B;Keratin, type II cytoskeletal 6AKRT6C;KRT6B;KRT6A >sp|P48668|K2C6C_HUMAN Keratin, type II cytoskeletal 6C OS=Homo sapiens GN=KRT6C PE=1 SV=3;>P48668 SWISS-PROT:P48668 Tax_Id=9606 Gene_Symbol=KRT6C Keratin, type II cytoskeletal 6C;>P04259 SWISS-PROT:P04259 Tax_Id=9606 Gene_Symbol=KRT6B Keratin, type II cyt12 0,06
Keratin, type I cytoskeletal 16 KRT16 >sp|P08779|K1C16_HUMAN Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4;>P08779 SWISS-PROT:P08779 Tax_Id=9606 Gene_Symbol=KRT16 Keratin, type I cytoskeletal 167 0,03
Keratin, type I cytoskeletal 9 KRT9 >sp|P35527|K1C9_HUMAN Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3;>P35527 SWISS-PROT:P35527 Tax_Id=9606 Gene_Symbol=KRT9 Keratin, type I cytoskeletal 9;>tr|K7EQQ3|K7EQQ3_HUMAN Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=27 0,03
Keratin, type II cytoskeletal 2 epidermal KRT2 >sp|P35908|K22E_HUMAN Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2;>P35908 SWISS-PROT:P35908 Tax_Id=9606 Gene_Symbol=KRT2 Keratin, type II cytoskeletal 2 epidermal13 0,03
Keratin, type I cytoskeletal 10 KRT10 >sp|P13645|K1C10_HUMAN Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6;>P13645 SWISS-PROT:P13645 Tax_Id=9606 Gene_Symbol=KRT10 Keratin, type I cytoskeletal 1018 0,02

















genome	 stability.	 Among	 the	 most	 devastating	 types	 of	 DNA	 damage	 are	 DNA	 double	
strand	breaks	(DSBs).	DSBs	can	be	generated	endogenously	by	physiological	processes,	for	





towards	DNA	damage	 is	 termed	the	DNA	damage	response	 (DDR).	The	signaling	of	DSBs	
is	 driven	 by	 posttranslational	 modifications	 (PTMs)	 (primarily	 phosphorylation	 and	
ubiquitylation)	 of	 proteins	 that	 function	 as	 DNA	 damage	 sensors	 or	 signal	 transducers.	
Ultimately	 this	 cascade	 of	 events	 regulates	 effector	 proteins	 that	 facilitate	DNA	damage	
repair	 and	 control	 cell	 cycle	progression.	 Since	 chromatin	often	 forms	 a	barrier	 for	DNA	
repair	proteins	to	access	the	damaged	DNA,	the	cellular	response	to	DNA	damage	demands	
accurate	 and	timely	 changes	 in	 chromatin	 structure	 to	 allow	efficient	 protection	 against	
DNA	 damage.	 Chromatin	modifiers	 and	 remodelers	 are	 capable	 to	 level	 this	 barrier	 by	
changing	 nucleosomal	 organization	 in	 the	 vicinity	 of	 DSBs	 and	modulating	 PTMs	 on	 for	
example	histones.	This	 leads	 to	a	 temporal	 increase	 in	 the	accessibility	of	 the	chromatin	
surrounding	the	 lesion	 (Smeenk	and	van	Attikum,	2013).	Hence	chromatin	modifiers	and	
remodelers	are	considered	to	be	key	players	in	the	DSB	response	and	their	loss	can	have	
severe	 effects	 on	 genome	 stability	 and	 consequently	 the	 development	 and	health	 of	 an	
organism.	Perhaps	not	surprisingly,	genetic	defects	in	these	chromatin	factors	are	frequently	
found	in	human	disorders.	Interestingly,	such	disorders	have	a	number	of	common	clinical	
characteristics	 like	 developmental	 defects,	 neurological	 degeneration,	 immunodeficiency	
and	 cancer	 predisposition.	 In	 order	 to	 identify	 the	molecular	 origin	 of	 these	diseases,	 it	





DSB	 repair	 via	 non-homologous	 end-joining	 (NHEJ)	 and	homologous	 recombination	 (HR)	
(Helfricht	et	al.,	2013)	(chapter	2).	Remodeling	and	Spacing	Factor	1	(RSF1),	on	the	other	
hand,	deposits	centromeric	proteins	at	DSBs.	These	proteins	appeared	to	be	critical	for	the	
RSF1-dependent	 recruitment	 of	 the	 important	 NHEJ-factor	 XRCC4	 to	 DSBs.	 Interestingly	
besides	NHEJ,	RSF1	 is	also	 involved	 in	the	efficient	repair	of	DSBs	via	HR	(Helfricht	et	al.,	
2013)	 (chapter	 3)	 and	 the	 function	 of	 RSF1	 during	 both	 DSB	 repair	 pathways	might	 be	
dependent	on	SUMOylation	(chapter	IV).	Moreover,	in	chapter 5 we discovered a role for 
ZBTB24	during	classical	NHEJ	by	means	of	promoting	PARP1	activity	and	stabilizing	PARP1-










EHMT1 involved in intellectual disability syndrome and the DDR
Epigenetic	processes	such	as	DNA	methylation	are	fundamental	for	(neuronal)	development	
and	 cognitive	 functioning	 (Day	 and	 Sweatt,	 2011).	 Consequently,	 the	 disruption	 of	 the	
methylation	machinery	can	cause	cognitive	disorders	(Miller	et	al.,	2010)	such	as	Kleefstra	
syndrome	 (KS)	 (OMIM	 #610253).	 KS	 is	 caused	 by	 haploinsufficiency	 of	 the	 histone	




















	 Gene	 expression	 analysis	 of	 heterozygous	 Ehmt1+/-	 mice	 already	 revealed	 a	
significant	upregulation	of	bone	tissue	related	genes,	which	 likely	results	from	decreased	
Ehmt1-induced	H3K9me2	levels	in	the	promotor	region	of	these	genes.	This	altered	gene	
expression	most	 likely	contributes	 to	 the	cranial	dysmorphic	 features	of	KS	 (Balemans	et	
al.,	2014).	 In	addition,	our	functional	studies	on	the	role	of	EHMT1	suggests	that	EHMT1	
is	 a	 factor	 involved	 in	 the	DDR	 that	may	act	as	a	negative	 regulator	of	53BP1	accrual	 at	
DSBs.	EHMT1	also	functions	in	DSB	repair:	in	chapter 2	we	showed	that	EHMT1	promotes	
DSB	 repair	 via	 both	 NHEJ	 and	 HR.	Whether	 EHMT1	 functions	 directly	 in	 DSB	 repair	 or	
mediates	DSB	repair	via	promoting	the	recruitment	of	DDR	signaling	proteins	such	as	53BP1	
requires	further	investigation.	To	this	end,	it	would	be	interesting	to	further	study	EHMT1’s	

























This	 study	described	a	 functional	 link	between	EHMT1	and	 several	 epigenetic	 regulators	
including	the	histone	H3K4	methyltransferase	KMT2C,	the	heterochromatin	binding	protein	
MBD5	and	the	nuclear	receptor	NR1I3.	Mutations	in	these	genes	and	the	core-component	
of	 the	 hSWI/SNF	 chromatin	 remodeling	 complex	 SMARCB1	 were	 identified	 in	 human	
individuals	 with	 severe	 intellectual	 disability	 that	 comprise	 features	 closely	 resembling	
those	of	KS	patients.	KMT2C,	MBD5	and	NR1I3	cooperate	with	EHMT1,	whereas	SMARCB1	
directly	interacts	with	KMT2C.	These	findings	lead	to	the	proposal	of	a	putative	conserved	






Dissecting the role of RSF1 in DNA repair



















timing	of	 foci	 analysis	 after	DNA	damage	 induction	 remains	elusive	and	 requires	 further	
investigation.	











2010;	 Yan	et	 al.,	 2010).	 FA	 is	 a	 rare	 genetic	disease	 that	 affects	1	 in	 160.000	 individuals	





to	unravel	 the	exact	role	of	RSF1	 in	 ICL	repair	and	other	cellular	processes.	For	 instance,	

















folding	 in	 vitro	 by	 monitoring	 chromatin	 fiber	 composition	 in	 biophysical	 experiments.	
Finally,	 it	would	be	interesting	to	know	whether	CENP	proteins	undergo	PTMs	upon	DNA	




RSF1	itself	does	not	display	any	enzymatic	activity,	yet	 it	 is	able	to	 load	CENP	proteins	at	
sites	of	DNA	damage	(Helfricht	et	al.,	2013)	(chapter	3).	A	step	towards	understanding	the	
mechanistic	role	of	RSF1	in	DSB	repair	is	to	elucidate	whether	RSF1	acts	individually,	with	
SMARCA5	as	 part	 of	 the	RSF	 complex	or	 even	 as	 a	member	of	 a	 another	 complex.	One	
approach	to	address	this	key	question	is	to	perform	DSB	repair	experiments	in	RSF1-	and/
or	SMARCA5-depleted	cells	and	monitor	whether	RSF1	and	SMARCA5	act	epistatically	or	











ICF1-4 ... is there a common mechanism?
ICF	patients	have	been	categorized	 into	 four	 subgroups	 (ICF1,	2,	3	and	4;	 causally	 linked	


















repeats.	 DNA	 methyltransferase	 1	 (DNMT1)	 maintains	 DNA	 methylation	 during	 DNA	
replication	and	has	been	shown	to	bind	non-covalently	 to	PARylated	PARP1,	which	 leads	
to	 DNMT1	 inactivation	 and	 subsequently	 to	 DNA	 hypomethylation	 (Reale	 et	 al.,	 2005).	
Whether	DNMT3B	also	binds	to	(PARylated)	PARP1	to	become	inactivated,	requires	further	
investigation.	One	possibility	is	that	DNMT3B	and	ZBTB24	compete	for	the	binding	of	PAR	
chains.	 In	 the	 case	 of	 ICF2	 patients,	 the	 established	 PAR	 chains	might	 become	 available	
for	DNMT3B	binding	due	 to	ZBTB24	 loss,	 leading	 to	 the	observed	DNA	hypomethylation	
phenotype.	However,	there	is	currently	no	obvious	mechanism	that	could	explain	the	DNA	






these	 proteins	 localize	 to	 sites	 of	 DNA	 damage,	 what	 their	 mode	 of	 action	 is	 in	 which	
biochemical	context	they	operate	at	DNA	lesions	is.
Chromatin modifiers in cancer
Recent	studies	have	indicated	that	human	cancers	exhibit	global	epigenetic	abnormalities	
as	well	as	genetic	alterations	(Jones	and	Baylin,	2007).	In	contrast	to	the	latter,	epigenetic	
changes	 are	 reversible	 and	 can	 be	 enzymatically	 restored	 to	 their	 non-disease	 state.	











	 While	 reduced	EHMT1	activity	 leads	 to	KS,	 the	overexpression	of	EHMT1	seems	








mutations	 have	 been	 identified	 in	 various	 cancers	 listed	 in	 the	 catalogues	 of	 somatic	
mutations	 in	 cancer	 (COSMIC).	Whether	 these	mutations	 affect	 RSF1	 expression	 and/or	
function	and	 influence	DNA	repair	 levels	 in	cancer	 is	an	 important	question.	 Intriguingly,	
RSF1	was	also	found	to	be	overexpressed	in	various	types	of	cancer	with	a	frequency	of	55%	
in	ovarian	carcinomas,	50%	in	colon	cancer	tissues	and	45%	in	prostate	cancer	specimens,	
and	 this	 phenotype	 correlates	 with	 a	 poor	 prognosis	 for	 the	 length	 of	 patient	 survival	







































usually	 in	 the	first	or	 second	decade	of	 life	mostly	 from	 the	disastrous	 consequences	of	
severe,	opportunistic	and	recurrent	 infections	(Weemaes	et	al.,	2013).	Hence,	 it	 is	rather	











adrenocortical	adenoma	 (Kubota	et	al.,	2004).	The	Hodgkin	 lymphoma	was	diagnosed	 in	





in	 this	 ICF1	 patient.	However,	 so	 far	we	 can	 only	 speculate	 about	what	 exactly	 leads	 to	
tumorigenesis	in	those	four	described	ICF	patients	and	whether	ICF	patients	in	general	are	
predisposed	to	develop	cancer.
Chromatin modifier-defects and therapy options
Cancer	 is	 a	 disease	 that	 is	 driven	by	 genomic	 instability,	 a	 feature	 that	 can	 arise	 from	a	
defective	DDR.	Currently,	 the	established	 approach	 to	 treat	 cancer	 is	 to	 kill	 tumors	 cells	
through	the	induction	of	DNA	damage	via	chemotherapy	or	radiation,	but	this	strategy	also	
targets	healthy	cells	for	cell	death.	Thus,	alternative	therapy	methodologies	that	specifically	
target	 cancer	 cells	 are	 to	 be	 found.	One	promising	 approach	 to	 enhance	 the	 efficacy	 of	
cancer	 therapy	 is	 the	use	of	 specific	 inhibitors	 that	 target	DDR	 factors	 in	 cancer	 cells	 to	
disable	 certain	 DNA	 repair	 pathways	 (Jackson	 and	 Bartek,	 2009).	 The	 DDR	 is	 therefore	
intensely	investigated	to	identify	novel	(chromatin-modifying)	factors	that	are	suitable	anti-	
drug	targets	in	anti-cancer	regimes.	
PARP	 inhibitors	 for	 instance	are	effective	 in	 cells	 comprising	a	defect	 in	HR;	HR-deficient	




expression	 of	 RSF1	 are	 likely	 to	 be	 sensitive	 to	 PARP	 inhibitors.	Whether	 the	 latter	 can	
also	provide	an	efficient	therapy	for	malignancies	that	comprise	altered	expression	levels	






















lead	 to	 an	 increase	 in	 treatment	 success	 rates	 for	 patients	 with	 genetic	 alterations	 in	
chromatin	factors,	as	is	the	case	for	the	majority	of	tumors	comprising	mutations	in	BRCA1	
or	BRCA2	(Bao	et	al.,	2015).	
	 Also	 the	 development	 of	 specific	 inhibitors	 that	 restrain	 the	 activity	 of	
overexpressed	 chromatin	 factors	 in	 cancer	 cells	might	 lead	 back	 to	 a	 non-disease	 state.	
For	instance	reversing	the	epigenetic	changes	induced	by	aberrant	EHMT1	activity	due	to	
its	overexpression	 in	certain	cancers	by	means	of	EHMT1/2	 inhibition,	might	 lead	 to	 the	
re-expression	of	genes	that	had	been	silenced	through	an	increase	in	EHMT1/2-mediated	
H3K9me1/2	marks.	Efforts	have	been	made	to	develop	small-molecule	inhibitors	for	EHMT1	
and	 EHMT2.	 A	 few	 of	 these	 inhibitors	 have	 recently	 been	 proven	 to	 provide	 a	 way	 to	
counteract	EHMT1	activity	in	breast	cancer,	esophageal	squamous	carcinoma	and	leukemia	
cells	 (Liu	 et	 al.,	 2013).	 Thus,	 EHMT	 inhibitors	may	 ultimately	 improve	 the	 poor	 survival	
prognosis	of	patients	with	aberrant	EHMT1	expression	in	the	future	(Curry	et	al.,	2015;	Guan	
et	al.,	2014;	Pappano	et	al.,	2015).	
	 ICF	 patients	 suffer	 from	 severe	 respiratory	 and	 opportunistic	 infections	
caused	 by	 their	 immunodeficiency.	 Current	 therapeutic	 opportunities	 for	 ICF	 patients	





is	 of	 great	 importance,	 since	 early	 immunoglobulin	 supplementation	 can	 improve	 the	
course	of	the	disease.	A	drawback	of	this	method	is	however	the	availability	of	a	compatible	
donor.	Therefore,	gene	therapy	might	form	a	potent	alternative	and	employs	the	transfer	
of	 a	 transgene	 via	 for	 instance	 viral	 infection	 to	 patient-derived	 HSCs.	 These	 cells	 are	
subsequently	transplanted	back	into	the	patient.	Notably,	this	form	of	gene	therapy	already	
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The	 human	 body	 consists	 of	 a	 variety	 of	 cell	 types,	 which	 all	 contain	 the	 same	 genetic	
information	that	is	encoded	in	the	DNA.	The	DNA	is	structured	into	specific	regions,	called	







day	 from	 such	 DNA	 damage-inducing	 assaults.	 Fortunately,	 our	 cells	 are	 equipped	 with	
sophisticated	DNA	signaling	and	repair	mechanisms,	commonly	termed	the	DNA	damage	
response	(DDR),	that	can	detect	and	repair	different	types	of	DNA	lesions.	If	DNA	damage	
is	not	 (correctly)	 repaired,	alterations	 in	the	basic	units	of	 the	DNA,	the	nucleotides,	can	
occur.	These	are	generally	referred	to	as	mutations	and	can	potentially	give	rise	to	cancer.	
Although	the	general	steps	of	the	different	DNA	repair	pathways	are	known,	novel	proteins	










In chapter 2,	 I	present	the	results	obtained	from	an	siRNA	screen	I	performed	to	identify	







In chapter 3,	my	findings	 reveal	a	novel	 role	of	Remodeling	and	Spacing	Factor	1	 (RSF1)	


















during	 immunoglobulin	 switching	 in	 B	 cells	 from	 ICF2	 patients.	 This	 leads	 to	 impaired	
immunoglobulin	 production	 and	 an	 imbalance	 in	 immunoglobulin	 subtype	 formation	 in	































signaleringsysteem	en	 verschillende	herstel	mechanismen,	 die	 allerlei	 types	DNA	 schade	
kunnen	 detecteren	 en	 repareren.	Maar,	 als	 de	 schades	 in	 het	 DNA	 niet	 of	 onzorgvuldig	
gerepareerd	worden,	kunnen	veranderingen	ontstaan	 in	de	basiseenheden	van	het	DNA,	























Euchromatic	 histone-lysine	N-methyltranferase	 1	 (EHMT1)	 kwam	als	 een	 prominente	 hit	
uit	 de	 screen;	 het	 eiwit	 bleek	 de	 53BP1	 ophoping	 te	 controleren.	 In	 vervolgonderzoek	
heb	ik	gevonden	dat	EHMT1	naar	laser-geïnduceerde	DNA	schade	gerekruteerd	wordt	en	














(SUMO)	 op	 de	 DSB	 herstel-gerelateerde	 rol	 van	 RSF1	 is	 beschreven	 in	 hoofdstuk 4. 





hiertoe niet langer in staat. 
In hoofdstuk 5	 vat	 ik	 onze	bevindingen	 samen	over	het	 Zinc	finger	 and	BTB	 (bric-a-bric,	
tramtrack,	 broad	 complex)	 containing	 24	 (ZBTB24)	 eiwit,	 waarvoor	 is	 aangetoond	 dat	
































Ursprung	 haben	 im	 Inneren	 unserer	 Zellen,	 wie	 z.B.	 Produkte	 chemischer	 Reaktionen.	
Nach	wissenschaftlichen	Schätzungen	entstehen	zwischen	1.000	und	10.000	DNA-Schäden	
pro	Zelle	pro	Tag	als	Folge	von	solchen	Angriffen.	Glücklicherweise	sind	unsere	Zellen	mit	
anspruchsvollen	 DNA-Signal-	 und	 Reparaturmechanismen	 ausgestattet,	 die	 verschiedene	
Arten	 von	 DNA-Schäden	 erkennen	 als	 auch	 reparieren	 können.	 Diese	 Mechanismen	
werden	unter	dem	Nenner	‚DNA	damage	response‘	zusammengefasst.	Wenn	DNA-Schäden	
nicht	(richtig)	repariert	werden,	können	Veränderungen	in	der	Basiseinheit	der	DNA,	den	
Nukleotiden,	 auftreten.	 Solche	 Veränderungen	 werden	 auch	 ‚Mutationen‘	 genannt	 und	










sehr	 schädlich.	 In	 Kapitel 1	 meiner	 Dissertation	 biete	 ich	 dem	 Leser	 eine	 ausführliche	
Einleitung	in	die	Signalmechanismen	und	die	Reparatur	von	DSBs.	Zusätzlich	erkläre	ich	den	
Zusammenhang	 zwischen	 der	 Grundlagenforschung	 zur	 Aufklärung	 der	Mechanismen	 in	
der	DNA	damage	response	und	menschlicher	Krankheiten,	wie	z.B.	Krebs,	und	möglicher	
Therapieentwicklungen.
Die	Resultate	 eines	 siRNA-Screens,	mit	 dem	 ich	noch	unbekannte	Proteine	 identifizieren	
wollte,	 die	 an	 der	 Signaltransduktion	 von	 DSBs	 beteiligt	 sind,	 werden	 in	 Kapitel 2 
präsentiert.	 Ich	 habe	 die	 Akkumulation	 der	 DNA-Schaden-Signalisierungsmarker	 γH2AX	
und	53BP1	in	Abwesenheit	von	Chromatin-modifizierenden	Proteinen	in	Zellen	untersucht,	
die	 mit	 ionisierender	 Strahlung	 (IS)	 behandelt	 wurden.	 Euchromatic	 histone-lysine	
N-methyltranferase	1	 (EHMT1)	 zeigte	 sich	dabei	 als	 prominenter	Hit	 für	 einen	negativen	


















dass	 die	 SUMOylierung	 von	 RSF1	 nach	 der	 Induktion	 von	 DNA-Schäden	 mit	 IS	 deutlich	
zunimmt.	 Eine	 nicht-SUMOylierbare	Mutante	 (SUMO∆)	 von	 RSF1	wurde	 noch	 immer	 zu	
Laser-induzierten	DSBs	 rekrutiert.	Aber	während	Wildtyp-RSF1	XRCC4	zu	DSBs	befördern	
kann,	war	RSF1	SUMO∆	dazu	nicht	länger	in	der	Lage.	
In Kapitel 5	 fasse	 ich	 unsere	 Forschungsergebnisse	 bezüglich	 des	 Zinc	 finger	 and	 BTB	
(bric-a-bric,	 tramtrack,	broad	complex)	containing	24	 (ZBTB24)	Gens,	 in	dem	Mutationen	
Immunodeficiency,	 Centromeric	 instability	 and	 Facial	 anomalies	 (ICF)	 Syndrom	 Typ	
2-verursachenden,	 zusammen.	 Wir	 zeigen,	 dass	 NHEJ	 in	 ICF2-Patienten	 während	 des	
Isotypenwechsels	 in	B-Zellen	durch	den	Verlust	 von	ZBTB24	beeinträchtigt	 ist.	Dies	 führt	
zu	 einer	 fehlerhaften	 Immunglobulin-Produktion	 und	 einem	 gestörten	 Gleichgewicht	 in	
der	 Bildung	 der	 verschiedenen	 Antikörper-Isotypen	 bei	 diesen	 Patienten.	 Bei	 weiteren	
Untersuchungen	der	mechanistischen	Details	haben	wir	eine	Interaktion	zwischen	ZBTB24	
und	 den	 Poly(ADP-ribose)	 Polymerase	 1	 (PARP1)-assoziierten	 Poly(ADP-ribose)-Ketten	
entdeckt.	 Diese	 sind	 erforderlich	 für	 die	 transiente	 Rekrutierung	 von	 ZBTB24	 zu	 Laser-
induzierten	 DNA-Schäden.	 Die	 schützende	 Bindung	 der	 Poly(ADP-ribose)-Ketten	 durch	
ZBTB24	wirkt	 deren	Abbau	 durch	 Poly(ADP-ribose)	Glycohydrolase	 (PARG)	 entgegen	 und	




Literatur.	Da	 alle	 drei	 Proteine	 in	 Zusammenhang	mit	 Krebs	 oder	 anderen	menschlichen	
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But	 to	 start	 a	 PhD,	 one	need	 an	 actual	 position,	 to	which	 I	was	 kindly	 patched	 through	


































‘Mein	 Fels	 in	 der	 Brandung’	 und	 ich	 hätte	 unzählige	 Einträge	 in	 ‘Mein	 liebes	 Tagebuch’	



















mij	waren	 en	mij	 regelmatig	 uit	 de	 promotieachtbaan	 hebben	 gehaald!	 Jane	 und	 Franz,	
vielen	Dank	 fürs	 Zuhören	 und	 die	Motivation.	 Anna,	 thanks	 for	 the	 countless	 runs	 after	
work,	for	listening	and	your	friendship.




ich	weiß	 die	mentale	Unterstützung	 von	 dir	 und	 Ricci	 sehr	 zu	 schätzen!	Das	 beste	 Anti-
Stressmittel	waren	für	mich	unsere	lustigen	Familien-wanderungen	in	den	Bergen.	
Met	veel	interesse	hebben	ook	jullie,	Cia,	Pieter	en	Tino	steeds	naar	de	verloop	van	mijn	
promotie	gevraagd.	Ontzettend	bedankt	voor	jullie	steun	en	aanmoedigende	worden.
And	then	last	but	for	sure	not	least,	Seger.	Wat	ben	ik	blij	dat	jij	in	mijn	leven	bent	en	dat	ik	
altijd	op	jouw	steun	kan	rekenen.	Bedankt	dat	je	me	steeds	weer	in	contact	hebt	gebracht	
met	de	rest	van	de	wereld	en	voor	alle	mooie	dingen,	die	we	samen	hebben	gedaan	naast	
mijn	promotie.

